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Summary 
 
A systematic review was conducted to explicitly identify interventions that alone, or in combination, 
were effective in improving antibiotic prescribing. The citation search strategy used in the present 
review provided a database of 365077 studies, of which only twenty-five were included in the final 
review (“review studies”).  Analysis of the interventions used within the review studies indicated that 
a combination of “guidelines” and “pharmacy” interventions have the greatest potential to improve 
antibiotic prescribing.   
 
Two types of qualitative research were conducted, semi-structured interviews and the collection of 
naturally occurring data.  Semi-structured interviews were conducted in order to determine NHS 
managers‟ perceptions of current policies used to improve antibiotic prescribing within selected 
Primary Care Trusts and highlighted the importance of pharmacy intervention, formularies or 
guidelines and improved prescribing analysis (IT based intervention) on improving antibiotic 
prescribing.  This was supported by the collection of naturally occurring data, which was used to 
provide further insight into interventions used to improve antibiotic prescribing.  
 
The Specialist Antibiotic Pharmacist (HD) produced and implemented an innovative electronic 
antibiotic prescribing analysis tool (the Antibiotic Database) to analyse and improve antibiotic 
prescribing in a consistent manner.  The key advantage of the Antibiotic Database was the time and 
money saved on producing visual electronic outputs containing an inaccurate outcome measure or 
time period for analysis.    
 
The results concluded that an IT based intervention, such as the Antibiotic Database should be used, 
in addition to the use of antibiotic guidelines and pharmacy intervention, within all sectors of the NHS 
in order to improve antibiotic prescribing and its analysis. 
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Glossary of terms 
 
The use of uppercase indicates the term was being used in accordance with the definition in the 
glossary. 
 
Academic Detailing – a process involving face-to-face education of prescribers by trained health care 
professionals 
 
Actual Cost - is available within the Prescribing Monitoring Documents (PMDs) and can be 
calculated by subtracting the national average discounts from the NIC and adding add the cost of the 
allowance for the container from the basic price of the prescription item 
 
Advertising – communication used to inform patients 
 
Analytic induction – aims to identify deterministic laws and the essential character of phenomena, 
involving an iterative process of defining a problem, formulating and testing an hypothesis, then 
reformulating the hypothesis until all cases „fit‟ the hypothesis 
 
Antibacterial STAR (01)-PUs - can be calculated in terms of the number of items (Items per 1000 
Antibacterial STAR (01)-PUs) or the net ingredient cost (NIC (£) per 1000 Antibacterial STAR (01)-
PUs) 
 
Antimicrobial Management Team – a team consisting of a combination of different health care 
professionals dedicated to improving antibiotic prescribing 
 
Antibiotic Stewardship Program – programs developed to improve antibiotic prescribing 
 
Audit – process of evaluating prescribing 
 
Baseline – the period before an intervention or combination of interventions was implemented 
 
Case studies - focus on any given situation (individual person, a group, a setting, an organisation, 
etc.)  
 
Compliance - measure used in studies to demonstrate the appropriateness of prescribing (i.e. in 
accordance with requirements within the intervention) 
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Computerised Decision Support – computer based information system used to assist improvement 
in prescribing 
 
Content analysis – both the content and context of documents are analysed  
 
Conversation analysis – focuses on the structure of conversation and classifies interaction in terms of 
key linguistic systems 
 
Discourse analysis – concerned with the way knowledge is produced within a particular discourse 
through the use of distinctive language or through the adoption of implicit theories in order to make 
sense of social action 
 
Education – any intervention used to impart knowledge, skill and judgment 
 
EPOC – Cochrane Collaboration Effective Practice and Organization of Care (EPOC) database 
 
Ethnographic accounts – largely descriptive and detail the way of life of particular individuals, 
groups or organisations 
 
Feedback - the process of current antibiotic prescribing being regulated by review of previous 
antibiotic prescribing  
 
Follow-up - the period after an intervention or combinations of interventions were implemented 
 
Formulary – a reference document used by health care professionals to influence antibiotic 
prescribing 
 
Grounded theory – involves the generation of analytical categories and their dimensions, and the 
identification of relationships between them 
 
Guidelines – a document used to guide decisions and criteria regarding diagnosis, management, and 
treatment of infections 
 
Incentive scheme – a formal scheme for inducing prescribers to improve their antibiotic prescribing 
 
Intervention - the period when an intervention or combination of interventions were implemented 
16 
 
 
Intranet - a private computer network using internet protocol technologies to securely share 
operational systems within an organisation 
 
Lectures - an oral presentation of information to teach the audience about a particular subject 
 
Life histories – can be analysed as single narratives, as collections of stories around common themes, 
or quarried to construct an argument based on comparison between different accounts 
 
Meeting GP‟s - organised events with one or more prescriber in order to influence improvements in 
antibiotic prescribing 
 
Minor Ailment Scheme – a scheme allowing pharmacies to provide free medication (from a selected 
list of products) to those patients who could receive free prescriptions 
 
MSDi antibiotics module – computer software produced by the pharmaceutical company Merck 
Sharp & Dohme Ltd. to extract information regarding antibiotic prescribing from all surgeries within 
Sandwell PCT to a centralised computer 
 
Narrative analysis – identifies the basic story which is being told, focusing on the way an account or 
narrative is constructed, the intention of the teller and the nature of the audience as well as the 
meaning of the story  
 
Net Ingredient Cost – is used in ePACT.net and measures the basic price of a drug listed in the Drug 
Tariff or the manufacturers‟ price list 
 
Newsletters – periodic publication containing topics of interest in order to establish frequent and 
constant communication with the target audience  
 
Nominal group technique – method of decision making for groups of any size who want to make 
their decision quickly, by vote, with everyone‟s opinions taken into account 
 
OTC prescription pads – an information sheet presented in the form of a prescription to provide 
patients with information on how to treat minor ailments without the use of antibiotics  
 
Patient leaflets – a piece of printed information regarding antibiotic prescribing  
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Pharmacy intervention – the involvement of a pharmacist(s) to improve antibiotic prescribing 
 
Pocket book – a pocket-sized paperback book used to provide guidance on antibiotic prescribing 
 
Policy and evaluation analysis – where analysis is targeted towards providing answers about the 
contexts for social policies and programmes and the effectiveness of their delivery and impact 
 
Posters – a piece of printed paper designed to be attached to a wall or vertical surface and contain 
information to teach the audience about a particular subject 
 
Practice based pharmacists – pharmacists employed to work within surgeries in order to influence 
the prescribing decisions of prescribers  
 
Practice profiling – the process of providing prescribing data to prescribers within any given surgery 
in order to influence improvements in antibiotic prescribing 
 
Prescribing alerts – the presence of computer software that allows the visual display of warnings 
associated with the decision to prescribe any given antibiotic 
 
Prescriber events – organised events with more than one prescriber in order to influence 
improvements in antibiotic prescribing 
 
Prescriber meetings – organised events with one or more prescriber in order to influence 
improvements in antibiotic prescribing 
 
Prescription numbers - measure used in studies to demonstrate the number of times an antibiotic 
was prescribed to a patient to treat any given condition 
 
Presentations – the act of presenting information to an audience in order to improve antibiotic 
prescribing 
 
Public education – the act of presenting information to members of the public in order to improve 
antibiotic prescribing 
 
QoF – Quality and Outcomes Framework is a voluntary annual reward and incentive programme for 
all GP surgeries in England, detailing practice achievement results. It is not about performance 
management but resourcing and then rewarding good practice 
18 
 
 
Semi-structured interview – the interviewee has an interview guide that serves as a checklist of 
topics to be covered and a default wording and order for the questions, but the wording and order are 
often substantially modified based on the flow of the interview, and additional unplanned questions 
are asked to follow-up on what the interviewee says 
 
STAR (01) – PUs - have been produced for eight leading therapeutic groups, gastrointestinal, 
cardiovascular, respiratory, central nervous system, infection, endocrine, musculoskeletal and skin.  
 
Structured interviews – has predetermined questions with fixed wording, usually in a pre-set order,  
The use of a greater number of open-response questions is the only essential difference from an 
interview-based survey questionnaire  
 
Surveillance – process of monitoring antibiotic prescribing 
 
Unstructured interviews – the interviewer has a general area of interest and concern but lets the 
conversation develop within this area  
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Abbreviations for interventions and outcome 
measures 
 
A = Audit 
AD = Academic Detailing 
AMT = Antimicrobial Management Team 
AP = Antibiotics prescribed 
ASP = Antibiotic stewardship program 
C =Compliance 
CDS = Computerised decision support 
CDSS = CDSS 
E = Education 
EM = Education material 
F = Feedback 
G = Guidelines 
L = Lectures 
MB = Mail Brochures 
N = Newsletters 
OTC = OTC prescription pads 
P = Posters 
PB = Pocket book 
PCE = Patient and clinical educational information 
PEM = Patient educational material 
PI = Pharmacy intervention 
PL = Patient Leaflets 
PP = Practice Profiling 
PR = Presentations 
S = Seminar 
SG = Small groups 
SM = Staff meetings 
T = Training 
TSPB = Teaching sessions post baseline 
TSPD = Teaching sessions post-declaration 
TSPRC = Teaching sessions post-refresher course 
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1. Introduction 
 
1.1 Background 
 
Excessive and inappropriate use of antibiotics is considered to be the most important reason for the 
development of bacterial resistance to antibiotics (Bjerrum, 2006).  This has become an increasing 
public health issue with alarming increases in the occurrence of antibiotic resistant bacteria, including 
the emergence of multi-resistant Gram negative bacteria, methicillin-resistant Staphylococcus aureus 
(MRSA), and vancomycin-resistant enterococci (VRE) (Dranitsaris et al., 2001).  The development of 
bacterial resistance has led to strenuous efforts to control prescribing and supply of antibiotics in order 
to ensure that their value as a therapeutic option is maintained. However, it is currently unclear which 
interventions produce the greatest impact on antibiotic usage.   Figure 1 below shows a timeline of the 
key antibiotic classes produced. 
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Figure 1:  A Timeline showing the development of key antibiotic classes 
 
The concerns over antibiotic resistance are not new and indeed originate with the discovery of these 
agents.  Alexander Fleming voiced concerns about resistance development in the New York Times 
(New York Times, 1945) stating that the misuse of antibiotics could lead to the selection of resistant 
strains of bacteria. 
1930 
1940 
1950 
1960 
1970 
1980 
1990 
2000 
2010 
Prontosil (sulphonamide) 
Penicillin (β-lactam) 
Chloramphenicol (phenylpropanoid) 
Chlortatracycline (tetracycline) 
Erythromycin (macrolide) 
Vancomycin (glycopeptides) 
Trimethoprim (dihydrofolate reductase inhibitors) 
Nalidixic acid (quinolones) 
Cephalexin (cephalosporins) 
Clindamycin (lincosamide) 
Pivmecillinam (mecillinams) 
Imipenem (carbapenems) 
Teicoplanin (glycopeptides) 
Linezolid (oxazolidinone) 
Daptomycin (lipopeptide) 
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Considering that the awareness of antibiotic resistance has been a major concern since the beginning 
of the antibiotic era, it is relevant to ask why such a major public health issue has developed.  The 
answer is complex and no single causative factor can be established or proven (Extending the Cure 
Report, 1997).  However, a wide range of issues have been identified which appear to be involved 
with the development of antibiotic resistance.   
 
1.2 Resistance 
 
Antibiotics have been used to save countless lives since the introduction of penicillin by reducing the 
number of deaths caused by infectious diseases and facilitating the expansion of other medical 
interventions, such as heart transplants (Amyes, 2001).  However the effectiveness of antibiotics is 
increasingly compromised by the growing levels of bacterial resistance (Department of Health UK, 
1998).  Bacteria have coped with the increasing encounters of a wide variety of antibiotics, by 
continually evolving through the process of natural selection to provide a genetic composition which 
can aid their survival by resistance.  The natural selection process is also supported by other variables 
of antibiotic use that also impact on the selection of resistance, such as dose and duration of treatment 
used, as well as patients‟ individual factors.  These include the penetration of the antibiotic into 
various parts of the body, and how the body absorbs, metabolises and excretes the antibiotic, resulting 
in differing concentrations of antibiotics remaining in various body tissues and organs (Extending the 
Cure Report, 1997).  Therefore the main factor for driving the production of new antibiotics has been 
to overcome resistance caused to the previous generations of antibiotics. 
 
The Health Protection Agency defined antibiotic resistance as microorganisms that are not susceptible 
to antibiotics, thus are not killed or inhibited and can continue to grow or multiply in the presence of 
antibiotics.  Resistance can occur in three ways; innately, clinically and acquired (House of Lords, 
1998).  Innate resistance is the consequence of exposure to antibiotics present in the natural 
environment which naturally lead to resistance (Extending the Cure Report, 1997).  However some 
organisms are more resistant than others as bacterial species differ in their susceptibility to resistance.  
This is an example of clinical resistance where the effectiveness of an antibiotic on an organism 
depends upon many factors including the precise location of the infection, the distribution of the drug 
in body fluids and the state of the patient‟s immune system (Amyes, 2001).  Acquired resistance can 
occur by horizontal or mutation transfer of genes.  Horizontal gene transfer is the movement of 
genetic information from one organism to another without being the offspring of that organism.  
Mutational resistance is exemplified by tuberculosis, where mutation occurs randomly in a small 
proportion of a particular bacterial population (House of Lords, 2001).   
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1.2.1 Mutational resistance 
 
Bacterial infections are composed of millions of individual cells called a colony.  The bacteria within 
these colonies contain some heterogeneity, meaning that most of them are sensitive to the antibiotic, 
some are super-sensitive and some are less sensitive.  Therefore the dose of antibiotic has to be high 
enough to inhibit all of the bacteria.  If the dose is insufficient, some of the bacteria will survive, grow 
and mutate to bacteria containing higher levels of resistance (House of Lords, 2001).  Chromosomes 
provide the bacteria with an opportunity for mutation, either through a single chromosomal mutation, 
or through a series of mutations.  Streptomycin resistance is an example of single chromosome 
mutation, where alteration in a ribosomal protein or amino acid present in the enzyme dihydropteroate 
synthesase results in a lower affinity for sulphonamides (Extending the Cure Report, 1997).  
Penicillin-resistant pneumococci occur due to a series of mutations in penicillin binding proteins.  One 
of the highly publicised resistant strains of recent years has been methicillin-resistant staphylococcus 
aureus (MRSA), which has spread worldwide.  In this case, the mutation enables methicillin to bind to 
its receptor site, as the cell wall is altered, making it resistant (Health Protection Agency, 2005).   
 
The result of this evolutionary process is the presence of micro-organisms capable of counteracting 
the effects of specific antibiotics.  The higher frequency exposure of bacteria to sub-therapeutic doses 
leading to sub-therapeutic outcomes increases the likelihood of antibiotic resistance developing 
through random changes.  Therefore antibiotic resistance is more likely to spread to other sites in the 
same patient, or transfer to other patients through cross-infection.  This explains why patients are 
required to complete a course of antibiotics, to ensure that the patient does not relapse with the 
resistant variant and to prevent the resistant bacteria moving onto other patients. 
 
1.2.2 The spread of antibiotic resistance 
 
Antibiotic resistance can spread in two ways, through the presence of the resistant genes on 
conjugative plasmids and the transposition of resistant DNA sequences from one cell to another 
(House of Lords, 2001).  Plasmids are circular DNA fragments carrying additional genes.  These 
genes contain information that can have a beneficial impact on cell survival, such as the ability to 
adhere to cells, or adapt better to changes in temperature.  Although plasmids are unable to survive 
outside of their host bacterial cell, they may be transferred when conjugation occurs.  Some plasmids 
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are promiscuous and can carry vital resistant information to many bacteria, and thus resistant genes 
are found in a wide variety of species.  For example, TEM-1 is the most common plasmid-mediated 
beta-lactamase in Gram-negative bacteria found to be widespread in Escherichia coli (Department of 
Health UK, 1998).  However it has also been responsible for penicillin resistance in Neisseria 
gonorrhoeae, and ampicillin resistance in Haemophilus influenzae (Extending the Cure Report, 
1997).  Transposons are smaller pieces of DNA, compared to plasmids, which are capable of 
integration into the chromosome or into plasmids.  The chromosome provides a more secure position 
for the gene, however transposons moving from chromosomes to plasmids allow genes to be 
disseminated more rapidly, as transfer of information is slowed down by the process of bacteria 
dividing.  Movement of resistant genes can occur via bacteriophages when they attach to a bacterial 
cell and transfer their DNA.   
 
 
1.3 Economic impact of resistance 
 
There have been many estimates calculated for the cost of overcoming antibiotic resistance, however 
it is very difficult to estimate the dose-response relationship between antimicrobial use and resistance 
because of the lack of time-series data to relate the two factors (Extending the Cure Report, 1997).  
Also there are many other factors which can impose direct or indirect costs onto the burden of treating 
antibiotic resistance, such as time lost at work or repeated stays at hospitals.  A key factor in the cost 
of treating antibiotics resistance is the cost of the newer, more expensive antibiotics, which are used 
even if older antibiotics retain considerable effectiveness, owing to the risk of treatment failure.  The 
new antibiotics also incur a higher cost as pharmaceutical companies obtain a patent for their 
production, thus increasing the cost of drugs during the patent period.  Sometimes a combination of 
antibiotics, or sequential use of antibiotics are required to treat infections which can also increase the 
cost significantly.   
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1.4 The use of antibiotics in animals 
 
The use of antibiotics as growth promoters, and as compensation for poor husbandry practices in food 
producing animals has resulted in the spread of antibiotic resistance through the food chain to 
humans.  Antimicrobial use originated in livestock in the 1940s when chlortetracycline fermentation 
waste was used to enhance the growth of poultry and pigs (House of Lords, 1997-1998).  Since then, 
antibiotics have been used as growth promoters to improve the growth rate and efficiency of feeding 
livestock, although their mode of action is not fully known.  Growth promoters are used at low 
concentrations and can lead to increase daily growth and food conversion by 3-11 percent (House of 
Lords, 1997-1998), depending on the species.  This could make the difference between profit or loss 
for livestock producers.  Growth promoters are also seen as an option for livestock therapy as they can 
be bought direct from manufacturers without the need for prescription and thus further reduce costs.  
Poor husbandry practices have resulted from the mass oral administration of antibiotics to all 
livestock to reduce the spread of infection, therefore increasing the likelihood of eventual antibiotic 
resistance.  Prophylactic antibiotic use is practical when treating predictable diseases or the outbreak 
of disease in livestock and is supplied as mass medication (“metaphylaxis”) through medicated feed 
or water.    
 
The issue of resistance in animals may become an issue of resistance in humans when agents reserved 
for animals are discovered to have clinical applications in humans.  A Committee on the Use of 
Antibiotics in Animal Husbandry and Veterinary Medicine (the Swann Committee) was appointed in 
1969 and produced legislation to ban the use of human therapeutic antibiotics as growth promoters for 
animals.  However no restriction was placed on therapeutic or prophylactic antibiotic use.  In 1992, 
the Veterinary Products Committee “discouraged” the use of prophylactic treatment on the basis of 
recommendations made by the Expert Group on Animal Feeding stuffs. 
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1.5 Controlling antibiotic use 
 
There are a variety of professions worldwide who are able to prescribe antibiotics.  Conventionally, in 
the UK medical practitioners have been the most prominent prescribers, however dentists, veterinary 
practitioners, nurses, and other independent and supplementary prescribers also frequently issue 
prescriptions for antibiotics (House of Lords, 2001).  The term “Prescribers” will be subsequently 
used in this thesis to define any person who can prescribe antibiotics to a patient or animal.  The 
factors that influence a prescriber‟s decision to provide antibiotics are difficult to assess, as each 
prescriber is likely to perceive the need for antibiotic therapy differently.  However, prescribing 
decisions will be generally based on the practitioner‟s views and practice habits that are supported by 
numerous influences in their local environment, which include administrative, educational, economic, 
personal, patient, and community based factors (Extending the Cure Report, 1997). 
 
The most effective way of slowing the spread of resistance is to reduce selection by stopping the use 
of antibiotics when they provide no medical benefit, however there are several reasons why antibiotics 
are prescribed unnecessarily.  Firstly, if the prescriber is unsure of the medical diagnosis a patient 
presents with then they are more likely to use an antibiotic.  Secondly, antibiotics are most likely to 
benefit a patient when started early in treatment.  Thirdly, patients can demand antibiotics and thus 
influence the decision to prescribe antibiotics (Amyes, 2001).  Another way to reduce the spread of 
resistance is to use narrow-spectrum antibiotics rather than the broad spectrum antibiotics.  However 
as mentioned before, if prescribers are unsure of a diagnosis they are more likely to not only prescribe 
antibiotics but also prescribe broad-spectrum antibiotics as they are more likely to work against an 
infection with unidentified bacteria.  The disadvantage of using broad-spectrum antibiotics is that they 
are also more likely to select for resistance in several bacterial species simultaneously (Amyes, 2001).  
 
Rapid diagnostic testing could be used to facilitate the shift in antibiotic use from broad- to narrow-
spectrum antibiotics, even in cases where broad spectrum antibiotics have been initially prescribed.  
However, many antibiotics that cause infections may not be easily detected with a rapid diagnostic 
test as they are not easily cultured and the tests that are available can take up to three days to provide 
results (Extending the Cure Report, 1997).  This asserts more pressure on prescribers to prescribe 
antibiotics earlier for those patients that are perceived to require treatment.  Rapid diagnostic tests 
could be improved with new technology, but there are no guarantees that the results will be one 
hundred percent accurate nor will their production be cheap.     
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1.6 Demographics 
 
Antibiotic resistance is an international issue, however, the potential factors that appear to influence 
the patterns of development of resistance vary widely between different countries.  Antibiotic use can 
be measured in terms of defined daily dose per 1000 population per year.  Based on the use of this 
indicator the general antibiotic prescribing rate in an international comparison was highest in France 
and lowest in the Netherlands (Extending the Cure Report, 1997).  The organism of great global 
concern is methicillin-resistant Staphylococcus aureus (MRSA) with the highest current incidences 
occurring in Romania. The USA and UK have the seventh and eleventh highest incidences of MRSA 
respectively (Extending the Cure Report, 1997).  Countries with high antibiotic prescribing rates do 
not necessarily have high levels of antibiotic resistance when compared to other nations.  For example 
Portugal has a higher antibiotic prescribing rate in terms of defined daily doses per 1000 population 
per year compared to the USA.  However, the incidence of MRSA is actually higher in the USA when 
compared to Portugal.  This indicates that other causal factors are involved (Extending the Cure 
Report, 1997). 
 
1.6.1 Antibiotic resistance in the developing world 
 
Resistance in the developing world results from the combination of many factors resulting in a real 
global threat of antibiotics resistance, much of which appears to be due to inappropriate and/or over 
prescribing of antibiotics and a lack of routine microbiological sensitivity testing and surveillance 
(Awad et al., 2006).  Infectious diseases in the developing world are often considered as 
overwhelming pathogens owing to the greater impact of diseases such as AIDS and tuberculosis in 
comparison to the developed world.  Moreover poverty stricken areas have been associated with the 
increased spread of resistance owing to the poorer living conditions, prevalence of disease and closer 
proximity of inhabitants.  Therefore more importance is placed on antibiotics to treat all illnesses and 
their greater availability can lead to increased resistance (Extending the Cure Report, 1997). 
 
Antibiotics are readily available to buy without a prescription in developing countries, with the cost 
being equivalent to that seen in industrialised countries.  Therefore the cost of antibiotics determines 
the length of treatment a patient receives, with many patients unable to afford the full course of 
treatment.  Another issue with over-the-counter sale of antibiotics is the lack of involvement of 
qualified health professionals in diagnosing the illness and providing the correct antibiotics 
(Extending the Cure Report, 1997).    
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1.7 Secondary Care 
 
Antibiotic resistance is of particular concern in hospitals as increased morbidity can lead to an 
increased length of stay.  MRSA is an example of a Gram positive infection, which became an 
important threat to community health in the late 1990s as it was isolated in patients without recent 
hospital exposure or predisposing factors.  However, the situation has been worsened further by the 
difficulty in controlling Gram negative pathogens such as Escherichia coli, Acinetobacter baumannii, 
Klebsiella pneumoniae, and Pseudomonas aeruginosa.  Currently there are few antibiotics available to 
treat infections caused by Gram negative pathogens.  As resistance to antibiotics develops, treatment 
options will continue to narrow (Coia, 2006). 
 
1.8 Primary Care 
 
There is widespread and inappropriate use of antibiotics for viral illnesses in Primary Care, which has 
contributed to the emergence of bacterial resistance (Department of Health UK, 1998).  Eighty 
percent of antibiotic prescribing in the UK occurs in Primary Care, principally in the oral form, with 
approximately half of these prescriptions being used to treat respiratory tract infections (Department 
of Health UK, 1998).  Many of these RTIs are likely to be of viral origin and thus antibiotics are 
unlikely to offer benefit (Department of Health UK, 1998).  Infections account for forty percent of 
consultations in Primary Care (House of Lords, 2002-2003) so to minimise inappropriate antibiotic 
use (for example in treating viral illnesses) greater emphasis is required in improving communication 
between patients and doctors. 
 
1.9 Patients 
 
Patients benefit from using antibiotics because they can reduce their recovery time and also help them 
avoid health complications.  However, these positive outcomes must be balanced against problems 
associated with antibiotic use such as possible patient allergy to antibiotics, associated side effects and 
the development of resistance.  Increasing resistance inevitably requires the continued development of 
new antibiotics to treat infections, which requires involvement of the pharmaceutical industry. 
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1.10 Pharmaceutical companies 
 
The pharmaceutical industry has played a vital role in the progressive development of antibiotic 
agents to counter the development of antibiotic resistance.  However, the cycle of developing new 
antibiotics in order to counter developing resistance inadvertently exacerbates the underlying 
problem: new antibiotics are often developed to overcome the outcomes of injudicious use of existing 
treatments.  The pressures upon pharmaceutical companies to maintain an economic return from 
research and development has rendered antibiotic research unfavourable compared to other areas of 
therapeutics that involve lifelong therapy.  In 2001, Eli Lilly and Bristol-Myers Squibb ceased to 
develop new antimicrobial drugs, and it would appear that many more companies have followed this 
approach, since the average numbers of new antibiotics reaching the market have dropped from three 
per year to one since 2003 (FierceBiotech Newsletter, 2007).   
 
There is currently research being conducted by Swiss scientists into the development of a new class of 
antibiotics, with phase one of clinical trials started in summer of 2010.  It is hoped that the new 
antibiotics produced will be used to treat patients infected with highly resistant forms of bacteria, such 
as Pseudomonas aeruginosa and Escherichia coli (Swiss Info, 2010). 
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1.11 The control of antibiotics within the UK 
 
International and national guidance concerning the cost-effective use of antibiotics places a great 
emphasis on the use of a variety of interventions on prescribers and the public (Keuleyan and Gould, 
2001).  This has been exemplified in England by the guidance produced by the House of Lords 
Committee on Science and Technology published a report (House of Lords, 1998).  The report 
included guidance on the prudent use of antibiotics in humans as well as animals.  Of the many 
suggestions made, the key changes included the need to: 
- Produce formularies/guidelines with the involvement of prescribers, including junior staff at 
all hospitals. 
- Improve the process by which junior doctors prescribe antibiotics. 
- Improve the speed of susceptibility testing as most results take roughly forty-eight hours to 
obtain, in which time doctors may prescribe inappropriately. 
- Improve prescriber feedback by pharmacists and senior nurses. 
- Modify antibiotic licensing to allow some antibiotics to be used in hospitals only, therefore 
ensuring they cannot be unnecessarily used by General Practitioners. 
 
This resulted in a report published by the Department of Health (House of Lords, 1998) for antibiotic 
prescribing within Primary and Secondary Care.  These included: recommendations for the production 
of local guidance in accordance with the British National Formulary (BNF) and the development of 
the National Institute for Clinical Excellence (NICE) guidance on appropriate antibiotic prescribing.  
To make these changes work more efficiently, there was also a huge drive to integrate these changes 
in tandem with computerised decision support systems. 
 
In 2001, a follow up progress report (House of Lords, 2001) expressed concern over the time being 
taken to implement the original recommendations.  This led to the publication of a further report in 
2003 by the Select Committee on Science and Technology (House of Lords 2002-2003) who 
suggested improvements to ensure control over infectious diseases.  Their recommendations included: 
- Improved collaborative relationships across the services. 
- Ensuring sufficient well-trained health professionals. 
- The development of electronic capture, analysis and dissemination of information about 
infection across relevant organisations. 
- The production of clear evidence-based priorities for, and facilitate development of vaccines 
and diagnostic tests. 
- Funding research to provide an evidence base for improving diagnosis, treatment, prevention 
and control of infection. 
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- The secure supplies of vaccines in case of epidemics. 
- The provision of clear advice and information to the public.  
 
The current NHS structure below will provide an insight into how these recommendations can be met.  
 
 
1.11.1 The National Health Service (NHS) 
 
The Department of Health is led by the Secretary of State for Health and was responsible for 
government policies in England covering social care, the NHS and health. The NHS was launched in 
1948 and has been an ever-present service within the UK.  Figure 2 provides an overview of the core 
responsibilities of DH and how it delivered them. 
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Figure 2: Overview of DH responsibilities and delivery (Department of Health, 2009) 
 
 
 
A budget is set to deliver the core responsibilities, which in the financial year of 2004/2005 was over 
£79 billion public funds.  As Parliament is ultimately held accountable for the use of funds, the DH 
advises ministers on how the objectives can be best achieved, with all reports made fully available to 
the public. The DH has released many policies and publications regarding antibiotics and their 
control, especially since the emergence of antibiotics resistance as a worldwide concern in the mid 
1990‟s.  The Policy Research Programme (PRP) sector of DH funds Primary and Secondary research 
to achieve the DH‟s strategic objectives and Public Service agreements.  Figure 3 below demonstrates 
the impact these publications and policies may have had on antibiotic prescribing since 1994. 
 
In July 2004, a progress report on Healthcare Associated Infections (HCAIs) was released ((National 
Audit Office, 2004) and concluded that the implementation of the Select Committee on Science and 
Technology of the House of Lords recommendations was patchy, owing to the lack of data provided 
on prescribing, the limited progress in implementing national mandatory surveillance programme for 
the NHS and the lack of evidence for the impact of intervention strategies implemented.   
 
In 2006, the Department of Health produced a code of practice for the prevention and control of 
Healthcare Associated Infections (the Code).  The purpose of this Code is to aid NHS bodies to plan 
and implement strategies to control Healthcare Associated Infections.  The document outlines a 
number of criteria for NHS managers to ensure patient care is conducted in a clean environment, 
where the risk of HCAIs is kept as low as possible.  However each NHS body is expected to have 
 
Core Responsibilities 
 
 
Delivering better public 
service 
 
 
Invest in the 
modernisation of the NHS 
 
 
Ensure activity, 
performance and 
efficiency 
 
 
Managing the workforce 
of the DH 
 
 
Delivery 
 
 
Set overall policies on health issues 
 
 
Provision of health services through the 
National Health Service 
 
 
Employing independent contractors such as 
General Practitioners (GP's), dentists, 
pharmacists and opticians 
 
 
Managing performance against its statutory 
responsibilities 
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systems in place in order to apply sufficient evidence of compliance with the Code.  If the Code 
criteria are not met, the Healthcare Commission are provided authority to issue an Improvement 
Notice or place the body under “special measures”.  With regards to antibiotic prescribing, this Code 
details the need for antimicrobial prescribing policies and the production of local guidelines, 
containing drug, regimen and duration of antibiotics which are harmonised with that provided in the 
British National Formulary (BNF).  The need for procedures to ensure prudent antibiotic prescribing 
is also stated. 
 
The Code was revised in 2008, and again in December 2009 to reflect the changes within healthcare 
regulation since the establishment of the Care Quality Commission (CQC) in 2009.  The aim of the 
CQC is to independently regulate health and social care in England, with the provision of increased 
powers to enforce compliance to the Code.  The revisions to the Code have also increased the detail 
within the criteria set for antibiotic prescribing.  Local prescribing guidelines are now not only 
required to be harmonised with the BNF, but also observe local Primary and Secondary Care 
guidance.  Secondly the need criterion for prudent antibiotic prescribing is now the responsibility of 
the Antimicrobial Management Team present within Secondary Care and includes the need for 
antimicrobial stewardship, with an on-going programme of audit, revision and update. 
 
The DH set the objective of reducing the prescribing of antibiotics within their Health Protection 
policies, resulting in the production of 139 policies and publications released from the DH since 1994 
targeting: Primary Care, Secondary Care, care homes and the public.   
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Figure 3:  Timeline of antibiotics prescribing and publications released within the United 
Kingdom 
 
 
 
All policies and publications released by the DH were searched using the Department of Health 
website.  “Antibiotics” and “Antimicrobials” were used as the search terms to retrieve all relevant 
policies and publications.  Figure 3 shows that 139 policies and publications have been released from 
the DH since 1994 to target Primary Care, Secondary Care, Care Homes and the public.  The number 
of publications released annually has fluctuated between the years 1997 to 2005, however between 
2006 and 2008 there has been an increasing number of publications released, which predominantly 
target Primary Care.  Figure 3 also shows that the level of antibiotic prescribing in 2009 has now 
increased to similar levels of antibiotic prescribing recorded in 1994, with antibiotics being prescribed 
the least in the financial year 2000-2001.  Therefore the increasing number of publications released by 
DH appears to have had no direct impact on national antibiotic prescribing, with the increase in 
publications released since 2004 actually coinciding with a period of increased national antibiotics 
prescribing.  It is therefore important to further analyse the role of SHAs and PCTs as antibiotics 
prescribing may have been affected by their capabilities in implementing DH publications. 
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1.11.1.1 Strategic Health Authorities 
  
The SHAs‟ role is to ensure that the NHS (in their region) runs effectively and that NHS services, 
staff and organisations are developed to meet the needs of the future without directly providing any 
services.  In order to achieve these targets SHAs are required to work closely with local health 
organisations to ensure that they operate effectively and in line with government policy, whilst also 
helping shape national policy based on local evidence and best practice.  Regulators such as the Care 
Quality Commission, Monitor and the Audit Commission, as well as professional bodies such as the 
General Medical Council also worked in collaboration with SHAs to ensure services work well and 
were fit for purpose.  Originally twenty-eight Strategic Health Authorities were created in 2002 which 
were reduced to ten in 2006 (National Health System, 2009).  The role and objectives of SHAs are 
summarised in Figure 4 below. 
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Figure 4:  The role and objectives of the SHA (SHA and PCT structure, 2011) 
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1.11.1.2 Primary Care Trusts 
 
In April 2010 there were 152 PCTs which in total were responsible for working with around 37, 000 
general practitioners and approximately 21, 000 NHS dentists (SHA and PCT structure, 2011).  PCTs 
also play a major role in commissioning Secondary Care and providing Community Care Services, 
which in total covers eighty percent of the NHS budget.  Some of the responsibilities and how they 
are delivered are detailed in Figure 5.  
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Figure 5: Roles and responsibilities of PCTs (SHA and PCT structure, 2011) 
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A key responsibility of all Medicines Management teams present within PCTs is the control of 
antibiotic prescribing, with their ability to do so being affected by regional differences in 
demographics such as ethnicity, age, socio-economic status, average size of family and prevalence of 
conditions.  The organisational structure of Medicines Management teams and their relationship with 
neighbouring Acute Trusts can also impact on their ability to control antibiotic prescribing.  Acute 
Trusts play a significant role in controlling antibiotic resistance by employing staff to analyse 
antibiotic prescribing trends, resistance and sensitivity patterns in order to inform prescribers of 
appropriate antibiotic use.  The advantages of collaboration between Medicines Management teams 
and their local Acute Trusts is the potential to implement cohesive strategies such as formulary 
implementation and maintenance, antibiotic prescribing surveillance and feedback to prescribers, 
although some PCTs provide no formal communication devoted to this mission.  The structure of 
Medicines Management teams can also have a large impact on antibiotic prescribing, with possible 
factors affecting team structure shown below in Figure 6. 
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Figure 6:  Possible factors affecting Medicines Management team structure 
 
 
The structure of any Medicines Management team depends on the balance of management influence 
against budgetary constraints with Heads of Medicines Management deciding to either control 
antibiotic use with the appointment of an Antibiotic Pharmacist, or delegating the responsibility to all 
or certain members of the team.   In doing so, the Head of Medicines Management may adopt a 
democratic, autocratic or laissez-faire style of management to maximise their team potential.  The 
chosen approach may either motivate or de-motivate members of the team, which in turn improve or 
worsen antibiotic prescribing. 
 
Budgetary constraints may determine the location of the Medicines Management team with members 
of the team being based at GP surgeries, and thus be called “practice pharmacists” or “practice 
technicians” From surgeries, pharmacists and/or technicians can complete audits and housekeeping 
tasks whilst providing direct feedback to prescribers.  The whole Medicines Management team may 
also be located in a central office from where they conduct their daily tasks.  This remote approach 
requires more influential education and feedback methods, such as formulary guidance and 
newsletters. Pharmacy technicians may be employed within Medicines Management teams to 
complete the housekeeping functions, although the number of technicians employed at any given PCT 
can fluctuate greatly with some Medicines Management teams‟ only employing pharmacists.  The 
Medicine Management 
Structure 
Qualifications 
Experience 
Number of pharmacists and/or 
pharmacy technicians 
Influence of management 
Team balance between management and 
housekeeping duties 
Employment of specialist pharmacists 
Budget 
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decision to employ technicians may be based on their lower salaries compared with that of 
pharmacists, thus making their employment an attractive option. 
 
 
1.11.1.3 How did SHAs and PCTs attempt to control antibiotic 
prescribing? 
 
Figure 4 shows that SHAs cannot directly influence prescribers or the public and are thus reliant on 
PCTs to achieve DH objectives.  One method by which SHAs aid PCTs are by providing analysis of 
current antibiotic prescribing using data provided by the NHS Prescription Services.  The NHS 
Prescriptions Service retrieve all prescriptions dispensed in Primary Care by pharmacists, appliance 
contractors, dispensing doctors and items personally administered by doctors in order to produce 
prescribing reports.  This service only covers prescriptions dispensed in England, thus those 
prescriptions which are written in the rest of the United Kingdom but dispensed in England are 
included.  Conversely, prescriptions written in England but dispensed in the rest of the United 
Kingdom are not included, also items dispensed in hospitals or on private prescriptions are not 
included.   
 
The NHS Prescription Service uses the retrieved data to produce several Prescribing Information 
Reports, including the Prescribing Analysis Reports and the Practice Prescribing Report.  The 
retrieved data is also made available to PCTs, SHAs and the DH in the form of an electronic database 
called PACT.  The Prescribing Analysis Report is produced at monthly and quarterly periods and 
contained analysis of the prescribing which has taken place during the reporting period.  The Practice 
Prescribing Report is further broken down into individual prescribers with results also summarised at 
surgery level.  The data covered within these reports include, the total level of prescribing, a 
breakdown of prescribing in the 6 highest cost BNF Therapeutic Groups, the top 20 leading cost drugs 
in the practice and the top 40 BNF Sections by cost in the practice.  Examples of Prescribing Analysis 
Report data are shown in Figures 7 and 8.   
 
Data supplied by the NHS Prescription Services can be used to help each SHA and PCT benchmark 
themselves against their peers and thus motivate an improvement or maintain success achieved.  The 
ePACT database can also be used to find the national financial cost of antibacterial prescribing, with 
the latest figures from financial year 2008/2009 showing that antibacterial prescribing had cost just 
under £150 million.  This alone highlights how much money has been spent to treat infections within 
Primary Care and why it is so important to control antibiotic prescribing, from just a financial 
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perspective.  Figures 7 and 8 provide examples of the type of data provided by the NHS Prescription 
Services. 
 
Figure 7:  A representation of antibacterial prescribing that can be produced at a PCT and 
SHA (April 2008 - March 2009) 
 
Figure 7 shows the prescribing of antibacterial drugs for all SHAs or PCTs in a league table format 
ascending from lowest to highest antibacterial prescribers.  The outcome measure used in Figure 7 is 
Items per antibacterial STAR (101)-PU. 
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Figure 8: A representation of antibacterial prescribing spends that can be produced at a PCT 
and SHA (April 2008 - March 2009) 
 
 
 
Figure 8 shows the overall spend on antibacterial drugs within SHAs or PCTs in a league table format 
ascending from lowest to highest antibacterial prescribers.  The outcome measure used in Figure 8 is 
NIC (£) per 1000 antibacterial STAR-PU. 
 
1.12 The future of antibiotics 
 
Antibiotics have gone from a period of optimism about their ability to treat infections to a general 
view of pessimism owing to the development of resistance.  Therefore it is important to examine the 
strategies used since the development of antibiotics in order to understand how this situation occurred.  
Antibiotics have been used readily to treat infections as there was always an assumption that new 
drugs would be produced to overcome the resistance caused to previous generations of antibiotics.  
However, very few new classes of antibiotics have been produced over the last forty years, which 
therefore requires the prudent use of existing antibiotics.  The lack of new classes of antibiotics 
produced is the result of the amount of financial return achieved by pharmaceutical companies or their 
inability to produce new antibiotics.  It has been stated that antibiotic research and development will 
cost any pharmaceutical company roughly 18.5% of their sales achieved (Amyes, 2001).  In 
comparison to other drug areas this percentage is much higher.    Therefore pharmaceutical companies 
are unwilling to invest so much into producing antibiotics, especially when there is no guarantee that 
they will reach the market.   
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2. Research question 
 
Which strategic and operational interventions are effective in improving antibiotic prescribing 
practices in the UK? 
 
2.1 Main aims and objectives 
 
2.1.1 Aims  
 
To identify and evaluate previously developed strategic and operational interventions designed to 
improve antibiotic prescribing. 
 
To determine optimal strategies and procedures that lead to improvements in antibiotic prescribing. 
 
To design and implement an intervention (or interventions) that lead to improvements in antibiotic 
prescribing. 
 
2.1.2 Objectives 
 
1. To undertake a systematic review designed to assess interventions aimed at improving 
antibiotic prescribing. 
2. To compare the interventions analysed within the systematic review to the interventions 
implemented in the National Health System within the UK. 
3. To undertake qualitative research designed to explore the impact of the method used to 
improve antibiotic prescribing in the National Health System within the UK. 
4. To identify an intervention that can be implemented within a PCT situated in the West 
Midlands region. 
5. To devise and implement an intervention within a PCT situated in the West Midlands region. 
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3. Research design and methodological 
considerations 
 
The present chapter should be referred to in association with the methods provided within Chapters 4 
and 5 of the present thesis in order to provide comprehensive details on the research designs and 
methodological considerations made regarding the systematic review and qualitative research aspects 
of the present research.   
 
3.1 Research design and methodological considerations 
involved in the conduct of the systematic review to assess 
interventions aimed at improving antibiotic prescribing 
practices   
 
3.1.1 The title 
The title of any systematic review is important in order to provide readers with enough information to 
decide whether the systematic review is relevant to them.  Two methods which could have been used 
to formulate the present systematic review title were PICO (Huang et al., 2006) and the Cochrane 
Collaboration standard format for titles (Cochrane, 2011).   PICO is commonly used to develop 
review questions and stands for population, intervention, comparison and outcomes.  The Cochrane 
Collaboration standard format aims at conveying information as quickly as possible by stating the 
intervention for any given problem in any given category.   
 
The title (in the present review) had to remain open, in order to incorporate as many studies as 
possible to confirm existing hypotheses or discover new hypotheses rather than stating the 
intervention for any given category. The only facet that needed to be addressed was the outcomes 
used, as it was essential for studies to mention how antibiotic prescribing was improved.  For these 
reasons, the method of question formulation used in the present review was PICO and the present 
review title was: “A systematic review to assess interventions aimed at improving antibiotic 
prescribing practices.” 
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3.1.2 Methodological considerations regarding outcome 
measures 
It is important to further analyse the use of outcome measures within the present review, given that 
outcome measures is the key component.  There are many ways of measuring improvements in 
antibiotic prescribing, such as; reductions in antibiotic prescribing, compliance with prescribing 
guidelines, reductions in cost of prescribing, reductions in antibiotic-associated conditions, or reduced 
admissions  to hospitals.  Studies reporting improvements in antibiotic prescribing may also use a 
combination of these outcome measures in order to report their results.  The present review will 
therefore require the division of study results into primary (essential) and secondary outcome 
measures as it is the primary results that will be addressed if sufficient studies are identified. 
 
3.1.3 Methods of selecting study outputs    
The decision on which studies should be included within the present review are based on the design of 
those studies and not the results achieved, therefore it is essential to produce inclusion criteria within 
the present review to ensure studies adhere to certain standards of publication.  This will be achieved 
in the present review through the QUOROM statement for reporting results of a systematic review 
(Mother, 1999) and the use of a study quality assessment. 
 
3.1.4 Quality assessment 
Guidelines have been published by international groups, such as the International Committee of 
Medical Journal Editors (ICMJE) and Committee on Publication Ethics (COPE) to ensure that each 
type of study published contains the required information.  Such guidelines, as important as they are, 
lack sufficient detail to ensure all important information is included. To overcome the lack of essential 
information contained in their respective study type, international groups have also published 
guidelines that allow readers to evaluate studies effectively. These include; the CONSORT 
(Consolidated Standards of Reporting Trials) guidelines for randomized trials (Altman, 1996; Begg et 
al., 1996; Moher et al., 2001), QUORUM (Quality of Reporting of Meta-analyses) (Clarke, 2001), 
MOOSE (Meta-analysis Of Observational Studies in Epidemiology) (Stroup et al., 2000) for meta-
analyses, and STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) for 
various sorts of observational studies (the majority of clinical studies in surgical disciplines) (Von 
Elm et al., 2000).   
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A decision was made to use the quality assessment tool produced by the EPOC group (Cochrane 
Library, 2007) in the present review as their scope of work focuses on interventions designed to 
improve professional practice and thus relates to the present review.  However, a limitation of the 
criteria described by the EPOC group was the focus of quality analysis in randomized controlled 
trials, quasi-randomised controlled trials, before and after studies and interrupted times series.  
Therefore an additional quality assessment tool had to be incorporated within the present review to 
analyse studies that may not have been accounted for by the EPOC group.  This was achieved with the 
checklist designed by the Centre for Statistics in Medicine at Oxford University (NICE, 2005).     
 
3.1.5 Dichotomous data 
Dichotomous data are data from outcomes that can be divided into two categories, where each 
participant must be in one or other category and cannot be in both (Cochrane library).  Dichotomous 
data in the present review could be exemplified by data showing antibiotics prescribed in the 
intervention group compared to antibiotics prescribed in the control group.  However, Ritchie and 
Lewis (2003) stated that it is possible for the data within the studies to be not truly dichotomous and 
thus a decision has been made to also consider antibiotics prescribed before and after an intervention 
has been implemented as dichotomous data in order to improve the ease of analysis and interpretation.   
 
3.1.5.1 Summarising dichotomous data 
 
Summary statistics can be used for dichotomous data within the present review in order to predict the 
likelihood of an intervention being able to improve antibiotic prescribing.  As mentioned earlier, there 
are many outcome measures that could be applied to the data and thus a decision has been made in the 
present review to define improvements in antibiotic prescribing as a reduction in antibiotic 
prescribing, as the impact can be measured statistically. 
 
Four summary statistics that can be used to analyse dichotomous data are; risk ratio, odds ratio, risk 
difference and numbers needed to treat.  Risk is the probability of having a specific event, with the 
event being classed as either positive or negative outcome.  An alternative statistic that can be used to 
measure the likelihood of an event occurring is odds ratios, which is the ratio of events to no-events.  
In terms of antibiotic prescribing, odds ratios could be used to calculate the ratio of antibiotics 
prescribed against antibiotics not being prescribed.   
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As well as comparing the risk in one group in comparison to another, it is also possible to compare 
them in terms of absolute difference between the two groups that is attributable to the experimental 
intervention (defined as risk difference).  Another way of analysing risk difference could be through 
the use of numbers needed to treat, where there are attempts to avoid the event.     
 
When deciding on the summary statistic for the present systematic review it was important to consider 
three key factors; communication, consistency of statistics across different studies and the mathematic 
properties.    The inclusion criteria set within the present review will lead to the presence of many 
different types of study designs.  Therefore it is important to consider the mathematical properties of 
summary statistics in order to ensure variance is estimated reliably.   Numbers needed to treat does 
not provide a useable estimate of its variance and thus cannot be used within the present review. 
 
A direct comparison of odds and risk ratios, in terms of their ability to communicate results shows 
that results analysed using risk difference can be put into words easier than results analysed using 
odds ratios.  However, odds ratios will be the summary statistic used in the present review as it most 
accurately measures the effectiveness of interventions in reducing antibiotic prescribing.      
 
3.2 Research deign and methodological considerations 
involved in the conduct of the qualitative research to assess 
interventions aimed at improving antibiotic prescribing 
practices   
 
 
There are many methods of qualitative research that could be used to collect the required data, 
however the choice of method could impact the results of a study.  Therefore the first stage of this 
qualitative research required a choice of data collection method.  Ritchie and Lewis (2003) divided 
qualitative methods into naturally occurring and generated data, with Table 1 summarising these in 
terms of the methods involved, the context and the detail they can obtain. 
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Table 1: An explanation of the data collection methods, their context and the detail they can 
obtain (Ritchie, J. and Lewis, J. (2003). 
 
 
Table 1 shows that both naturally occurring and generated data provide many advantages to collecting 
qualitative data, therefore the present research will combine both methods in order to achieve 
understanding in the natural context and allow interviewees to provide their personal knowledge on 
related issues.  Both generated and naturally occurring data were further analysed to determine how 
these methods should be used in the present research. 
 
  
 Naturally Occurring Data Generated Data 
Methods 
Involved 
- Observations 
- Documentary analysis 
- Discourse analysis 
- Life stories 
- Narratives 
- Interviews 
- Group discussions 
- Focus groups 
Context 
Preferred if understanding is critical in the 
natural context i.e. by observing or 
experiencing 
Allows interviewees to describe the 
personal or organisational contexts in 
which the research issue is located 
and how they relate to it 
Obtaining 
sufficient 
accurate detail 
 
- If people are unlikely to be willing to talk 
frankly about something 
- If understanding recent history is critical to 
making sense of an interaction so that existing 
data will not „speak for themselves‟ 
 
A well designed structure to 
generated data provides a truthful 
account 
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3.2.1 Conduct of data generation 
 
Table 1 shows the variety of methods that can be used to obtain generated data, however interviews, 
focus groups and questionnaires were further evaluated as these three choices offer different 
opportunities for the type of data sought, the subject area and the nature of the study group (see Table 
2). 
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Table 2: Differences between face to face interviews, focus groups and questionnaires (Ritchie, J. and Lewis, J. (2003). 
 
 Focus groups Interviews Questionnaires 
Nature of data 
Offer less opportunity for detailed interviewee 
accounts 
Allow depth of focus on the individual 
Data are affected by the characteristics 
of the respondents (e.g. their memory, 
knowledge, experience etc.) 
Allows interaction with other interviewees and thus 
provides opportunities to illuminate the generation of 
accounts 
Used to understand personal context and 
detailed subject coverage 
Offer less opportunity for detailed 
interviewee accounts 
Provide opportunities for interviewees to refine what 
they say 
 
 
Enhances creative thinking, solutions and strategies   
Provide a social context   
Subject matter 
Enables group discussions on abstract, intangible or 
conceptual topics 
Addresses very complex systems, processes 
or experiences 
Respondents may not report their beliefs, 
attitudes, etc. accurately 
Allow analysis of views and attitudes of interviewees 
Offers opportunity to understand 
motivations and decisions 
Care is required in the composition of 
questionnaires in order to retrieve the 
required information 
Care is required in the composition and conduct of the 
group, unless social norms are desired 
 
 
Research 
population 
The need to come to a common location will inhibit 
the chances of the research occurring 
More accessible to potential interviewees 
and thus best for busy study groups 
Appropriate when targeting a number of 
respondents although low response rate 
is common 
Differences in status should be avoided 
Appropriate if interviewees have nothing in 
common or if the fact they know each other 
restricts their contribution 
They can be extremely efficient at 
providing large amounts of data, at 
relatively low cost, in a short period of 
time 
Appropriate for interviewees who prefer the comfort 
of group environment rather than on-to-one discussion 
 
They allow anonymity which can 
encourage participation and involvement 
Smaller groups allow more privacy in research and 
allow interviewees more time to talk 
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Based on the analysis of focus groups, interviews and questionnaires a decision was made to use 
interviews in the present research in order to promote personal context and detailed subject coverage.  
Focus groups were not considered owing to the potential for conflicts to occur between interviewees, 
and questionnaires were not considered as the interviewer/researcher would not be able to instantly 
expand on any specific answers provided.  Further advantages of interviews are summarised below in 
Table 3. 
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Table 3: Key features and advantages of interviews (Ritchie, J. and Lewis, J. (2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interviews can be conducted in a structured, semi-structured or unstructured format.   
A decision was made to use semi-structured interviews in the present research in order to provide 
flexibility in the wording and order of the questions set within the checklist whilst also allowing for 
any additional unplanned questions to follow-up on any points made by interviewees.  Structured 
interviews were not considered because of the strict ordering of questioning required and the lack of 
flexibility in asking follow-up questions to interviewees.  Unstructured interviews were not 
considered for use as the interviews may not have maximised the information retrieved owing to the 
lack of question structuring (Robson, 2011).   
 
Feature Advantages 
Combine structure with flexibility 
Flexibility is sufficient enough to allow topics to 
be covered in a structure suitable to the interviewee 
The interviewer can fully probe and explore 
responses 
Allow the interviewer to respond to relevant issues 
raised spontaneously by the interviewee 
The interview is interactive in nature 
Interaction between the interviewer and 
interviewee generates material 
An initial question can be asked by the interviewer 
in order to encourage the interviewee to answer 
questions openly 
The interviewees answer will determine the 
interviewers next intervention 
The interviewer uses a range of probes 
and other techniques to achieve 
penetration, exploration and 
explanation of answer 
The interviewer will use follow-up questions to 
obtain a detailed understanding of the interviewees 
meaning to initial “surface” level answers 
Allows the interviewer to explore fully all the 
factors that underpin interviewee‟s answers 
The interview is generative 
The interviewee will at some point be directed (by 
the interviewer or themselves) to new avenues of 
thought 
Interviewees may also be invited to put forward 
ideas or propose solutions on a particular topic 
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3.2.2 Naturally Occurring Data 
 
The second stage of qualitative research involved the retrieval of naturally occurring data on 
interventions used to improve antibiotic prescribing.  There were many types of naturally occurring 
data that could be obtained, such as ethnographic accounts, narrative analysis, content analysis, 
conversation analysis, discourse analysis, analytic induction, grounded theory and policy and 
evaluation analysis.  A decision was made to use a combination of naturally occurring data in the 
present research consisting of ethnographic accounts, content analysis, conversation analysis and 
policy and evaluation analysis.  This approach will be subsequently referred to as the “combined 
approach”. 
 
3.2.2.1 Ethnographic accounts 
 
Ethnography was a key element of the qualitative research as it allowed the research to evolve, 
without the need for pre-structuring the research by using sensitive methods that do not disturb the 
research setting (Punch, 2005).  Ethnographic accounts were obtainable from naturally occurring data 
but not from the conduct of case studies, thus being the key reason why case studies were not used in 
the present research.  Table 4 summarises the key differences between case studies and ethnographic 
accounts. 
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Table 4: A summary of the key characteristics needed to conduct case studies and ethnographic 
accounts (Punch, 2005). 
 
Case studies Ethnographic accounts 
The case requires identification of the boundaries from 
the context 
Shared cultural meanings of the group are crucial to 
understanding its behaviour 
The case requires clarity on the need for the study and 
translates into specific purposes and research 
questions 
Ethnographic study will be designed, and its data 
collection technique organised in order to elicit 
required knowledge from informant participants 
Multiple sources of data and multiple data collection 
methods are likely to be used, typically in a 
naturalistic setting 
The group will always be studied in its natural setting.  
Therefore, the researcher has to become part of that 
natural setting 
 Ethnography is likely to be an unfolding, evolving 
study.  Research questions and hypotheses will be 
used, but are likely to develop as the study proceeds 
 Any data collection technique might be used, but 
fieldwork is essential 
 Ethnographic data collection is typically prolonged 
and repetitive in order to be comprehensive and 
detailed 
 
3.2.2.1.1 Observation methods 
 
Observation is very closely associated with the conduct of an ethnographic study, where the actions 
and behaviour of people in a natural setting are observed, analysed and interpreted (Robson, 2011).  
There are two key types of observations, participant and structured, with the present research adopting 
the participant observation approach.  The key differences between both approaches are shown below 
in Table 5. 
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Table 5:  Key differences between participant and structured observations (Robson, 2011). 
 
Participant observation Structured Observation 
The observer seeks to become a member of the group 
being observed. 
The observer takes a detached “pure” observer stance. 
The observer has to establish some role within the 
group. 
The aim is to quantify behaviour. 
The observer is required to conceal their role as an 
observer, although the observer is required to inform 
those in the setting about the research. 
The observer might use qualitative approaches but has 
tended towards fixed designs and quantitative, 
structured methods. 
The observer is more likely to use flexible designs and 
qualitative, unstructured approaches. 
 
 
The participant observations were conducted informally in order to allow considerable freedom in 
what information was gathered and how it was recorded in order to achieve a higher level of 
complexity and completeness in data retrieved.  However, disadvantages of the informal approach 
included lower reliability and validity of data retrieved (Robson, 2011).  The very nature of 
participant observations mean that data was collected opportunistically, from the questions asked and 
answers provided by group members.  This information could then be used to describe the key 
information retrieved.   
 
3.2.2.2 Content, conversation and policy analysis 
 
In addition to ethnographic accounts, the researcher also conducted analysis of documents, 
conversations and policies with Table 6 summarising the sources of information used for each. 
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Table 6: Sources of information used for analysis of documents, conversations and policies 
(Robson, 2011). 
 
Documents Conversation Policies 
All documents produced by the 
Medicines Management, Public 
Health departments that contain the 
word “Antibiotic” or 
“Antimicrobial” 
All colleagues working within the 
Infection Control department of 
Public Health and the Medicines 
Management department 
All policies produced by the 
Medicines Management, Public 
Health departments that contain the 
word “Antibiotic” or 
“Antimicrobial” 
Documents included: 
- Minutes of meetings 
- Letters 
- Memoranda 
- Diaries 
- Speeches 
- Prescribing software 
 
Colleagues included: 
- Head of Medicines 
Management 
- Senior Pharmacists 
- Pharmacy Technicians 
- Practice Pharmacists 
- Infection Prevention 
Nurses 
- Data analysts 
Policies included: 
- Clinical guidelines 
- Algorithms 
- Formularies 
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4.  A systematic review to assess interventions aimed 
at improving antibiotic prescribing practices 
 
4.1 Background 
 
Traditional reviews (such as literature reviews, narrative reviews, critical reviews or commentaries) 
have been used by individuals to ensure they keep up-to-date with the ever increasing evidence that 
accumulates in their field of interest.  In some instances the level of evidence has increased so much 
that individuals find it difficult to read and critically evaluate evidence on a regular basis.  This 
ultimately led to literature reviews becoming unreliable sources of information, especially after 
Antman et al (1992) and Lau et al (1992) highlighted the inadequacies of traditional reviews.   This 
was based on their findings that if original studies of the effects of clot busters after heart attacks had 
been systematically reviewed, the benefits of therapy would have been apparent as early as the mid-
1970s.  Secondly, narrative reviews were woefully inadequate in summarising the current state of 
knowledge. 
 
To overcome the unreliability of literature reviews (as stated by Antman et al (1992) and Lau et al 
(1992 above), the emphasis has now been placed on conducting systematic reviews.  A systematic 
review focuses on answering a given research question by identifying, appraising and synthesising all 
the empirical evidence that meets pre-specified eligibility criteria (The Cochrane Library, 2007).  The 
conduct of systematic reviews requires the explicit explanation of methods aimed at minimizing bias, 
in order to produce more reliable findings that can be used to inform decision making (The Cochrane 
Library, 2007). 
 
The research question set in section 2 of the thesis was to identify interventions to improve antibiotic 
prescribing practices.  In total there have been four systematic reviews conducted regarding 
interventions to improve antibiotic prescribing practices (Arnold and Straus, 2005; Davey et al., 2005; 
Steinman et al., 2006; Ranji et al., 2008).  Table 7 summaries the key differences in the conduct of 
these four systematic reviews. 
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Table 7: Analysis summary for the four systematic reviews published regarding interventions to improve prescribing practices 
  
Interventions to improve 
prescribing practices in ambulatory 
care (Arnold, S. R. and S. E. Straus, 
2005) 
Interventions to improve prescribing 
practices for hospital inpatients (Davey, 
P., E. Brown, et al., 2005) 
Improving antibiotic selection - a 
systematic review and quantitative 
analysis of quality improvement 
strategies (Steinman, M., S. Ranji, et al., 
2006) 
Interventions to reduce 
unnecessary antibiotic 
prescribing a systematic review 
and quantitative analysis (Ranji, 
S., M. Steinman, et al., 2008) 
Types of studies included 
within the systematic 
review 
Randomised Controlled Trials, Quasi 
Randomised Controlled Trials, 
Controlled Before and After Studies 
and Interrupted Time Series Studies 
Randomised Controlled Trials, Quasi 
Randomised Controlled Trials, Controlled 
before and after studies and Interrupted 
Time Series (with at least 3 data points 
before and after implementation of the 
intervention) 
Patient- and Cluster-Randomised Controlled 
Trials, Controlled Before-after Studies and 
Interrupted Time Series (with at least 3 data 
points before and after implementation of the 
intervention) 
Randomised Controlled Trials, 
Controlled Before and After 
Studies and Interrupted Time 
Series Designs 
Participants included within 
the systematic review 
Studies of healthcare consumers, 
qualified physicians of all ages 
and level of experience and physician 
extenders who prescribe 
antibiotics and provide primary care in 
community or academic 
ambulatory settings were included 
Health care professionals who prescribe 
antibiotics to hospital in-patients receiving 
acute care.  
Treatment of patients presenting with acute 
infections in the outpatient setting 
Antibiotic prescribing for acute 
outpatient illnesses for which 
antibiotics are inappropriately 
prescribed 
Excluded participants Studies including only medical trainees 
The review excluded interventions 
targeted at residents in nursing homes or 
other long term healthcare 
settings. 
    
Exclusion criteria 
Studies published in languages other 
than English 
Descriptions of interventions to change 
antibiotic prescribing 
without measurement of the effect of these 
interventions on prescribing 
or other outcome measures 
Studies published in languages other than 
English 
Studies published in languages 
other than English 
Surveys of hospitals to establish the range of 
measures used to 
control or optimise antibiotic prescribing 
    
Inclusions   Studies in all languages     
Search method for study 
identification 
Embase and Medline OVID and EPOC 
Cochrane, Medline, EMBASE, EPOC, 
Personal file and contacting authors 
EPOC, MEDLINE, EMBASE, CINAHL, 
manual review of article bibliographies 
EPOC, Medline, EMBASE, 
CINAHL, manual review of article 
bibliographies 
Data collection & analysis 
Assessed by both authors according 
to the criteria described by the EPOC 
group 
Criteria described by EPOC group Criteria described by EPOC group Criteria described by EPOC group 
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Table 7 highlights a number of key areas within each systematic review and the differences 
and comparisons that were used to achieve the set aims and objectives for each study.  The 
results of these systematic reviews also provided an insight into which interventions have 
been reviewed previously and how effective they have been in improving antibiotic 
prescribing, these will be discussed below.   
 
The two systematic reviews conducted by Steinman and Ranji both produced three key 
conclusions.  Firstly more “active” interventions (one-to-one or small group interactions) 
were superior to less active interventions (lectures, distribution of printed materials) within 
the same study.  Secondly trials using clinician education alone produced superior 
performance in trials compared with trials that combined clinician education with audit and 
feedback.  Finally they did not find interactive, multifaceted, or sustained interventions to be 
more effective than their counterparts.   
 
A further conclusion made in the review: Interventions to reduce unnecessary antibiotic 
prescribing a systematic review and quantitative analysis (Ranji and Steinman, 2008) was that 
broad campaigns using mass media campaigns and active clinician education produced 
significant reductions in overall antibiotic prescribing. 
 
Arnold and Straus (2005) also agreed with the conclusions made by Steinman and Ranji 
however elaborated further to suggest that many of these studies failed to provide information 
on the durability of the effect of the intervention and the cost-effectiveness of such 
interventions have not been assessed. Arnold and Straus (2005) also stated that the most 
effective interventions to improve antibiotic prescribing appear to be condition and situation 
specific and thus the ultimate goal of any intervention is to overcome barriers to change.   An 
example of this is the use of delayed prescriptions to allow prescribers to overcome patient 
demand for antibiotics.   
 
The systematic review conducted by Davey and Brown (2005) provided a different insight 
into the impact of interventions as they broadly categorised all interventions as either being 
“persuasive”, “restrictive” or “structural”.  Persuasive interventions were seen as those that 
could influence prescribers into changing their behaviour, such as educational material, 
educational meetings, audit and feedback. Restrictive interventions were interventions that do 
not allow prescribers to influence prescribing, such as formulary restriction and automatic 
stop dates.  Structural interventions were seen as changes within processes or organisations 
that may influence prescribing, such as changing from paper to computer records.   
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The main conclusion within this review was that restrictive interventions were more effective 
than persuasive interventions in improving antibiotic prescribing. This conclusion therefore 
contradicts with the findings of the other systematic reviews discussed as they all focused on 
persuasive interventions to improve antibiotic prescribing.   
 
The review of these four key systematic reviews has highlighted the need for a further 
systematic review to be conducted to assess interventions aimed at improving antibiotic 
prescribing practices in order to overcome the exclusion criterion applied in the respective 
studies.  In doing so, a comprehensive systematic review can be completed which analyses 
studies that may have been missed within previous systematic reviews.  Therefore the present 
review will apply no restrictions on the type of studies and participants included, and will not 
exclude studies written in other languages.  Section 4.4 to section 4.9 will provide further 
details of the methods used within the present review that will achieve the set aims and 
objectives as shown below. 
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4.2 Aims 
 
 To explicitly identify interventions that alone, or in combination, are effective in 
improving antibiotic prescribing, in a reproducible manner.  
 To systematically review the literature and, where appropriate, meta-analyse studies 
investigating methods to improve antibiotic prescribing. 
 
4.3 Objectives 
 
1. To undertake a systematic review designed to assess interventions aimed at 
improving antibiotic prescribing and use, through: 
a) Development of citation terms. 
b) Selection of relevant databases to search. 
c) Development and application of specific inclusion and exclusion criteria to retrieved 
studies. 
d) Development of quality assessment checklists. 
e) Tabulating information from studies included in the systematic review. 
f) Summarise effects observed in studies included in a systematic review. 
g) Determining whether meta-analysis is possible and/or appropriate based on the study 
effects observed. 
h) The use of a funnel plot to explore the possibility of publication and related biases of 
studies included in the systematic review. 
i) The use of an L‟Abbe plot to compare the significance in results, with respect to the 
intervention versus control result comparisons. 
j) The analysis of results to determine the effectiveness of strategies in improving 
antibiotic use. 
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4.4 Criteria for considering studies for this review 
 
No exclusion criteria were placed on the type of study, participants, interventions, or outcome 
measures within this systematic review.  Instead a flow chart was used to determine whether 
studies contained the required criteria for inclusion, as recommended by the QUOROM 
statement for reporting results of a systematic review within the systematic review (Mother, 
1999), see Figure 9. 
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Figure 9: Flow chart showing the method to select outputs from the review citation 
search strategy as recommended by the QUOROM (Mother, 1999) statement for 
reporting results of a systematic review 
 
 
  
Potentially relevant studies identified and 
screened for retrieval  
(n=365077) 
Studies excluded (n=364270) because: 
- No mention of antibiotics in the title 
- No mention of intervention in the title 
- No mention of prescriber involvement in the                 
title 
 
Studies retrieved for more detailed 
evaluation (n=807) 
Duplicate studies excluded (n=396) 
 
Studies retained for more detailed 
evaluation (n=411) 
Studies excluded (n=262) because of no detail 
present in the abstract concerning: 
- Intervention 
- Prescriber involvement  
- Method used 
- Data collection and analysis 
- Conclusion  
 
Studies excluded (n=124) because of no detail 
present in the full study concerning: 
- Intervention 
- Prescriber involvement  
- Objectives 
- Selection criteria 
- Data collection and analysis 
- Main results (including details of results from 
control group, as well as those from intervention 
group) 
- Reviewers‟ conclusion  
Studies with usable information within systematic review 
(n=25) 
Studies retained for more detailed 
evaluation (n=149) 
 
 
 65 
4.5 Search methods for identification of studies 
 
The mind mapping technique (Buzan, 2000) (Appendix 1) was used in order to compile a 
comprehensive catalogue of concepts relevant to the issues surrounding the management of 
antibiotic prescribing and usage.  A number of sources were used to aid the development of 
the mind map including; broadsheet newspaper articles, the internet (Google), and personal 
communication from other individuals.  Newspaper articles were searched using Lexis-Nexis 
Executive.  This site contained not only national newspapers, but also international papers, 
which were translated to English if necessary.   
 
The aim of the literature search was to retrieve all relevant studies with high sensitivity and 
specificity.  Sensitivity is defined as the proportion of high quality studies that are retrieved 
for this present review and specificity is defined as the proportion of low quality articles not 
retrieved (Sackett and Straus et al., 2000). In order to achieve this aim, the present review 
searches used fifty-one different combinations of terms (shown in Appendix 2) in the 
literature search. 
 
Boolean search strategy combinations “AND”, “OR” and “NOT” were used in the present 
study.  No limitations were imposed on the initial searches (such as a starting date of articles) 
in order to retrieve as comprehensive array of outputs as possible.  Medline allowed study 
searches from 1945 (the year when Fleming first mentioned antibiotic resistance as an issue).  
Any articles which were not available in English were translated in as much detail as possible 
by volunteers from Aston University in order to determine whether their inclusion was 
justified. 
 
Basic key search terms were derived from the mind mapping exercise. Concepts generated 
were filtered and prioritised by collaboration with a leading academic research microbiologist 
in the autumn 2006.  Search terms and term combinations for the literature search strategy 
were then generated using a nominal group technique, which included a leading academic 
research microbiologist and two professors of clinical pharmacy.  This whole process 
produced fifty-one different combinations of terms (shown in Appendix 2), all of which were 
considered relevant to this systematic review.   
 
Key references cited in retrieved studies were used to widen the search.  This was achieved by 
using the search engine Medline, which provided a facility to search for related studies.  The 
index terms of retrieved studies were also used to widen the search.  This was achieved by 
using the index terms of retrieved studies as search terms within the chosen search engines. 
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In order to develop a comprehensive search strategy, mindful of bias reduction, the search 
strategies included Medline (Med-line, 2007) as a high yielding medically based database, 
Pharm-Line (Pharm-line, 2007) for a pharmaceutical perspective and The Cochrane Library 
(The Cochrane Library, 2007) as a speciality in systematic review studies.  Retrieved articles 
were stored and manipulated using reference management software (Endnote 9).   
 
4.6 Data Collection and analysis 
 
Two reviewers independently applied pre-determined exclusion criteria to identify only those 
studies of relevance, with a plan to resolve disagreements in chosen studies by discussion 
between the reviewers.   However, the present review provided no discrepancy in the choice 
of relevant studies.  The stages of the exclusion process are shown in Figure 9 as some 
abstracts were subject to word limits, the key requirement of the presence of a control group 
was only assessed when reviewing full papers. 
 
Quality assessment involves the appraisal of the individual aspects of a study‟s design, 
conduct and analysis (quality items).  As many study designs were found in review studies, it 
was important to quantify quality items based on each paper‟s own merits.  For example, 
papers using randomised controlled trials were assessed through the use of different quality 
items to those for systematic reviews.  The decision of what quality items to use for each 
study design was aided with the use of two quality assessments (NICE, 2005; The Cochrane 
Library, 2007). 
 
Appendix 3 provides the details of the quality assessments used for each study design in this 
present review.  Each review study was analysed in order to extract the required information 
in order to determine whether the required criteria were met.   
 
Any criteria highlighted in red in the quality assessment checklist indicated an aspect of the 
study design that was of high importance, and thus its inclusion within an article was 
considered essential.  All quality criteria were placed in a table, and the results of their 
inclusion in each article in terms of sufficiency of detail were rated as either “met”, or “not 
met”, or “not stated”.   
 
A weighting system was used for this systematic review which favoured the inclusion of 
specific quality indicators for different study designs (NICE, 2005).  On this basis, a score of 
four was given to the presence of a required quality item within a given study.  For example, 
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if the type of randomisation was stated in a randomised controlled trial, then a score of four 
was obtained.  For any other quality item present in a study, a score of two, rather than three, 
was set in order to add more value to the presence of the specific quality items required with 
any study design.  For example, if a randomised controlled trial contained details on the 
completeness of follow-up within the study, then a score of two was given.   
 
The score was then totalled and divided by the number of required quality items.  For 
example, randomised controlled trials required the presence of six quality items, so the total 
score of a study was divided by six.  This equates to the weighting score, which would be 
compared to all other scores in order to provide their ranking.  
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4.7 Statistical heterogeneity 
 
The level of Statistical heterogeneity determines whether studies are similar enough to use 
statistical analyses such as the use of Forest plots, an L‟Abbe plot and a Funnel plot.  The 
present review incorporated all of these three types of statistical analysis. 
 
4.7.1 The Forest plot 
 
Forest plots were used in the present review to display estimated results, summary estimates 
and confidence intervals of each quantitative study.  The order of the data could be changed 
(chronologically or by country in which the study was conducted) in the present review to 
reveal patterns in the data.  The following statistical tests were required to produce Forest 
plots in the present review. 
 
4.7.1.1 Fixed Effects (Mantel-Haenszel, Robins-Breslow-
Greenland) 
 
The Mantel-Haenszel method was used to analyse the relationship between a dichotomous 
outcome and risk factors.  This was achieved by assuming a fixed effect model to estimate the 
pooled odds ratio for all strata.  The Robin, Breslow and Greenland variance formula was 
used to calculate the confidence interval for the Mantel-Haenszel odds ratio.   
 
4.7.1.2 Fixed Effects (Conditional Maximum Likelihood) 
 
Consistent estimators of panel data models were constructed using Conditional Maximum 
Likelihood in the presence of individual specific effects.  The Fisher Exact test was used for 
evaluating two-by-two contingency tables. 
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4.7.1.3 Non-Compatibility of Studies 
 
Breslow-Day and Cochrane Q tests were used to test non-compatibility.  The Cochran Q test 
was used to test differences between three or more matched sets of frequencies between 
related samples. 
 
4.7.1.4 Random Effects (DerSimonian-Laird) 
 
Heterogeneity was calculated using the Cochrane Q test by weighting the sum of squared 
differences between individual study and pooled effects across studies.  Q was included in 
each StatsDirect meta-analysis function as it formed part of the DerSimonian-Laird random 
effects pooling method.   
 
4.7.2 The funnel plot 
 
Funnel plots were used in the present review to investigate the presence of publication and 
small study bias within review studies.  The funnel plot itself is a scatter plot of study 
precision versus effect size.  It is assumed that as the study size increases the level of 
precision will increase.   
 
4.7.3 The L’Abbe plot 
 
An L‟Abbe plot was produced by plotting the proportion of events in a control group against 
the proportion of events in the intervention group.  This analysis was then used to determine 
the risk or benefits of using a particular intervention.   
 
  
 70 
4.7.4 Statistical Methods 
 
Heterogeneity was analysed with the use of computer software (StatsDirect, manufactured by 
StatsDirect Ltd).  P values of <0.05 are considered significant, P values of <0.01 are 
considered very significant and P values of <0.001 are considered highly significant in the 
present study. 
 
4.7.4.1 Summary Statistics 
 
Data from two groups within a study (the intervention and control group) can be compared 
using several summary statistics, such as, a risk ratio, the risk difference and the odds ratio.  
For the present study a decision was made to use odds ratio because this statistic provided a 
straightforward and clinically useful interpretation, while providing consistency of the 
statistic across different studies.    An odds ratio could easily be calculated by dividing the 
odds of the event in the intervention group by the odds of the event in the control group. 
 
All of the studies in the present review were required to contain details of not only the 
intervention, but also control group or baseline results, therefore this data was extracted from 
each study and recorded in a table (see Appendix 4).  If more than one outcome measure was 
used to calculate results, a decision was made to use the primary outcome measure results.   
 
The data on intervention and control groups were entered into the StatsDirect package to 
calculate the odds ratio score and the corresponding confidence intervals (set at 95%).  
 
The required data for odds ratio calculation were: total number of patients in the intervention 
group, total number of patients in intervention group with the specified outcome, total number 
of patients in the control group, and total number of patients in control group with the 
specified outcome. 
 
4.8 Sensitivity analysis 
 
Sensitivity analysis analyses the association between study differences and outcomes.  This 
was achieved in the present review by evaluating different sub groups of studies and 
systematically excluding studies to determine how this affects the conclusions reached.  For 
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example, the researcher could exclude all before and after studies to determine how the results 
would change.   
 
4.9 Moderator variables 
 
A moderator variable can be a quantitative or qualitative factor which affects the relationship 
of independent or dependent variables.  Sub group analysis and moderator variables were 
used to analyse the impact of moderator variables on major variables within the present 
review.  This was achieved at study level by examining varying study characteristics, such as 
the settings, groups of outcomes or patients.   
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4.10 Results 
 
4.10.1 Implementation of selection processes 
 
The citation search strategy used in the present review provided a database of 365077 studies 
from Medline, Pharm-Line and the Cochrane databases.  However, of the 365077 studies 
retrieved, only twenty-five were included in the final review after the exclusion criteria were 
applied (as shown in Figure 9) and their quality assessment scores are shown in Table 8 
below.  These twenty-five outputs will be subsequently referred to as “the review studies”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 73 
 
Table 8: Quality assessment scores achieved by each review study 
 
Study 
Weighting 
score 
 Briel (2006) 6 
 Walker (1998) 5 
 Melander (1999) 4.7 
 Paul (2006) 4.6 
 Van Driel (2007) 4.6 
 Seager (2005) 4 
 Monette (2007) 3.8 
 Altiner (2007) 3.3 
 Dranitsaris 
(2001) 
3.3 
 McGregor (2005) 3.3 
 Rautakorpi 
(2006) 
3.3 
 Hadi (2008) 3 
 Schwartz (2007) 3 
 Arnold (2006) 2.3 
 Smabrekke 
(2002) 
2.3 
 Buising (2008) 2 
 De Santis (1994) 2 
 Mainous (2000) 2 
 Molstad (1989) 2 
 Ng (2008) 2 
 Bjerrum (2006) 1.6 
 Gonzales (1999) 1.6 
 Hickman (2003) 1.6 
 Pastel (1992) 1.6 
 Angunawela 
(1991) 
1.3 
 
 
3.0 Average weighting score 
 
Table 8 shows that the weighting achieved by the review studies varied between 6 (achieved 
by Briel, 2006) and 1.3 (achieved by Angunawela, 1991).   Four studies produced a weighting 
score of 3.3 and 1.6 with the average weighting score being 3.  Figure 10 below analyses the 
range and frequency of study designs reported in the review studies. 
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Figure 10: A representation of the range and frequency of study designs reported in the 
review studies 
 
 
Figure 10 shows the range and frequency of experimental designs reported in the review 
studies.  A total of thirteen different study designs were used within the 25 review studies 
meaning that some studies utilised more than one method of study design. “Control” and 
“randomised” were the most popular terms used to describe study designs.  One review study 
mentioned the use of “streamline” as a study design, however the definition of “streamline” 
was not included within the study text.  Only three of the review studies mentioned the use of 
blinding (Briel et al., 2006; Dranitsaris et al., 2001; McGregor et al., 2006).  
 
4.10.2 Primary outcome measures used in the review 
studies 
 
Twenty-three of the twenty-five review studies used more than one outcome measure, 
although there were only two primary outcome measures used in the twenty-five review 
studies.  Nine studies used a measure of “compliance” and sixteen studies used an evaluation 
of the “prescription numbers”.  “Compliance” is used in the present study to describe an 
outcome measure which demonstrates the appropriateness of prescribing (i.e. in accordance 
with requirements within the intervention), whereas, “prescription numbers” describes 
measures used as a simple evaluation of changes in volume measures of prescribing before 
and after an intervention.  Table 9 below shows other outcome measures recorded within the 
review studies.  
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Table 9: Outcome measures recorded within review studies 
 
Outcome measures 
Number of times 
recorded within review 
studies 
Adverse events 1 
Antibiotic costs 1 
Antibiotic sales 1 
Antibiotics prescribed 1 
Characteristics of participating physicians 1 
Clinical response 1 
Compliance 9 
Costs related to antibiotics stewardship program 1 
Demographic characteristics of patients 1 
Distribution of focus for infections 1 
Frequency of testing for Clostridium difficile 1 
Hospital antimicrobial costs 1 
Indication for antibiotic prescriptions 1 
Length of hospital stay 1 
Length of hospitalization 1 
Measurement of severe disease 1 
Mortality 1 
Number of prescriptions 16 
Patient mortality 1 
Patient satisfaction 1 
Percentage of consultations with antibiotic prescribing in 
relation to focus for respiratory tract infections 1 
Percentage of patients with specified or presumed types 
of infections 1 
Quality of antibiotic use 1 
Rate of subsequent physician visits 1 
Relation to allergies documented 1 
Time spent by team managing antimicrobial utilisation 1 
Types of antibiotics used for respiratory tract infections  1 
 
Table 9 shows that there were a total of 27 outcome measures recorded within the review 
studies.  The two outcome measures highlighted in yellow were the primary outcomes and the 
only measures to be recorded more than once within review studies.  Nine studies used a 
measure of “compliance” and sixteen studies used an evaluation of the “prescription 
numbers”.   
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4.10.3 Measure of systematic review bias (Funnel Plot) 
Funnel plots were constructed for the review studies‟ data in order to assess the presence of 
bias.  The funnel plot should resemble a symmetrical inverted funnel where the precision of 
the estimated intervention effect increases as the size of the study increases.  
 
Figure 11: A funnel plot of review study outputs comparing the effectiveness of the 
intervention(s) in controlling antibiotic use 
Figure 11 shows that only three studies produced standard error scores greater than 0.4 
(circled green, Figure 11), indicating that most review studies produced precise outcomes.  
 
With the exception of three studies (circled red, Figure 11) there is an indication of funnel 
symmetry between results presented in Figure 11.  The reasons for any asymmetry could 
include studies being of lesser/poorer quality compared to other review studies or having been 
conducted in an atypical population/situation.   
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4.10.4 Assessment of study data heterogeneity 
(L’Abbe plot) 
 
Analysis of sources of heterogeneity in a meta-analysis is imperative and can be achieved 
using an L‟Abbe plot.  The sizes of each symbol in Figure 12 represent the sample size within 
the study (larger symbols represent larger sample sizes).   The experimental (y-axis) and 
control percent (x-axis) represent the proportion of patients which improved with the control 
or experimental intervention(s) implemented.  
 
Figure 12: An L'Abbe plot of the review study outcomes 
 
 
Figure 12 shows an L‟Abbe plot showing the comparative success of interventions and 
controls within the review studies.  
 
The heavy diagonal line in Figure 12 is the line of equality and study results lying on this line 
would have equally successful interventions and controls.  Symbols lying to the right of the 
line of equality indicate that the control group had more successful results compared to the 
intervention group and vice versa for symbols to the left of the line of equality. 
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The lighter dashed line in the L‟Abbe plot (Figure 12) represents the overall success of the 
control or interventions.  If the dashed line is present to the right of the line of equality, the 
control groups are likely to be more successful than interventions. Figure 12 indicates that this 
is the case, implying that most interventions used have had no effect (or even a detrimental 
effect in some cases) in beneficially influencing antibiotic use.  This is further supported by 
the five studies circled in green, which indicate that the control groups are much more 
successful than their corresponding intervention groups in influencing antibiotic use. 
 
4.10.5 Forest Plot 
 
The Forest Plot is a visual output used to show information from individual studies, allowing 
demonstration of the relative effectiveness of interventions in comparisons of multiple 
quantitative scientific studies.  Forest Plots will be used in this review to determine the 
success of intervention methods on controlling antibiotic use. 
 
The Forest Plot is presented in two columns.  The left-hand column lists the names of the 
studies in alphabetical order.  Some studies are presented more than once depending on 
whether they present results for multiple interventions.  The second column is a plot of the log 
odds ratio results for each study (and each intervention used within studies) incorporating 
horizontal bars which represent the associated 95% confidence intervals.  The relative weight 
of a study is represented by the size of the black square symbol, with studies containing a 
comparatively higher number of participants being represented with a larger black square 
symbol. 
 
The vertical heavy solid line presents a log odds ratio score of 1.  For an intervention to be 
deemed successful it has to achieve a log odds ratio score of greater than 1.  The unfilled 
diamond and dotted vertical line represents the summary effect of all the interventions.  This 
also needs to be greater than 1 in order for the overall effect of interventions to be proven 
successful for controlling antibiotic use. 
 
The following three Forest Plots (Figure 13, 14 and 15) display results from the review 
studies highlighting BASELINE, INTERVENTION and FOLLOW-UP periods. In the present 
systematic review, BASELINE periods are those set before interventions are conducted.  
INTERVENTION results are classed as those produced once the interventions are complete 
and the FOLLOW-UP plots are derived from post-intervention results intended to determine 
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the long term success of the interventions implemented.  The interventions and outcome 
measures have been abbreviated but are described in the abbreviations section on page 19.   
 
Figure 13:  Forest Plot of review studies' BASELINE data 
 
Figure 13 shows that only eleven of the twenty-five review studies recorded BASELINE 
results.  The overall log odds ratio score was 0.96 which unsurprisingly confirms that control 
of antibiotic use had not been successful before any interventions were implemented. 
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SMABREKKE (2002): E+G/AP 0.48 (0.18, 1.12) 
MONETTE (2007): E/AP 
1.01 (0.67, 1.53) 
MOLSTAD (1989): E/AP 0.88 (0.63, 1.25) 
MELANDER (1999): A/AP 0.81 (0.69, 0.96) 
MAINOUS (2000): PEM+F/AP 1.17 (1.13, 1.21) 
MAINOUS (2000): F/AP 0.88 (0.85, 0.91) 
MAINOUS (2000): PEM/AP 1.04 (1.01, 1.08) 
HICKMAN (2003): E+PR+SM+OTC+P+N/AP 0.50 (0.40, 0.63) 
GONZALES (1991): PCE+PP/AP 0.80 (0.70, 0.92) 
GONZALES (1991): PEM+PP/AP 1.29 (1.12, 1.48) 
DE SANTIS (1994): E+MB+G+AD/AP 1.36 (1.15, 1.62)  
BJERRUM (2006): G/AP 1.19 (1.03, 1.39) 
ARNOLD (2006): AMT+G/AP 1.22 (1.03, 1.44) 
ANGUNAWELA (1991): W+S/AP 1.37 (1.15, 1.64) 
ANGUNAWELA (1991): W/AP 0.97 (0.80, 1.17) 
ALTINER (2007): T+PL+P/AP 0.47 (0.39, 0.58)   
Combined [random] 0.96 (0.87, 1.06) 
Odds ratio (95% confidence interval) 
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Figure 14: Forest Plot of review studies' INTERVENTION data 
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SCHWARTZ (2007): E/AP 5.19 (2.07, 14.15) 
RAUTAKORPI (2006): G+EM/AP 0.83 (0.78, 0.88) 
PAUL (2006): CDS/AP 1.47 (1.01, 2.13) 
PASTEL (1992): PI/AP 4.35 (1.40, 13.79) 
NG (2008): ASP+L+F+G/AP 0.57 (0.49, 0.67) 
MONETTE (2007): E/AP 0.91 (0.67, 1.25) 
MOLSTAD (1989): E/AP 0.47 (0.34, 0.66) 
MELANDER (1999): A/AP 0.46 (0.39, 0.55) 
MCGREGOR (2006): ASP+CDS/AP 0.98 (0.87, 1.11) 
MAINOUS (2000): PEM+F/AP 0.86 (0.83, 0.89) 
MAINOUS (2000): F/AP 0.67 (0.65, 0.69) 
MAINOUS (2000): PEM/AP 0.70 (0.68, 0.72) 
HICKMAN (2003): E+PR+SM+OTC+P+N/AP 0.74 (0.57, 0.95) 
HADI (2008): G+PB+TSPB/AP 0.33 (0.19, 0.55) 
HADI (2008): G+PB+TSPRC/AP 0.04 (0.02, 0.07) 
HADI (2008): G+PB+TSPT/AP 0.03 (0.01, 0.06) 
HADI (2008): G+PB+TSPD/AP 0.16 (0.09, 0.29) 
GONZALES (1991): PCE+PP/AP 0.80 (0.69, 0.93) 
GONZALES (1991): PEM+PP/AP 1.28 (1.10, 1.50) 
DRANITSARIS (2001): A/AP 1.35 (0.79, 2.29) 
DE SANTIS (1994): E+MB+G+AD/AP 1.01 (0.80, 1.28) 
BUISING (2008): CDSS/AP 0.07 (0.04, 0.13) 
BUISING (2008): AD/AP 
1.36 (0.93, 1.99) 
BRIEL (2006): T+E+G+S+F/C 0.75 (0.40, 1.40) 
BRIEL (2006): T+E+G+S/C 0.83 (0.46, 1.49) 
BRIEL (2006): T+E+G+S+F/AP 0.57 (0.35, 0.92) 
BRIEL (2006): T+E+G+S/AP 0.68 (0.44, 1.07) 
ARNOLD (2006): AMT+G/AP 1.47 (1.12, 1.94) 
ANGUNAWELA (1991): W+S/AP 
0.75 (0.67, 0.83) 
ANGUNAWELA (1991): W/AP 0.45 (0.40, 0.52) 
ALTINER (2007): T+PL+P/AP 0.28 (0.23, 0.35) 
Combined [random] 0.69 (0.63, 0.76) 
Odds ratio (95% confidence interval) 
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Figure 14 shows that 24 of the 25 studies recorded results immediately after the 
INTERVENTION period.  Bjerrum (2006) was the only study failing to state 
INTERVENTION results; however this study included both BASELINE AND FOLLOW-UP 
results.  From Figure 14 the overall log odds ratio score was 0.69, which indicates that the 
interventions were generally unsuccessful in reducing antibiotic use. 
 
Figure 15: Forest Plot of review studies' FOLLOW-UP data 
 
 
 
Figure 15 shows that only five of the twenty-five studies recorded FOLLOW-UP results.  The 
overall FOLLOW-UP log odds ratio score of 0.84 indicates that these intervention methods 
were also unsuccessful in reducing antibiotic use in the long term. 
 
The results of the three previous Forest Plots (Figures 13, 14 and 15) have been summarised 
in Figure 16 in order to show comparisons for the intervention(s) used in review studies.  
Figure 16 also indicates the countries where the review studies were conducted. 
 
0.2 0.5 1 2 5 
MONETTE (2007): E/AP 1.48 (0.97, 2.25) 
DE SANTIS (1994): E+MB+G+AD/AP 1.22 (0.99, 1.52) 
BJERRUM (2006): G/AP 0.67 (0.58, 0.77) 
ANGUNAWELA (1991): W+S/AP 0.99 (0.88, 1.11) 
ANGUNAWELA (1991): W/AP 0.99 (0.88, 1.11) 
ALTINER (2007): T+PL+P/AP 0.32 (0.26, 0.39) 
Combined [random] 0.84 (0.59, 1.18) 
Odds ratio (95% confidence interval) 
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Figure 16: Histogram showing the log odds ratio scores achieved by review studies for each intervention period, including the corresponding overall log odds 
ratio score for comparison 
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4.10.6 Determination of the “ideal” intervention 
 
Figure 17 shows three outcomes possible when an intervention(s) is implemented.   
 
Figure 17:  Modelled data for antibiotic use with control interventions 
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Figure 17 shows that there is generally a period of “noise” before any intervention is implemented 
where prescribing fluctuates slightly above and below a “normal average” value, followed by three 
possible effects that the interventions could have on prescribing.  The optimal line is the desired result 
with antibiotic prescribing reducing when an intervention is introduced and remaining low once the 
intervention is complete (if reduction is desirable i.e. not cases where you want to promote 
appropriate use).  However Figure 17 shows that no study displayed these desired characteristics.  A 
time limited result involves the reduction of antibiotic prescribing when an intervention is 
implemented, however unlike an optimal intervention(s), prescribing subsequently increases moving 
towards “normal average” levels.  A failing intervention never results in a reduction in antibiotic 
prescribing below “normal” levels and may even lead to an increase (promotion) in antibiotic 
prescribing. 
 
The interventions implemented in the review studies varied markedly. However, the present study has 
categorised all of the interventions used into sub-sets, within which similar approaches and methods 
were taken.  Table 10 summarises each intervention categorised using key areas of analysis; the 
influence of intervention, the general type of intervention used and the target audience. 
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Table 10: Classification of intervention definitions used within review studies 
 
 
Intervention 
mentioned in review 
study 
Abbreviated 
term 
Intended 
influence on 
prescribing 
Type of intervention 
Target 
audience 
Audit AUDIT Long term 
Education & Feedback & 
Surveillance 
Prescribers 
Academic Detailing ACADEMIC Long term Education & Feedback Prescribers 
Antimicrobial 
Management Team 
MANAGEMENT 
TEAM 
Long term 
Education & Feedback & 
Surveillance 
Prescribers 
& Patients 
Antibiotic Stewardship 
Program 
STEWARDSHIP Long term Education 
Prescribers 
& Patients 
Computerised 
Decision Support 
IT Long term Education & Feedback Prescribers 
Education EDUCATION Long term Education 
Prescribers 
& Patients 
Education Material MATERIAL Long term Education 
Prescribers 
& Patients 
Feedback FEEDBACK Long term Education & Feedback 
Prescribers 
& Patients 
Guidelines GUIDELINES Long term Education Prescribers 
Lectures LECTURE Long term Education Prescribers 
Mail Brochures BROCHURE Long term Education Prescribers 
Newsletters NEWSLETTER Long term Education Prescribers 
Prescription Pads PADS Long term Education & Feedback Patients 
Posters POSTER Long term Education Patients 
Pocket books POCKET BOOK Long term Education Prescribers 
Pharmacy Intervention PHARMACY Long term 
Education & Feedback & 
Surveillance 
Prescribers 
& Patients 
Patient Leaflets LEAFLET Long term Education Prescribers 
Practice Profiling PROFILING Long term 
Education & Feedback & 
Surveillance 
Prescribers 
Presentations PRESENTATION Long term Education Prescribers 
Seminar SEMINAR Long term Education Prescribers 
Staff Meetings MEETING Long term Education & Feedback Prescribers 
Training TRAINING Long term Education Prescribers 
Teaching sessions TEACHING Long term Education Prescribers 
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4.10.7 INTERVENTION results 
 
Analysis of INTERVENTION results from Figure 16 show that eleven studies achieved a log odds 
ratio score greater than 1.  However it is also important to consider the log odds ratio scores of 
corresponding BASELINE and FOLLOW-UP period from each study (if recorded), as they could also 
indicate whether an intervention was successful.   
 
Figure 16 shows that eight studies produced log odds ratio greater than 1 with an INTERVENTION 
log odds ratio score greater than that of the corresponding BASELINE periods.  Table 11 below 
summarises the interventions used in these eight studies (Arnold et al., 2006; Buising et al., 2008; 
Dranitsaris et al., 2001; Pastel et al., 1992; Paul et al., 2006; Schwartz et al., 2007; Seager et al., 
2006; Van Driel et al., 2007) in order to determine any patterns of interventions used.    
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Table 11: Comparison of the interventions used in the review studies that achieved a log odds ratio score of greater than 1 
 REVIEW STUDIES (INTERVENTION LOG ODDS SCORE ACHIEVED)  
INTERVENTION 
SCHWARTZ 
(2007) (5.19) 
PASTEL 
(1992) (4.35) 
ARNOLD 
(2006) (1.47) 
PAUL 
(2006) 
(1.47) 
BUISING 
(2008) (1.36) 
DRANITSARIS 
(2001) (1.35) 
VAN DRIEL 
(2007) (1.25) 
SEAGER 
(2006) (1.23) 
TOTAL NUMBER OF TIMES 
INTERVENTION USED 
ALGORITHM X      X  2 
ANTIMICROBIAL 
MANAGEMENT TEAM 
  X      1 
AUDIT X     X   2 
CHOICE RESTRICTION     X    1 
CLINICAL CASE 
VIGNETTES 
      X  1 
COMPUTERISED 
DECISION SUPPORT 
   X     1 
GUIDELINES X  X  X X X X 6 
LAMINATED CARDS     X   X 2 
MONTHLY 
NEWSLETTER 
  X      1 
NATIONAL ABX 
PRESCRIBING 
    X    1 
PATIENT 
INFORMATION 
LEAFLET 
      X X 2 
PHARMACIST 
INTERVENTION 
 X    X  X 3 
POCKET SIZED 
BOOKLETS 
X        1 
POSTERS     X    1 
PRESENTATIONS X      X  2 
QUARTERLY SPECIFIC 
REPORTS 
  X      1 
RESEARCH EVIDENCE       X  1 
WEEKLY 
AGGREGATED 
REPORTS   X      1 
TOTAL NUMBER OF 
INTERVENTIONS 5 1 5 1 5 3 6 4  
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Table 11 shows the combination and range of interventions used in those studies producing a 
log odds ratio score of greater than 1 in the INTERVENTION period.   
 
From Table 11 eight studies (Arnold et al., 2006; Buising et al., 2008; Dranitsaris et al., 2001; 
Pastel et al., 1992; Paul et al., 2006; Schwartz et al., 2007; Seager et al., 2006; Van Driel et 
al., 2007) used a combined total of eighteen interventions, eleven of which were only used 
once.   “Guidelines” was the most frequently used intervention in the successful review 
studies. 
 
 
The study with the highest log odds ratio score was conducted by Schwartz (2007) which 
used a combination of 5 different interventions. However, overall the number of interventions 
employed does not appear to correlate with the success of a study, since the next most 
successful review study (Pastel, 1992) only used a single intervention.   This latter measure 
involved the intervention of pharmacists to monitor and highlight antibiotic prescribing 
inconsistencies, which was also used in two other successful review studies (Dranitsaris, 2001 
and Seager, 2006). 
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4.11 Discussion 
 
A systematic review has been conducted on literature describing interventions to improve 
prescribing practices with the aim of providing possible solutions to the escalating issue of 
bacterial resistance.  The selection criteria used in this systematic review (Figure 9) resulted 
in the omission of 365,052 studies, with twenty-five containing information which met the 
study criteria and thus being categorised as the review studies.   
 
The review studies were conducted worldwide, including work conducted in developing 
countries, resulting in the use of markedly differing layout and content, however none of the 
review studies required English translation.  One possible limitation of systematic reviews 
revolves around the risk of failing to identify all crucial published work. However, the 
chances of studies being missed were minimised by employing rigorous search terms, using a 
range of databases and conducting reverse searches using citation and hand searching 
techniques.  A limitation of the present review may have been the limited databases searched 
in comparison to other key systematic review.  However the present review‟s study retrieval 
process was applied to other key databases such as EMBASE, OVID or CINAHL and found 
to produce no extra studies that may have been missed within the present review. 
 
4.11.1 Overall results 
 
Forest Plots were used to calculate the log odds ratio scores of BASELINE, 
INTERVENTION and FOLLOW-UP periods.  The overall log odds ratio score for the 
INTERVENTION period was 0.69 whilst the BASELINE and FOLLOW-UP scores for 
interventions were 0.96 and 0.84 respectively, which indicate increased antibiotic use during 
the INTERVENTION period.  However, it also has to be noted that out of the twenty-five 
review studies only eleven presented BASELINE and five presented FOLLOW-UP results.   
 
The lack of studies including BASELINE and FOLLOW-UP results may have had a 
significant impact on the results obtained in the present review as the absence of these results 
may have skewed overall averages.    Therefore, study designs requiring the reporting of 
BASELINE and FOLLOW-UP results should be fundamental to all future research conducted 
in controlling antibiotic use to determine the actual impact and time course of any 
intervention(s). 
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4.11.2 Results in terms of review studies 
 
The log odds ratio results were used to construct Forest Plots for individual studies.  More in-
depth analysis of interventions, however, demonstrated a lack of detail necessary to explain 
how interventions were conducted.  For example “guidelines” were used nine times in review 
studies with most failing to detail the target audience, the duration of implementation and the 
“guideline” format and content. 
 
It is possible that a study producing a low log odds ratio score actually used poor “guidelines” 
and/or failed to implement “guidelines” effectively during the INTERVENTION period.  
Therefore, the variability within studies cannot be precisely accounted for, which is a limiting 
factor of the present systematic review.   
 
In cases where there have been multiple interventions adopted, little information was 
provided on how interventions were combined, why certain combinations were chosen and 
who exactly implemented them. 
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4.11.3 Study design of review studies 
 
A quality assessment tool was used to determine the robustness of review study methods 
based on NICE (2005) and The Cochrane Library (2007).  Both the present systematic review 
and the systematic reviews summarised in Table 7 have used the criteria described by the 
EPOC group, as described in the Cochrane Library.   
 
A key difference between the present review and the reviews analysed in Table 7 was the 
inclusion of all types of studies in the review.  The criteria described by the EPOC group only 
allowed quality analysis of randomized controlled trials, quasi-randomised controlled trials, 
before and after studies and interrupted times series.  Therefore an additional quality 
assessment tool had to be incorporated within the present systematic review to analyse studies 
that may not have been accounted for by the EPOC group.  This was achieved with the 
checklist designed by the Centre for Statistics in Medicine at Oxford University (NICE, 
2005).     
 
A key limitation of the present systematic review was the ability to meta-analyse such 
possibly heterogeneous results.  This was minimized by the requirement for all studies to 
contain control group results, however results should also have been qualitatively analysed.  
In doing so, the differences in study design, participants, and outcome measure used may 
have been accounted for more suitably.   
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4.11.4 Weighting system 
 
The present systematic review did not place any exclusion criteria on the type of studies 
included.  In doing so the probability of heterogeneity was increased, and encouraged within 
the present systematic review.  In doing so the likelihood of including important studies in the 
present review was increased, in comparison to previous systematic reviews. 
 
A limitation of the present systematic review was the implementation of a personalized 
weighting system.  An alternative method to calculate study weighting could have been 
adopted to reduce the value of specific quality items included within studies by using a score 
of three, instead of two for those quality items not considered essential for inclusion within 
any given study design.   However the results achieved by using this alternative method 
produced no differences in the ranking of review studies (in terms of study quality) in 
comparison to the personalized weighting system used in the present review. 
 
Regardless of the several weighting system adopted, the quality assessment process 
highlighted the lack of explanation and detail for the methods used, making overall analysis 
of interventions difficult to achieve.  Therefore, interventions were grouped and classified 
pragmatically.    
 
4.11.5 Control groups 
 
One methodological area regularly described inadequately was the use of control groups. This 
may have occurred owing to the circumstances faced when conducting research on 
prescribing, with some studies using retrospective control groups.  The main limitation for 
studies using retrospective control groups was the unknown influence on results of factors 
other than the interventions used.   
 
One flaw within some review studies which cannot be explained was the use of control group 
results without previously mentioning their involvement in the methods description.  Overall 
there were thirteen study designs mentioned in the review studies, proving researchers used 
many different study methods in attempts to achieve intervention(s) success.  “Control” was 
the most used term as the use of control groups were a requirement for inclusion in the 
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present systematic review.  This is an example of poor methodological description and is an 
area that can be improved in future research. 
 
The inadequacy of the review studies in reporting control group data could be explained by 
the inclusion of all study designs within the present review.  The systematic reviews analysed 
in Table 7 shows that those key reviews only included randomized controlled trials, quasi-
randomised controlled trials, before and after studies and interrupted times series.  In doing 
so, the reviews ensured the presence of control groups within the data as they are an essential 
requirement within these study designs.   
 
4.11.6 Primary outcome measure 
 
It was striking that a wide range of outcome measures were used in the review studies and 
these were often employed in a range of complex combinations. The detail of descriptions of 
these measures was frequently limited and also there was little clear rationale for the use of 
any given intervention or combination. 
 
The two outcome measures most commonly mentioned by the review studies have been 
“prescription numbers” and “compliance”.  Studies using “prescription numbers” analysed 
how many prescriptions of antibiotics were issued by prescribers to patients.  Conversely, the 
outcome measure “compliance” involved how prescribers adhered to prescribing 
recommendations and was relatively subjective since there was limited consistency in 
measuring adherence within the review studies.   
 
 
4.11.6.1 Review studies using both “compliance” and 
“prescription numbers” 
 
The studies by Van Driel (2007) and Briel (2006) highlight the impact of the chosen outcome 
measures on the apparent effectiveness of interventions: the outcome measure “compliance” 
resulted in a larger log odds ratio score when compared to the corresponding score achieved 
using the outcome measure “prescription numbers”.  This raises the question of which 
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outcome measure should be used to assess the impact of interventions in controlling antibiotic 
use. 
 
If minimising the spread of antibiotic resistance is merely a question of reducing antibiotic 
use then “prescription numbers” is appropriate, however “compliance” would be the ideal 
outcome measure if the primary aim was the measurement of improvement in antibiotic use.  
When using “compliance” as an outcome measure it is essential for studies to detail the 
“guidelines” implemented to determine whether leniency in adherence resulted in higher log 
odds ratio scores.    
 
In light of the differences in results achieved by studies reporting either of these outcome 
measures, a limitation of the present review was the meta-analysis of studies reporting either 
“compliance” and “prescription numbers”.  This provides further support for the use of 
qualitative analysis to analyse the review studies rather than meta-analysis.  
 
4.11.7 Limitations and strengths of this systematic 
review 
 
The present systematic review has highlighted a number of limitations which have restricted 
the quality of the results obtained.  These limitations must be juxtaposed with the potential 
significance of the results achieved: this systematic review has successfully reviewed all 
international studies reporting an intervention intended to control antibiotic use.  This has not 
been previously completed and the results can be used to influence future work and improve 
not only how research in this area is conducted but also how the findings are presented.  
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4.12 Conclusion 
 
In conclusion most research conducted on the control of antibiotic use has not been of the 
quality required to provide robust results, therefore more appropriate research is required in 
the future.    
 
The outcome measures used to assess the impact of an intervention in controlling antibiotic 
use also need to be validated and refined.  Using “prescription numbers” is an easy way of 
gathering results but does not truly reflect “control” of antibiotic use.   
 
Antibiotic prescribing can fluctuate depending on seasons, with more prescriptions issued in 
cooler seasons, because of the rise in associated respiratory tract infections.  If “prescription 
numbers” is used as an outcome measure, careful consideration of the intervention period is 
required to reflect the natural fluctuations that occur.  This issue should however also be 
supported by the use of appropriate control groups. 
 
The analytical research carried out raises the question of how success in controlling antibiotic 
use is defined.  This review has highlighted many limitations in review studies which may 
have hindered the precise determination of which interventions improve antibiotic use.   
Therefore if this systematic review is to be repeated in the future, it is essential to 
qualitatively analyse results.  
 
Ideally future research would provide an accurate, complete definition of any intervention(s) 
with an appropriate log odds ratio score that reflects success; the latter should be greater than 
1, greater than all other intervention(s) in the review, and show optimal success (as defined in 
Figure 17) in reducing antibiotic use, thus demonstrating sustained success.  The present 
systematic review has failed to highlight any study showing this pattern of success.  
 
In order to identify a successful intervention able to improve antibiotic prescribing practices, 
future research must define and document intervention(s) and record the effects of 
BASELINE, FOLLOW-UP and INTERVENTION scores.  This would require long term 
analysis of the effects of any interventions implemented.  This is in addition to the inclusion 
criteria set within the QUOROM flow chart in Figure 9. 
 
Regardless of the improvements that need to be made with future research, the results of the 
present systematic review do indicate that a combination of “guidelines” and “pharmacy” 
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intervention have the greatest potential to improve antibiotic use.  Therefore pharmacists 
should be employed within healthcare systems to achieve appropriate prescribing by 
educating prescribers with the use of antibiotic guidelines as an initial best guess before 
categorical evidence based data is obtained. 
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5. Exploration of the current policies to improve 
antibiotic prescribing with NHS managers 
 
5.1 Introduction 
 
The systematic review described in Chapter 4 reported a number of interventions used to 
improve antibiotic prescribing practices, with pharmacists being a key intervention to 
improve antibiotic prescribing.  Therefore this chapter will focus on exploring the impact of 
methods used by pharmacists working within the National Health System (National Health 
System managers) to improve antibiotic prescribing. 
 
5.2 Aim 
 
 To explore, examine and gain a detailed understanding of the optimal strategies and 
procedures used by National Health System managers to improve antibiotic 
prescribing. 
 
5.3Objectives 
 
1. To conduct semi-structured interviews with NHS managers working in selected 
Primary Care Trusts to determine what interventions are, and have been, used to 
improve antibiotic prescribing and how antibiotic use is analysed, through: 
a. Attainment of ethical approval. 
b. The selection of sampling strategy. 
c. The development of an interview guide. 
d. The conduct of a pilot interview. 
e. Digitally recording semi-structured interviews conducted. 
f. Transcription of semi-structured interviews conducted. 
g. Thematic analysis of semi-structured interviews conducted. 
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2. To collect naturally occurring data from a selected PCT to determine what 
interventions are, and have been, used to improve antibiotic prescribing and how 
antibiotic use is analysed, through: 
a. The selection of sampling strategy. 
b. The selection of storage method for data collected. 
c. Identification of themes and concepts.  
d. Generalisation of data. 
 
5.4 Choosing data collection methods for qualitative 
research 
 
The aims and objectives of the present research heavily influence how qualitative research is 
used to obtain the required information (Ritchie and Lewis, 2003).  Qualitative research itself, 
can be divided into naturally occurring data and generated data (Ritchie and Lewis, 2003), 
with the present research combining both naturally occurring and generated data in order to 
achieve the set aims and objectives.   
 
 
5.5 Sampling strategies for the present qualitative 
research  
 
Qualitative research uses non-probability sampling to select the population for study, where 
units are deliberately selected to reflect particular group.  Therefore, a decision was made in 
the present research to purposively sample NHS managers within Medicines Management 
teams in order to generate data, and obtain naturally occurring data within one of these 
Medicines Management teams on the basis of their previous ability to improve antibiotic 
prescribing.   
 
The first advantage of using a purposive sample was to ensure that the chosen participants 
were relevant to the research aims of identifying and examining previously developed 
strategic and operational interventions designed to decrease the development of antibiotic 
resistance through improved antibiotic prescribing practices.  The second advantage of using 
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a purposive sample was the ability to ensure the chosen participants provide enough diversity 
to explore the impact of the characteristic concerned.  The stages of purposive sampling will 
be discussed in further detail below.   
 
 
5.5.1 Identifying the population for study 
 
The key population within this present research are NHS managers working within Medicines 
Management departments, who are all situated within Primary Care Trusts and are involved 
in improving antibiotic prescribing within their given region.  Therefore an assumption can be 
made that the required population is homogenous, with a small sample providing the internal 
diversity required.  As a result, a sample of four NHS managers was considered appropriate in 
order to provide the internal diversity required to generate data and one Medicines 
Management department required appropriate to obtain naturally occurring data.  
 
5.5.1.1 The choice of purposive selection criteria 
 
The choice of the four NHS managers required for the data generation process will be based 
upon their PCT‟s current and previous antibiotic prescribing figures (over the past ten years) 
in order to provide the internal diversity required.  The first PCT was chosen as they had gone 
from being one of the highest prescribers of antibiotics to one of the lowest in comparison to 
all other PCTs across the country.  The second PCT was chosen because their antibiotic 
prescribing had risen from being one of the lowest to one of the highest prescribers in 
comparison to all other PCTs across the country.  The final two PCTs were chosen as they 
were either consistently high or low prescribers of antibiotics in comparison to all other PCTs 
across the country.  The participating NHS managers have to be the Heads of Medicines 
Management within their respective PCTs.   
 
5.5.1.2 Deciding on the locations for the study 
 
The chosen location for the qualitative research was the West Midlands Strategic Health 
Authority as this region contained PCTs that achieved the desired selection criteria set in the 
previous section and thus maximises the financial resources available.  
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5.6 The conduct of semi-structured interviews 
 
An interview guide was produced and consisted of semi-structured questions required to yield 
relevant responses from interviewees.  All interviewees were sent the study topics prior to the 
set meeting with explanations of why they had been incorporated within the interview to 
maximise the retrieval of information (see Table 12).  Also interviewees were instructed that 
the interview would be conducted over an hour period. 
 
5.6.1 Ethical considerations 
 
Ethical approval was sought from all interviewees‟ Primary Care Trusts, who concluded that 
no ethical approval was required as the research was considered as feedback from clients on 
professional practice.  However, all interviewees were provided with information about the 
purpose of the study, the funder, how the data was going to be used and what participation 
was required from them prior to their consent to participate in the interview. Table 12 below 
shows the study topics that were discussed with all interviewees and thus provide an idea of 
how much time would be required.  Also all interviews were conducted out of work hours to 
ensure interviewees did not commit any of their work time to the interviews. 
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Table 12: Justification for the use of the chosen study topics. 
 
 
5.6.2 Pilot 
 
A pilot semi-structured interview was conducted in order to analyse the quality of responses 
achieved from the questions posed.   
 
5.6.3 Purposive sampling 
 
A purposive sample of four current Heads of Medicines Management were selected and 
approached to participate in the semi-structured interviews.  They were chosen as their 
respective PCTs showed marked differences in antibiotic prescribing over the past ten years.  
Therefore the heterogeneous sample would maximise differences and facilitate the collection 
of diverse data and uncover similarities in approaches used to improve antibiotic prescribing 
Study topics Decision for use 
Antimicrobial 
Specialist/role of the 
Primary Care Trust 
Used to determine the employee(s) responsible for devising strategies 
to control antibiotic use within their Primary Care Trust level  
Government 
Involvement 
To clarify the perceived support Primary Care Trusts receive from 
the government. 
Present policies 
Used to determine what interventions have been put in place to 
control antibiotic use, and why they have been used 
Antibiotic data 
Used to analyse how Primary Care Trusts deal with antibiotic data, 
and how they determine whether antibiotic use is reaching levels that 
require control 
Outcome measures 
There are many different outcome measures that can be used to 
present data, therefore this area of analysis was used to determine 
what outcome measure was chosen and why 
Previous policies 
Used to assess the representatives knowledge of what interventions 
had been used previously to control antimicrobial use, and deem 
whether they were successful or not 
It was also important to determine whether these interventions were 
continued to be used, or discarded, and why 
Time frame 
Used to determine how long it takes to introduce an intervention and 
how long they are utilised 
Follow-up 
It was essential to find out how interviewees decide on how effective 
an intervention has been, do they use audits to analyse? 
 
Final comments 
Used to conclude  the interview and obtain  any final pieces of 
information that the interviewees want to disclose 
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and opinions on how antibiotic prescribing is controlled nationally (Ritchie and Lewis, 2003).  
The four Heads of Medicines Management from these selected PCTs agreed to participate in 
the semi-structured interviews and will be referred to as the „interviewees‟ from this point on.  
The research settings were allocated for the convenience of the four heads of Medicines 
Management, thus ensuring their participations in the semi-structured interviews.   
 
5.6.4 Digital recording 
 
Digital recordings were used to encapsulate the depth and tone of the interviewee‟s own 
language in order to add another dimension to the analysis of interviewee responses.   
 
5.6.5 Transcribing 
 
The interviewer transcribed verbatim each interview as Word documents on the same day that 
they were conducted (see Appendix 5). 
 
5.6.6 Thematic analysis 
 
The process of transcription aided familiarisation with the information provided by 
interviewees.  An index was generated using the transcribed data with information tagged into 
the relevant sub-topics to identify connections between them. 
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5.7 Key features of the combined approach 
 
The combined approach provided an opportunity to seek plausible accounts of how antibiotic 
prescribing was controlled  by focusing on the use of language and descriptive understanding 
to capture and interpret common sense, substantive meaning in the data and to identify all key 
themes, concepts and categories.   The key features of the combined approach are explained 
below. 
 
5.7.1 The setting for the combined approach 
 
The West Midlands SHA region was used as the setting for the combined approach and 
contained a total of seventeen PCTs.  In order to maximise the quality of the data obtained a 
decision was made to conduct the combined approach within one PCT rather than all PCTs 
within West Midlands region.  The combined approach was used to obtain naturally occurring 
data from Sandwell PCT with 37.5 hours a week, between December 2008 and October 2009 
dedicated to the collection of data.   
 
Sandwell PCT was the ideal choice of PCT within the West Midlands SHA region owing to 
the demographics and location of departments within the PCT.  The key demographic factors 
that were considered within the present research were a low level of white ethnicity and a 
high level of deprivation within a given region.  In doing so, issues and impact of residents 
who are culturally diverse and living a lower quality of life were accounted for in the present 
research.   Within the West Midlands, Sandwell was the second most deprived region (The 
English Indices of deprivation, 2008) and contained the second lowest percentage (79.7%) of 
people of white ethnicity (Sandwell Trends, 2008).  Heart of Birmingham PCT contained the 
most deprived population and lowest percentage (30%) of people of white ethnicity (Heart of 
Birmingham, 2008) within the West Midlands.  However Sandwell PCT was chosen as the 
source of naturally occurring data as the Public Health and Medicines Management 
departments were located within the same building and thus excluded environmental factors 
as sources of differences between how the two departments are able to improve antibiotic 
prescribing. 
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5.7.2 The primary focus of the combined approach 
 
There were two main approaches to analysis, analytical and substantive meanings (Ritchie 
and Lewis, 2003).   In the present research a decision was made to capture and interpret 
common sense, substantive meanings in the data.  This was achieved with all the naturally 
occurring data techniques incorporated within the combined research.  
 
5.7.2.1 Data storage 
 
The combined research could potentially yield a high volume of data, especially as the data 
was scheduled to be collected over a ten month period.  Therefore attempts had to be made to 
store the data appropriately in order to allow effective analysis.  Consequently, data reduction 
was a necessity and was achieved in the following research by using thematic summaries 
(descriptive accounts) and graphic displays of synthesised data.  Data was produced within 
Microsoft Office and stored on a computer to allow ease of storage. 
 
5.7.2.2 Concepts generation 
 
When analysing qualitative studies, a decision was made not to apply any initial labels on the 
data and instead allow participants to provide their own terminology.  These findings could 
then be developed into more definitive concepts at a later stage. 
 
5.7.2.3 Applying concepts to the data 
 
There were two methods that could have be used to organise and analyse labels and 
categories, cross sectional „code and retrieve‟ and non-cross sectional analysis (Mason, 2002).  
Cross sectional coding involves the application of categories to the whole data set and 
therefore allows the retrieval of data.  Non cross-sectional data organisation requires the 
separate analysis of all parts of the data and thus requires an alternative conceptualisation of 
categories.  A decision was made to use cross-sectional coding within the present research as 
it offered a systematic overview of the data.  Therefore all data was separated into folders, 
depending on the labels and categories placed on them.   
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5.7.2.4 Analytical tools 
 
In order to undertake robust analysis, it was important to refine and interpret the data 
collected.  As mentioned earlier, all the data was stored on a computer, with data placed in 
separate folders, depending on the category or categories they encompass.  An advantage of 
using this storage system was the ease within which new categories could be developed with 
emergent ideas or concepts and the ease with which the naturally occurring data could be re-
analysed if required.   
 
As the data was manipulated and stored within different folders it was important to ensure 
that copies of the naturally occurring data were kept in the original format.  Therefore an 
“original” folder was used to store all primary data. 
 
5.7.2.5 Identifying themes and concepts 
 
The first stage of concept generation was familiarisation with the data, which was further 
enhanced by personally conducting all qualitative research (including the semi-structured 
interviews).  Following on from this, the second stage involved identifying recurring themes 
with the data.  The combination of these first two steps produces the initial conceptual 
framework. 
 
Once produced, the conceptual framework was applied to the data obtained and was thus 
called „indexing‟ (Richards and Richards, 1994).  Indexing was applied manually and 
involved reading each graph, phrase, sentence and paragraph and determining which part of 
the index it applied to.  The index was then stored on a computer and was used to 
electronically move data into the required categories.  In some instances, the same data would 
be placed into more than one category, depending on the content. 
The final stage of concept generation involved summarising the data.  In order to ensure that 
the essence of the data was maintained, it was important to follow three key steps.  Key terms 
and phrases were retained as much as possible, interpretation was kept to a minimum and 
material was not dismissed as irrelevant if their inclusion was not immediately clear. 
 
  
 106 
5.7.2.6 Generalisation of data 
 
Hammersley (1992) discussed generalisation as either empirical or theoretical, both of which 
could be applied to populations or settings other than the study sample.  Empirical 
generalisation was defined as the application of qualitative research findings and theoretical 
generalisation was defined as the generation of theoretical concepts.  As it was very difficult 
to distinguish between both empirical and theoretical generalisation, generalisation could be 
clarified as having three linked but separate concepts.  These three concepts were defined as, 
representational, inferential and theoretical generalisation (Ritchie and Lewis, 2003).   
 
Representational generalisation was the question of whether the results of the research sample 
could be generalised to the parent population from which the sample was drawn.  Inferential 
generalisation took this concept further to determine whether the results could be generalised 
to other settings beyond the sampled one.  Finally theoretical generalisation drew principles 
or statements that could be applied generally. 
 
All these concepts were used in order to maximise the results obtained throughout the 
qualitative research process, which are shown below. 
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5.8 Results 
 
The results section will be divided into the semi-structured interviews and combined 
approach.  The discussion will then compare the results of both methods in order to determine 
the impact of methods used to improve antibiotic prescribing by current National Health 
System managers. 
 
5.8.1 Semi-structured interview results 
 
A key area of analysis during the semi-structured interviews was the intervention methods 
used by interviewees to improve antibiotic prescribing.  Figure 18 summarises the 
interventions mentioned by interviewees. 
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Figure 18: A chart showing the intervention methods mentioned by interviewees during 
their semi-structured interviews 
 
 
 
Figure 18 shows that there were twenty-three different intervention methods mentioned, all of 
which had been used in the review studies (Chapter 4). 
 
Intervention methods mentioned by all interviewees were INCENTIVE SCHEMES and 
PRACTICE BASED PHARMACISTS.  Three interviewees mentioned FORMULARIES and 
MEETING GPs on a one-to-one basis.  There was no one intervention mentioned by all 
interviewees that were classed as effective, or ineffective in controlling antibiotic prescribing.   
 
Interviewees 1, 2 and 4 thought PRACTICE BASED PHARMACISTS were influential in 
improving antibiotic prescribing.  Interviewee 1 quoted “The biggest success is having a 
pharmacist in the practice so they can nag the GPs really.”  This view was supported by 
interviewee 4 who quoted that “Practice pharmacists are very much clinical and so they can 
look at an individual practice basis and they can go to a practice meeting and say look 
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antibiotic prescribing is rubbish, what are we going to do to improve it.”  Interviewee 2 also 
stated that PRACTICE BASED PHARMACISTS were a “standard technique used in 
changing behaviour”.   Interviewee 3 also considered PRACTICE BASED PHARMACISTS 
to be a good idea, however felt that “As soon as you take pharmacists out of that practice the 
GPs will just carry on with their same behaviour.” Therefore Interviewee 3 has focused on 
interventions that “change patient and GPs‟ behaviour towards antibiotics”. 
 
The use of INCENTIVE SCHEMES was another intervention discussed by interviewees.  
Interviewee 4 did not directly express whether it was effective, or ineffective in improving 
antibiotic prescribing by quoting “We have got prescribing incentive scheme this year, which 
has got in it a little about cephalosporin and ciprofloxacin.  Basically if the practice has got a 
greater than average antibiotic use, they must agree to reduce the use of those antibiotics as 
part of their QOF target.  If they don‟t, they will have their reward reduced by 50%.  So it is 
fairly tough.  If they are below average then they won‟t have to address it because they are not 
too bad.  It is just the top few practices that tend to use them”.  Interviewees 1, 2 and 3 all 
were quoted as saying that the incentive scheme was effective in improving antibiotic 
prescribing.  Interviewee 2 quoted “We have used that as a measure in many incentive 
schemes and so that brings volume down a bit because people take notice of it.”  Interviewee 
3 also was quoted as saying “We also have a prescribing incentive scheme, which has been 
knocked around in the last couple of years.  But if you get it right it is probably the best way 
to get changes in prescribing.”   
 
Interviewee 1 also agreed but raised the issue of how financially costly it could be by quoting 
the following “Incentives always help but you have to get the funding for it.”  Funding was 
also a factor raised by Interviewee 3 who was quoted as saying “We are fairly lucky because 
we are a fairly cash rich PCT, and because of the work my team has done, if I wanted another 
post to do something specific, I can always get funding for that from this PCT.” 
 
Interviewees also provided their opinions on the success of other interventions used to 
improve antibiotic prescribing.  Interviewee 2 discussed ACADEMIC DETAILING, 
NEWSLETTERS and ADVERTISING and said “Academic detailing, the newsletter type 
thing that doesn‟t work.”   Interviewee 2 also believed ADVERTISING could not 
successfully control antibiotic prescribing and quoted “So the government can do their 
campaign, it will raise public awareness, fine.  But that won‟t affect the volume of antibiotics 
prescribed.”  
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Interviewee 3 provided an opinion on the effectiveness of FORMULARIES by quoting “You 
shouldn‟t have a formulary for antibiotics because GPs are very simple creatures.  If you say 
to them use amoxicillin for simple chest infections, they will hear it is okay to use 
amoxicillin.”  This view wasn‟t expressed by Interviewees 1 and 4 who used formularies to 
influence their prescribing and believe that GPs actually need a formulary, with Interviewee 4 
quoting “Many of ours need a formulary frankly.”  Interviewee 1 was quoted as saying 
“Antibiotic formulary that is agreed and updated every year with the local microbiologists and 
clinicians obviously, and that goes out and is available on our website on our intranet and that 
supports GPs and their prescribing and it is a guideline and formulary, you know, this is first 
line, this is second line, and why, so I am fairly confident we do prescribe pretty much to 
formulary.”  Interviewee 2 didn‟t provide an opinion on the use of FORMULARIES but did 
state that “We don‟t have a formulary. That was flagged up by the Healthcare Commission, 
we are actually developing that at the moment.” 
 
Of the present policies mentioned, three of the four interviewees considered PRACTICE 
BASED PHARMACISTS to be a successful method of controlling antibiotic use, with the 
only exception being interviewee 3 (as discussed earlier).  The use of FORMULARIES was 
also mentioned as a current intervention used, or about to be used, by all interviewees except 
interviewee 3.  The systematic review completed (Chapter 4) also supported the interviewees 
views, with two possible successful interventions being the use of PHARMACISTS and the 
implementation of GUIDELINES. 
 
5.8.1.1 Time frame 
 
Figure 18 shows that there are a number of possible interventions available to aid NHS 
managers improve antibiotic prescribing.  A key area of discussion within the semi-structured 
interviews was the time frame used for their chosen intervention.  There was a general 
consensus from interviewees that priorities were set each year and then reassessed for the 
forthcoming year, with only interviewee 3 adopting a “two-year plan” for set priorities.  
Interviewee 1‟s response summarises how long Interviewees 2 and 4 also set their 
interventions for with the quote “We do them in yearly blocks, so if you have an initiative 
going, we‟ve got priorities this year and antibiotics is up there we will continue to monitor 
and feeding stuff throughout the year and we will monitor prescribing feedback from our 
team.” 
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5.8.1.2 Antimicrobial specialist/role of Primary Care Trust 
 
All interviewees mentioned the presence of antimicrobial specialist(s) at hospitals within their 
region.  Interviewee 4 stated that they were also appointing an antibiotic pharmacist within 
their department “who can look at the use in primary care, nursing homes” in order to „Close 
the loop”.  Interviewee 1 only mentioned the presence of an antibiotic pharmacist at their 
local hospital “who we can call upon”.  Interviewee‟s 2 and 3 however provided more detail 
of their direct relationship with the antibiotic pharmacists used to produce a “joint formulary”.  
 
5.8.1.3 Antibiotic data and outcome measures 
 
The semi-structured interviews confirmed that all Primary Care Trusts used outcome 
measures for antibiotic prescribing.  However there seemed to be no universal outcome 
measure used to present antibiotic data at Primary Care level, which could lead to 
inconsistency in the analysis of antibiotic prescribing between PCTs.   Interviewee 1 stated 
that “Items of antibiotics prescribed don‟t give you the full picture” whilst Interviewee 3 was 
quoted as saying “You have to remember changing antibiotics isn‟t about cost, but because 
we have done it we‟ve probably saved around 250000 pounds a year on reduced prescribing 
within this PCT, so you can justify doing it anyway.”  Interviewee 4 mentioned that antibiotic 
prescribing data was provided by “ePACT” who provide a “quarterly toolkit”, however did 
not provide knowledge of exact outcome measures used.    In comparison, Interviewee 2 
provided details of outcome measures used and was quoted as saying “Previously for 
antibiotics we have used items per STAR-PU and the number of scripts per patient.” 
 
5.8.1.4 Government involvement 
 
All interviewees provided a wide range of views on how the government helps/influences 
antibiotic prescribing and how information on improving antibiotic prescribing was 
disseminated to Primary Care Trust level.  Interviewee 4 stated “I don‟t understand why when 
the government are looking at MRSA and C Diff in hospitals so bad that and that there is a 
link to antibiotic use, why they don‟t they get the message out to the public and the GP‟s.  I 
know there is a perception that the public are requesting it, but in some of our areas it actually 
 112 
is.”  Interviewee 1 also quoted that “There is government funding coming down for infection 
prevention control but not for antibiotics, nothing related to prescribing.”   
 
All interviewees discussed the role of the Strategic Health Authority (SHA) and provided 
differing views of their impact on antibiotic prescribing.  Interviewees 2 and 3 both stated that 
the role of the SHA “has never been well established” and thus they “don‟t know” exactly 
what their role is.  Contrarily, Interviewee 4 quoted that “They liaise between the Department 
of Health and PCT level, so it‟s that kind of cascade of information.”  Interviewee 1 also 
stated that representatives from the SHA “did presentations around the other PCTs”. 
 
The level of communication between the Heads of Medicines Management of Primary Care 
Trusts also seemed to be an issue as all four interviewees met regularly, although it was 
ambiguous whether these were successful for exchanging ideas.  Interviewee 4 was quoted as 
saying “we do work a lot together”, whilst Interviewee 2 quoted that “there is certainly shared 
practice”, Interviewee 3 only mentioned that the Heads of Medicines Management “meet as a 
group” and did not provide any more information. 
 
5.8.2 Results of the combined approach conducted at 
Sandwell PCT 
 
The combined approach was conducted at Sandwell PCT in order to analyse exactly how a 
Medicines Management department within PCTs attempt to improve antibiotic prescribing.  
The results will detail all the interventions used within the Medicines Management team to 
control antibiotic prescribing in terms of; who was responsible for the implementation and 
progress of intervention, what the intervention entails and when the intervention was 
implemented. 
 
5.8.2.1 Audits 
 
Audits have been used for many years to evaluate the quality of prescribing, with antibiotics 
audited to determine the indication for use, dosing and length of treatment. 
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5.8.2.1.1 How were audits completed? 
 
The Medicines Management team had always completed audits on a range of drugs on behalf 
of surgeries within the Sandwell PCT.  However the detail of the completed audit depended 
largely on the ability of the Medicine Management team to balance the number of audits 
requested against the time available within surgeries to complete the required audits.   
 
For example if a surgery required an antibiotic audit to be completed, a member of the 
Medicines Management team would arrange a series of dates with the surgery to complete the 
audit.  The detail in which audits were completed depended on the number of patients 
prescribed antibiotics in a given period of time balanced against the amount of time available 
to the Medicines Management team member to complete the audit.  If the designated member 
of the team did not have enough time available in their schedule to complete the antibiotics 
audit in detail, time would be saved by reducing the number of criteria required to complete 
the audit, such as the indication for use and the patient date of birth.   
 
Antibiotics were mainly audited at those surgeries participating in the antibiotics incentive 
scheme (explained further in section 5.8.2.1.8) or where the number of antibiotics prescribed 
exceeded the average antibiotic prescribing within Sandwell PCT. 
 
5.8.2.1.2 Pharmacist and technician involvement 
 
The structure of the Medicines Management team had resulted in an inconsistent spread of 
pharmacists and technicians working at surgeries within Sandwell PCT, meaning that any 
pharmacist and/or technician could be required to complete an audit.  The differing levels of 
expertise, qualifications and experience may have therefore had an impact on the results and 
detail present within audits. 
 
5.8.2.1.3 Audit template 
 
All audits conducted by the Medicines Management team have required the completion of an 
audit template on a Microsoft Excel spread sheet.  The audit templates were individualised to 
the drug(s) being audited, with antibiotics audit templates including information such as age 
of patients, drug name and indication for use.   
 
 114 
The responsibility for the template content was delegated to the pharmacist present within the 
surgery.  However, if no pharmacist was present within a surgery then a technician was 
delegated the task of completing the audit template produced with the help of a pharmacist 
from the Medicines Management team.  Pharmacists had autonomy in the design of audit 
templates produced and thus there were no single standardised templates used, which resulted 
in inconsistent results. 
 
5.8.2.1.4 Prescribing software 
 
The lack of control demonstrated by Sandwell PCT over the choice of a single prescribing 
software choice for surgeries resulted in the use of five different prescribing softwares within 
surgeries in Sandwell PCT.  These were Synergy, EMIS, SystmOne, Torex and Vision, all of 
which contained unique programs to produce audits and thus influenced the inconsistent 
retrieval of results.  For example Vision did not allow patient numbers or indication for 
antibiotic use to be searched like all other software, instead patient records had to be analysed 
manually to retrieve the required data.  
 
5.8.2.1.5 Length of audit period 
 
The chosen length of audit period was ultimately decided at the discretion of the pharmacist 
or technician completing the audits, thus leading to inconsistent lengths of audit periods.  
Their judgement was dependant on the amount of time they had to complete the audits, the 
number of patient records they would have to search through to complete an audit template, 
their ability to maximise the computer software and the quality of records kept by prescribers.  
There was no direction from the Head of Medicines Management on how many patient 
records were required to validate the audit, or deadlines for the audits.   
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5.8.2.1.6 Antibiotics audited 
 
Antibiotics prescribed in Primary Care included; cephalosporins, quinolones, macrolides, 
penicillins and tetracyclines with the choice of antibiotics chosen for audit depending on their 
association to cases of resistance (and the consequences of resistance).  Therefore audits in 
Sandwell PCT focused on cephalosporin and quinolone prescribing within surgeries.  A 
drawback of focusing on specific antibiotic groups was the lack of knowledge the reduction 
of one antibiotic class had on the use of others.  For example focusing on reducing 
cephalosporins may have increased the use of co-amoxiclav. 
 
5.8.2.1.7 Actions set and follow up 
 
The results of completed audits were reported back to prescribers, from which actions were 
set with prescribers to improve prescribing.  However once actions were set there was no 
consistency in the follow up audits to ensure actions were completed successfully.  This 
negated the importance of the audit as the follow up on improvements were not consistently 
assessed.   
 
5.8.2.1.8 Prescriber incentives 
 
There were two incentive schemes provided to surgeries by the Medicines Management team 
called the Prescribing Incentive Scheme (PrIS) and mm6.  The aims of these prescribing 
incentives were to motivate prescribers to improve prescribing by providing financial rewards 
based on the results of audits completed at the start and end of the financial year. 
 
The PrIS was developed by the Medicines Management team in 2006 with financial rewards 
provided for improvements within surgeries.  A selection of audit targets were provided each 
year to all surgeries, with the final choice of targets being decided in a meeting between 
prescribers representing a surgery and a pharmacist representing the Medicines Management 
team.     
 
In June 2003 the government modernised general practice by producing an NHS contract 
between PCTs and surgeries (not individual prescribers) called the GMS contract.  Under the 
Medicines Management section of the GMS contract surgeries were provided points for 
achieving targets (called mm6). The financial rewards were calculated using a formula based 
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on the number of points achieved and the surgery population profile, such as list turnover for 
each surgery and the cost of living for staff. 
 
5.8.2.1.9 Quality of record keeping 
 
The success of any audit was dependent on the quality of record keeping by prescribers, 
therefore it was essential for all prescribers to record all patient consultations appropriately on 
their prescribing software.  The quality of record keeping may have been affected by many 
factors, two of which include IT literacy and prescriber motives.   
 
The lack of IT literacy demonstrated by a prescriber affected the quality of patient records 
kept on the computer software with the prescriber writing very minimal notes on the 
prescribing software or relying on paper notes, thus reducing the amount of information 
retrieved on audits.   
 
The motives of prescribers also affected results of audits as information may have been 
purposely omitted in the hope that the Medicines Management could not retrieve the required 
data to complete audits.  In doing so it was impossible for actions to be set, as the results were 
considered invalid. 
 
5.8.2.2 Newsletters 
 
There were two newsletters produced by the Medicines Management team every financial 
quarter that targeted pharmacists and prescribers.  The contents of the newsletters were based 
on current topics of interest or issues pharmacists within the Medicines Management wanted 
to feedback to either GP‟s or pharmacists, meaning that the issue of antibiotics and resistance 
would only be mentioned in newsletters on an adhoc basis when there were growing concerns 
over antibiotic prescribing. 
 
A pharmacist within the Medicines Management team was responsible for the continuing 
production of the Newsletters and decided on the content after discussion with all members of 
the Medicines Management team. 
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5.8.2.3 Policies and formulary 
 
The Sandwell PCT Formulary was revised by the Head of Medicines Management every two 
years and contained an antibiotics section focusing on treatments for general conditions seen 
within Primary Care.  There was no consultation with the infection team present at the Acute 
Trust on the choice of antibiotics in order to factor in local sensitivity and resistance data.  
The impact of the formulary had never been analysed as data retrieval failed to assess 
compliance to formulary guidance.   
 
5.8.2.4 Prescriber meetings 
 
Prescriber meetings were the most popular strategy used by the Medicines Management team 
to inform prescribers, ranging from one-to-one meetings to practice meetings.   The meetings 
were facilitated by all members of the Medicines Management team and involved discussion 
of any issues that needed flagging with prescribers.  The prescriber meetings were either 
arranged on a regular basis or on an ad hoc basis. 
 
5.8.2.5 Prescribing alerts 
 
Alerts were an option used on some prescribing software and involved linking the choice of a 
drug with a pop up message appearing on the computer screen.  Once installed, the 
prescribing alerts could only be stopped if uninstalled by the Medicines Management team.  
In the case of antibiotics, alerts were used to link the use of cephalosporins and quinolones to 
the rise of Clostridium difficile.  Alerts had been implemented to some surgeries by different 
members of Medicines Management, thus leading to inconsistency in the content and 
appearance of the prescribing alerts.   
 
5.8.2.6 Prescribing events 
 
The Medicines Management team have conducted prescribing events for target audiences in 
an ad hoc manner because of requests to do so or events organised by the Medicines 
Management team.  Antibiotic events have not been conducted regularly with only one large 
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event held in the past 3 years to address the issues of antibiotics and resistance to prescribers, 
with the presence of an influential guest speaker.   
 
There was one event held every quarter called the Protected Learning Time (PLT) event 
available for prescribers who were incentivised to attend by providing a prescriber (free of 
charge) to cover their absence from their surgery.  The contents of each PLT event was 
organised by the Medical Director who occasionally provided the opportunity to the 
Medicines Management team to influence a large audience of prescribers with presentations. 
 
5.8.2.7 Surveillance 
 
Antibiotic prescribing was analysed by a member of the Medicine Management team on a 
monthly basis using ePACT with all surgeries graphically placed in ranking order, from the 
highest prescribers of any given antibiotic at the top and the lowest at the bottom.  Antibiotics 
associated to cases of resistance (and the consequences of resistance), which have been 
analysed in this manner include cephalosporins and quinolones.  Analyses of the impact of 
individual interventions were never attempted with prescribing analysis, instead the focus was 
placed on how the PCT compared to the national average for total antibiotics, cephalosporin 
and quinolone prescribing. 
 
5.8.2.8 Interaction with other Primary Care Trusts 
 
There was very little communication between Sandwell PCT and neighbouring PCTs 
regarding antibiotics and infection control.  Sandwell PCT shared the same Acute Trust as 
Heart of Birmingham PCT, however tackled issues of antibiotic control very differently.   
 
Heart of Birmingham PCT did not have a Specialist Antibiotic Pharmacist and thus measured 
success in terms of prescription numbers with the objective being to reduce the number of 
total antibiotics prescribed.  Alternatively, Sandwell PCT measured prescribing in terms of 
compliance with the objective of improving prescriber adherence to the formulary.   
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5.9 Discussion 
 
Qualitative research was conducted in order to explore the impact of methods used to improve 
antibiotic prescribing by current National Health System managers within selected Primary 
Care Trusts.  Two types of qualitative research were conducted, semi-structured interviews 
and the combined approach.  The use of a combination of generated and naturally occurring 
data provided varying insights in order to achieve the aim set in section 5.2. The achieved 
results stimulated discussion of three areas which affect antibiotic prescribing; interventions, 
outcome measures used to analyse prescribing and government involvement to improve 
antibiotic prescribing. 
 
5.9.1 Interventions 
 
The qualitative research process highlighted a number of interventions that have been, and are 
currently used to improve antibiotic prescribing.  However a key finding from the semi-
structured interviews was the lack of agreement on which interventions successfully control 
antibiotic prescribing.  The combined approach highlighted why this was the case, as the 
impact of interventions was never analysed.  Instead the interviewees provided their opinions 
on which interventions they felt have worked within the multifaceted approach present within 
their PCT.  Interviewees may have reached an agreement on the impact of interventions if 
focus groups were used and thus the use of semi-structured interviews may have been a 
limitation in this respect. 
 
The most commonly mentioned interventions within the semi-structured interviews were 
incentive schemes, practice based pharmacists (pharmacy intervention), formularies or 
guidelines and meeting GPs on a one-to-one basis.  The use of pharmacy intervention was 
highlighted as a key intervention used to improve antibiotic prescribing by Pastel (1992), 
Dranitsaris (2001) and Seager (2006) within the systematic review completed in Chapter 4.  
However, they also stated that caution was needed when generalising these findings to other 
settings as studies provided insufficient detail and comparisons in how pharmacy intervention 
was best achieved.   
 
The use of guidelines was also seen as a key intervention used to improve prescribing within 
the systematic review completed in Chapter 4.  This was supported by the systematic review 
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completed by Thomas et al (1999), who also concluded that caution was needed when 
generalising these findings to other settings as studies provided insufficient detail.  Therefore 
more research was required in the application of both pharmacy intervention and guidelines to 
improve antibiotic prescribing within Primary Care, this was achieved through the combined 
approach used.   
 
The combined approach also highlighted the importance placed on the use of incentive 
schemes to improve antibiotic prescribing within Primary Care.  However, research 
conducted by Doran et al. (2011) and Campbell et al. (2009) on the impact  of financial 
incentive schemes within Primary Care in England produced two key conclusions.  Firstly, 
improvements in prescribing were associated with the use of incentive schemes, sometimes at 
the expense of quality of care with non-incentivised indications.  Secondly, continuity of care 
was reduced after the introduction of the incentive scheme.  Therefore the use of financial 
incentive schemes to improve antibiotic prescribing within Primary Care may be successful, 
however has to be balanced against the possibility of reduced quality of care in other areas of 
practice and also the need to for continuing incentives to ensure improvements in antibiotic 
prescribing were met.    
 
The combined approach also highlighted the lack of importance placed on the use of audits to 
improve antibiotic prescribing, with their effectiveness in improving prescribing being 
supported by three systematic reviews conducted Ostini, et al (2009), Grindrod, et al (2008) 
and Arnold and Straus (2007).  The combined approach identified that audits required the 
involvement of practice based pharmacists to provide analysis of prescribing at surgeries 
(especially those participating in the incentive scheme) by using the formulary to justify 
appropriate antibiotic prescribing.  The results of the audits were then presented back to 
prescribers through practice meetings or one-to-one meetings.   
 
Overall, the qualitative research has highlighted the scope of interventions available to 
improve antibiotic prescribing within Primary Care, however more research has to be 
undertaken to determine their impact on antibiotic prescribing.  Therefore the outcome 
measures used analyse antibiotic prescribing is an important issue and will be discussed 
further below.  
 
  
 121 
5.9.2 Outcome measures used to analyse antibiotic 
prescribing 
 
The interviewees mentioned several outcome measures that had been used to analyse 
antibiotic prescribing, with only interviewee 4 indicating where this prescribing data was 
obtained from.  Therefore there was no clarity on how these outcome measures were decided 
upon, or where this data was obtained or calculated.  These questions were answered with the 
use of the combined approach as the source of data was found to be ePACT, which also 
contained agreed national outcome measures for antibiotic prescribing.  These outcome 
measures were number of prescriptions and items per STAR-PU and were available to PCTs.  
The outcome measures were decided after consultation and agreement with all NHS bodies 
and were an example of assistance provided by the government to improve analysis of 
prescribing.   
 
5.9.3 Government involvement in improving antibiotic 
prescribing 
 
All interviewees demonstrated a lack of knowledge on how information was disseminated 
from the government to the Primary Care Trust level.  This could firstly be the result of too 
many publications and policies produced by the Department of Health to guide control of 
antibiotic use, which made it difficult to track policies produced for antibiotics.  Secondly 
there could be a lack of communication between the Department of Health, the Strategic 
Health Authorities and Primary Care Trusts in implementing the policies produced. 
 
The level of communication between the Heads of Medicines Management of Primary Care 
Trusts also seemed to be an issue as all four interviewees met regularly, although it was 
ambiguous whether these were successful for exchanging ideas.   
 
With regard to the direct implementation of interventions by the government, the interviewees 
expressed a need for national promotion of the implications of antibiotic use to the public.  
The interviewees felt that national awareness campaigns would help ease the pressures placed 
on prescribers and thus reduce overall antibiotic prescribing.  Questions regarding the 
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influence of the SHA on antibiotic prescribing also provided mixed opinions with the 
majority of interviewees stating that they provided little assistance to improve prescribing.   
 
Analysis of these issues through the combined approach seemed to provide agreement with 
the majority of views expressed by interviewees.  The SHA provided little or no assistance to 
PCTs to improve antibiotic prescribing and the government never prioritised improvements in 
antibiotic prescribing as a national promotional campaign.  The Department of Health website 
did contain antibiotic leaflets and posters which could be downloaded or ordered and used 
within healthcare practices.  However no incentives were placed to use these documents, nor 
were they promoted to all health care bodies.  
 
5.9.4 Limitations of the qualitative research used 
 
The semi-structured interviews and combined research approaches used within the present 
research achieved the aim and objective set.  However there were limitations in the research 
conducted which will be discussed further below. 
 
5.9.4.1 „Theoretical saturation‟ 
 
Ritchie and Lewis (2003) stated that “The key criteria for selection in theoretical sampling are 
theoretical purpose and theoretical relevance.  Sampling continues until „theoretical 
saturation‟ is reached and no new analytical insights are forthcoming.  In so doing, the 
researcher does not look just for confirmatory evidence but also searches for „negative cases.”    
 
The results of the semi-structured interviews highlighted that „theoretical saturation‟ was not 
reached on many issues discussed as there were no firm conclusions on many issues covered.  
Therefore it can be assumed that more than four interviewees should have been selected to 
conduct the semi-structured interviews.  The combined approach provided many answers to 
the issues concerned within the semi-structured interviews, however it could be argued that a 
limitation of the approach was that the research was only conducted in one SHA and PCT 
region.  This limitation also applies to the selected interviews as they were all located within 
one SHA, therefore the results were maybe not representative of the situation in the rest of the 
United Kingdom.  In hindsight, the purposive sample should have included more than four 
interviews and offered all Heads of Medicines Management within England the opportunity 
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to participate in the semi-structured interviews.  More attention should have also been paid to 
the role of prescribers to improve antibiotic prescribing and they should have also been 
invited to participate in the semi-structured interviews as their insight may have provided 
more avenues to improve antibiotic prescribing and provide further insight into how effective 
the current government structure is in improving antibiotic prescribing.   
 
5.9.4.2 Bias 
 
Bias is a limitation that has already been touched upon within the discussion of „theoretical 
saturation‟ as the qualitative research was only conducted within one SHA region.    However 
bias may also have been present within interviewee responses and the behaviour of staff when 
conducting the combined approach.  A key disadvantage of the semi-structured interviews 
was the balance between answers provided by interviewees against their openness in 
answering questions, although it was likely that a number of factors affected the answers 
obtained.  These include, the location for the conduct of interviews, the time available to 
complete interviews, the interviewee interest in antibiotics resistance and the experience of 
the interviewees in their current roles.  All attempts were made to keep the qualitative 
research as consistent as possible, however the nature of semi-structured interviews and 
combined approach means any bias present may have affected the approach adopted by 
interviewees and PCT staff. 
 
5.9.4.3 Reliability  
 
Semi-structured interviews are difficult, if not impossible to repeat exactly since many of the 
questions are not pre-determined and the interviewees are encouraged to talk freely and in-
depth about many issues.   Reliability was also an issue within the combined approach as it is 
very difficult to replicate the methods within other PCTs as the structure and availability of 
staff could vary greatly.  Therefore reliability may have been a limitation within the present 
research. 
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5.9.4.4 The rigour of qualitative research conducted 
 
A limitation of the present research was the use of a single pilot semi-structured interview in 
order to analyse the quality of responses achieved from the questions posed.  Ideally, two 
interviews would have been used to pilot the interview schedule and the lack of pilot research 
and quality assurance approaches ultimately led to an oversight in how the interviews were 
approached and conducted.  An example of this was the great variability in the information, as 
interviews were conducted at convenient locations for the interviewees and thus conducted 
within an open or private office.  Conducting interviewees in open-plan offices may have led 
to interviewees not providing honest responses because of the presence of other colleagues 
within the office.  In hindsight the qualitative research conducted was not as rigorous as it 
could have been and can be considered as a major limitation. 
 
5.10.5 Further work 
 
The qualitative research raised a number of areas within Primary Care where improvements 
can be made to improve antibiotic prescribing, focusing on increased communication, 
improved prescribing analysis and employment of antibiotic pharmacists.   
 
5.10.5.1 Employment of Antibiotic Pharmacists 
 
The semi-structured interviews have identified the presence of antimicrobial specialist staff 
either employed within PCTs, or employed at the local Acute Trust.  However, the lack of 
knowledge between interviewees of which interventions successfully controls antibiotic use 
suggest that either there is poor communication between the antimicrobial specialist (working 
within Acute Trust and/or PCT) and heads of Medicines Management.  To overcome this lack 
of information a Specialist Antibiotic Pharmacist should be employed at SHA level to 
evaluate the strategies implemented at PCT level, improve collaborative work between all 
PCTs in the region and to produce a detailed prescribing feedback tool. 
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5.10.5.2 Prescribing analysis 
 
The qualitative research has identified the inconsistent analysis of antibiotic prescribing being 
undertaken at PCT level where different antibiotics were analysed and different outcome 
measures used to analyse their prescribing.  Therefore a prescribing feedback tool should be 
produced which allows analysis of all antibiotics prescribed in Primary Care.  The production 
of the feedback tool should be undertaken at SHA level to ensure there is consistency in the 
outcome measure used and antibiotics analysed.  The data should be specific to surgery level 
and be disseminated to PCTs who can then analyse and disseminate results to their respective 
surgeries.  The prescribing feedback tool can also be used to analyse the impact of any 
intervention used and thus determine whether interventions are worth continuing. 
 
5.10.5.3 Communication 
 
There needs to be more effective communications within Primary Care to improve antibiotic 
prescribing.  Therefore there needs to be more focused meetings on how to control antibiotic 
prescribing, which can be facilitated by an Antibiotic Pharmacist present at SHA level.  It is 
also important for more collaborative work to be conducted between PCTs and their nearest 
Acute Trust in order to identify areas where improvements in antibiotic prescribing can be 
made, for example with the production of a collaborative formulary or joint presentations to 
prescribers. 
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5.11 Conclusions 
 
Overall the qualitative research provided comprehensive analysis of the issues faced, and 
attempts made to improve antibiotic prescribing within Primary Care.  The semi-structured 
interviews facilitated discussion of very complex issues regarding the control of antibiotic 
prescribing and the combined approach allowed analysis of how improvements in antibiotic 
prescribing were attempted.  
 
The qualitative research used in the present research achieved the set aim and objective, 
however there were many limitations in the choice of qualitative research methods chosen and 
how it was implemented.  These limitations however must be juxtaposed with the potential 
significance of the results achieved.   
 
The first key conclusion from the qualitative research was the lack of intervention analysis 
conducted within Primary Care.  Therefore interviewees were unable to provide evidence for 
the success of particular interventions implemented and thus focused on the impact of a 
multifaceted approach.  Even the impact of their multifaceted approaches were only analysed 
in comparison to other PCTs and SHAs rather than against their own long term prescribing.   
 
The second key conclusion was the lack of importance placed by interviewees on the use of 
audits to improve prescribing.  Many interventions were mentioned by interviewees 
throughout the semi-structured interviews, however it was only the conduct of the combined 
approach that highlighted the importance of audits within Primary Care.  Many of the 
interventions deemed as important by interviewees in improving antibiotic prescribing were 
actually used as a component of the audit process.  It may be that the uses of audits were so 
embedded within Primary Care that interviewees failed to acknowledge it as a noteworthy 
intervention. 
 
Outcome measures used to analyse antibiotic prescribing was a key area of analysis within the 
qualitative research.  The semi-structured interviews failed to obtain much information from 
interviewees on how they analyse antibiotic prescribing.  However the combined approach 
provided a very detailed insight into not only what outcome measures were used, but also 
how and when this information was obtained.  This area of analysis alone highlights how the 
variations in the qualitative research facilitated the retrieval of accurate and detailed 
information by using a combination of qualitative research.  The key outcome measures used 
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within Primary Care were number of prescriptions and items per STAR-PU.  This data could 
be regularly obtained through ePACT. 
 
The final key conclusion focuses on the lack of communication between the Government, 
Department of Health, Strategic Health Authorities and PCTs.  Overall there is agreement that 
antibiotic prescribing is a national concern, however there seems to be no cohesive approach 
between all Healthcare bodies to improve antibiotic prescribing.  Instead there seems to be 
reluctance by all Healthcare bodies to take responsibility for the improvements in antibiotic 
prescribing and thus place more importance on other bodies to find solutions to improve 
prescribing. 
 
Overall the qualitative research has highlighted a number of issues that need to be addressed 
in order to improve antibiotic prescribing.  These include, improving prescribing analysis 
(and thus determine the impact of any given intervention), employing specialist Antibiotic 
Pharmacists within Primary Care and improving communication between all Healthcare 
bodies. 
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6. Development and implementation of the 
prescribing analysis tool 
 
The qualitative research conducted in Chapter 5 highlighted the potential importance of 
improved communication, improved prescribing analysis and employment of antibiotic 
pharmacists on improving antibiotic prescribing within Primary Care.  A qualified pharmacist 
who specialises in antibiotics (HD, who will be subsequently referred to as the referred to as 
the “Specialist Antibiotic Pharmacist”) personally produced and implemented the aims and 
objectives (as shown below) in order to improve antibiotic prescribing through improved 
antibiotic prescribing analysis and communication within a selected Primary Care Trust.   
 
6.1 Aim 
 
 To devise and implement an antimicrobial prescribing analysis tool within a Primary 
Care Trust. 
 
6.2 Objectives 
 
1. To produce and implement the prescribing analysis tool within Sandwell Primary 
Care Trust to analyse prescribing: 
a) By Sandwell Primary Care Trust. 
b) By all General Practitioners within Sandwell PCT. 
c) Every financial quarter. 
d) In terms of their chemical substance (for example ciprofloxacin being the 
chemical substance instead of Ciproxin tablets). 
e) To practice level. 
f) By using two outcome measures for analysis of prescribing called: 
 Number of prescriptions for antibacterial drugs (5.1) per Star-PU. 
 Number of prescription items for cephalosporins and quinolones as a 
percentage of the total number of prescription items for selected 
antibacterial drugs (BNF 5.1). 
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2. To produce the prescribing analysis tool on Microsoft Excel because: 
g) All members of the Medicines Management team were familiar with 
Microsoft Excel. 
h) It enables analysis of trends in prescribing using drop down menus. 
i) It uses a number of visual electronic outputs with different visual displays. 
 
3. To use the  prescribing analysis tool as an intervention to achieve reductions in 
overall antibiotic, cephalosporin and quinolone prescribing within Sandwell Primary 
Care Trust, in comparison to: 
j) The previous financial year. 
k) The West Midlands Strategic Health Authority average prescribing rate. 
l) The national average prescribing rate. 
 
4. To use log odds ratios (using 95% confidence intervals) to analyse the significance of 
the prescribing analysis tool on reducing overall antibiotic, cephalosporin and 
quinolone prescribing within Sandwell Primary Care Trust, in comparison to: 
m) The West Midlands Strategic Health Authority average prescribing rate. 
n) The national average prescribing rate. 
 
5. To evaluate the significance of the prescribing analysis tool on reducing overall 
antibiotic, cephalosporin and quinolone prescribing within Sandwell Primary Care 
Trust, in comparison to: 
a) The West Midlands Strategic Health Authority average prescribing rate. 
b) The national average prescribing rate. 
 
6.3 Source of data for the prescribing analysis tool 
 
The qualitative research conducted in Chapter 5 identified two key sources of data that could 
achieve the objectives set in section 6.2 (ePACT and the completion of audits).  Therefore 
both options were further evaluated in order to determine which would be used as the source 
of data within the prescribing analysis tool, as shown in Table 13 below. 
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Table 13: Evaluation of ePACT and audits as a source of data for the prescribing 
analysis tool 
 
ePACT Audits 
Data can be extracted from all surgeries by 
one person 
Data extraction from all surgeries requires 
involvement of more than one person 
Consistency in data extraction can be 
achieved 
Data extraction can be inconsistent 
Training on one database is required to 
retrieve data 
Training on five different prescribing software 
required to retrieve data 
Prescriptions that are not entered within GP 
prescribing systems can be accounted for 
Does not include antibiotics not entered on the 
GP prescribing system 
All required data can be downloaded in 
minutes 
Data extraction can last hours  
Outcome measures are already applied to 
prescribing data 
Outcome measures have to be manually applied 
to prescribing data  
Provides an opportunity to produce an 
efficient national prescribing feedback 
system 
Producing a national surveillance system is 
possible 
Access to ePACT requires use of password 
Access to GP prescribing systems requires use of 
a password 
ePACT can be accessed from any location 
within the PCT 
GP prescribing data can only be accessed from 
the respective surgeries 
Reasons for why antibiotics were prescribed 
is not retrievable 
Provides opportunity to read patient notes and 
obtain details of why antibiotic was prescribed 
 
ePACT was chosen to provide data for the prescribing analysis tool owing to the key 
advantages (in comparison to audits) highlighted green in Table 13.  Therefore a key 
disadvantage of using ePACT instead of audits was the inability to determine indications for 
antibiotic prescribing.  Appendix 6 details how ePACT was used to retrieve the required data 
and produce the prescribing analysis tool. 
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6.4 The completed design of the Database 
 
The final version of the prescribing analysis tool was produced using Microsoft Excel and 
contained data on 117 drugs present in Chapter 5 of the British National Formulary (BNF), 
from Q2 04/05 to the present, thus making it a unique form of feedback within Primary Care.   
 
The Antibiotic Database currently contained data for antibacterial, antifungal, antiviral, 
antiprotozoal and anthelmintic drug categories which could be selected between by using the 
Medication category column (as shown in Figure 27).  However, the Specialist Antibiotic 
Pharmacist named the database the “Antibiotic Database” as it was only used to analyse 
antibacterial prescribing. 
 
The layout of the Antibiotic Database was divided into three distinct areas of surveillance, (1) 
Prescribing Table, (2) Summary Graphs and (3) Key Antibiotic Analysis Graphs as shown in 
Figure 19 below. 
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Figure 19: Screen capture of the Antibiotic Database 
 
 
 
 
 
 
 
  
Prescribing Table 
 
Summary Graphs Key Antibiotic Analysis 
Graphs 
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6.4.1 The Prescribing Table 
 
The Prescribing Table contained details of all the drugs (from Chapter 5 of the BNF) 
prescribed by a practice or PCT within a selected period of time. Figure 20 shows the 
prescribing table in more detail. 
 
Figure 20: Screen capture of the Prescribing Table 
 
 
 
 
 
 
 
 
The Prescribing Table contained two columns, the first contained the names of drugs 
prescribed and the second column contained the number of times they were prescribed.  If a 
chemical substance from Chapter 5 of the BNF was not prescribed within a given quarter then 
the drug name did not appear in the Prescribing Table.  The user could select the data for any 
quarter since (and including) Q2 04/05 by using the selection tab.  When a new quarter was 
selected the data within the prescribing table automatically updated to present the prescribing 
data from the selected quarter.    
Selection tab 
Selected quarter 
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6.4.2 Analysis of antibiotics prescribed 
 
Figure 21 below shows that the analysis of antibiotics was achieved using the six summary 
graphs.  Five of these graphs allowed analysis of any given chemical substance from Chapter 
5 of the BNF, and the sixth graph was used to present the summary results of the five analysis 
graphs. 
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Figure 21: Screen capture of visual electronic outputs used to analyse antibiotics 
prescribed by a practice, PCT, SHA or nationally 
 
 
 
 
 
The Summary Graphs allowed the user to view prescribing in a variety of ways as shown 
within Figures 22 to 30. 
  
Summary for the five analysis graphs Five Analysis graphs 
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Figure 22: An example of Analysis Graphs 
 
 
 
The Analysis Graphs could be automatically updated using data within the table above the 
graph.  The table contained four criteria, (1) Total items or Items per STAR-PU (explained 
further in section 6.4.3), (2) Quarter (explained further in section 6.4.4), (3) Medication 
category (explained further in section 6.4.5) and (4) Medication (explained further in section 
6.4.6).   
 
6.4.3 Outcome measure selected within Analysis 
Graphs 
 
Total items or Items per STAR-PU were abbreviations for the outcome measures contained 
within the Antibiotic Database.  “Items” refers to the outcome measure “prescription 
numbers” and Items/STAR-PU was an abbreviation for measuring antibiotic use in terms of 
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“Items per STAR-PU”.  The user can select between the two outcome measures as shown in 
Figure 23. 
 
Figure 23: Selection between outcome measures used within the Analysis Graphs 
 
 
 
 
 
The drop down options (shown by the green arrow in Figure 23) can be used to select 
between the two outcome measures.  The chosen outcome measure was then displayed within 
the Analysis Graph, as shown by the two arrows in Figure 23.  Figure 24 shows how the data 
and appearance of the graph changed automatically when a different outcome measure was 
chosen. 
 
 
 
  
Outcome measures Selected outcome measure 
results  
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Figure 24: An example of the Analysis Graph when the outcome measure was changed 
 
 
 
 
 
 
6.4.4 Time period for analysis selected within Analysis 
Graphs 
 
The column called “Quarter” allowed the user to select a time period for analysis.  The time 
period was abbreviated to contain the financial quarter in question, for example Figure 25 
shows that the chosen quarter was 30910, which indicates that the third quarter for financial 
year of 2009 to 2010 was selected.  Figure 25 shows how the time period for analysis can be 
changed. 
 
Outcome measure changed Outcome measure used to analyse 
prescribing automatically updates 
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Figure 25: The time period chosen for analysis 
 
 
  
 
Figure 25 shows how the user can change the time period analysed with use of the drop down 
menu (as shown by the green arrow).  Figure 26 shows how the graph changes when a new 
time period was chosen. 
 
 
 
 
 
 
 
  
Choice for period of analysis  
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Figure 26: An example of the Analysis Graph when the time period was changed 
 
 
 
 
 
When a new financial quarter was chosen the analysis graph automatically updated to present 
the selected data.  The purple arrow shows the location of the selected quarter data and the 
three preceding financial quarters.  The green arrows shows the new time period selected. 
 
 
 
 
 
  
Quarter 4 selected Graph updated to selected quarter 
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6.4.5 Medication category selected for analysis within 
Analysis Graphs 
 
As mentioned earlier in section 6.4, the Antibiotic Database contained all drugs present within 
Chapter 5 of the BNF.  As the data required for the Antibiotic Database was taken from 
ePACT, any changes to the drug list present within Chapter 5 were automatically updated 
within the Antibiotic Database.   
 
Figure 27: Screen capture of the Medication Category chosen for analysis 
 
 
 
 
 
Figure 27 shows the five medication categories included within the Antibiotic Database 
which the user could choose between.  The selected category then automatically updated the 
medication column of the analysis graph, as shown in Figure 28. 
 
Medication categories 
user can choose from 
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Figure 28: Screen capture of the medication chosen for analysis 
 
 
 
 
 
  
The chemical substance choices are dependent on 
the medication category chosen 
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6.4.6 The chemical substance selected for analysis 
with Analysis Graphs 
 
The Medication column of the analysis graph was used to present the chemical substances 
available within each Medication category.  Therefore, if the Medication category 
Antibacterial was chosen then the Medication column would allow the user to select between 
all chemical substances used as an Antibacterial, as shown in Figure 28.  
 
Figure 29 shows the drop down menu for the Medication column changed when a new 
Medication category was chosen. 
 
Figure 29: An example of the Analysis Graph when the Medication category was 
changed 
 
 
 
 
The Chemical substance options changes 
when Medication category is changed 
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Figure 30 shows how the display of the graph changed when a new chemical substance was 
chosen. 
 
Figure 30: An example of the Analysis Graph when the medication was changed 
 
 
 
 
 
 
The data selected in the Analysis Graphs were updated automatically onto the graph used to 
summarise the five Analysis Graphs, as shown in Figure 31.   
 
 
 
 
 
  
The graph updates automatically to 
present the selected criteria selected 
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Figure 31: An example of the Summary Graph produced using the five Analysis Graphs 
present within the Antibiotic Database 
 
 
 
The summary for the five Analysis Graphs allowed the user to visualise a snapshot of any 
number of specific criteria and summarise the results in one graph.  
 
6.4.7 Key Antibiotics Analysis Graphs 
 
The Key Antibiotics Analysis Graphs differ from the Summary Graphs as only selected 
antibiotic(s), outcome measures and time periods could be analysed.  The advantage of the 
Key Antibiotic Graphs was that the prescribing of the chosen antibiotic(s) could be analysed 
over the last four years and thus provide more detailed analysis.  An example is shown below 
in Figure 32. 
 
Cephalosporins and quinolones were included within the key antibiotic analysis graphs 
because the HPA (2008) stated that use of cephalosporins quinolones should be minimised 
owing to their association with the increase in clostridium difficile cases reported.  Therefore, 
appropriate prescribing of cephalosporins and quinolones have been included as QoF targets 
in order to limit their use.   
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Figure 32: An example of a Key Antibiotic Analysis Graph 
 
 
 
6.5 Implementation of Antibiotic Database as an 
intervention within Sandwell PCT – intervention period 
 
The Antibiotic Database was implemented as an intervention within Sandwell PCT in quarter 
3 (autumn/winter) of financial year 2009/2010 by the Specialist Antibiotic Pharmacist.  The 
intervention process can be divided into three distinct stages; the launch of the Antibiotic 
Database, the introduction of Antibiotic Database to Sandwell PCT prescribers and the 
presentation of personalised data to all surgeries. 
 
6.5.1 Launch of the Antibiotic Database 
 
The first stage of the implementation of the Antibiotic Database as an intervention within 
Sandwell PCT was gaining the approval of the Sandwell PCT board for its use.  The 
information contained in sections 6.1 to 6.4 of the present thesis were presented to the board 
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in order to explain how the Antibiotic Database worked and how it could be used within 
Sandwell PCT.  The Antibiotic Database was then used to demonstrate the latest Sandwell 
PCT antibiotic prescribing data, including an insight into how antibiotic prescribing 
(especially cephalosporins and quinolones) had fluctuated over the past three years.  The 
board unanimously approved the use of the Antibiotic Database within Sandwell PCT to 
improve prescribing and provided the Specialist Antibiotic Pharmacist with a requested 
fifteen minute allocation to present antibiotic prescribing data at the next PLT event held at 
the start of Quarter 3 (2009). 
 
6.5.2 Introduction of Antibiotic Database to Sandwell 
PCT prescribers 
 
The Specialist Antibiotic Pharmacist used the fifteen minute allocation at the PLT event to 
present the latest antibiotic prescribing trend analysis graphs produced from the Antibiotic 
Database (see Appendix 7).  The aim of this presentation was to promote the need for 
improvements in prescribing of all antibiotics, especially quinolones and cephalosporins.  In 
total there were around 200 prescribers present at the event, with representation from every 
practice within Sandwell.  All attendees were made aware that the Specialist Antibiotic 
Pharmacist would be organising meetings at all surgeries between October and December 
2009 (quarter 3 of financial year 2009/2010) to present surgery specific antibiotic prescribing 
data produced using the Antibiotic Database. 
 
6.5.3 Presentation of personalised data to all surgeries 
 
In total there were sixty-three surgeries within Sandwell PCT who were contacted via 
telephone by the Specialist Antibiotic Pharmacist and agreed to the presentation of their 
personalised antibiotic prescribing data using the Antibiotic Database.  The presentation 
focused on the importance of prudent antibiotic prescribing, analysis of their overall and key 
antibiotic prescribing and ended with actions that can be implemented to improve their 
antibiotic prescribing (see Appendix 8 for a template of these presentations).  It was 
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anticipated that these presentations would take fifteen minutes with time allocated at the end 
for questions and the agreement of actions to improve antibiotic prescribing by all attendees.  
All prescribers and the manager within each surgery were requested to attend the organised 
meetings, with the Specialist Antibiotic Pharmacist arranging one-to-one meetings to discuss 
surgery presentations and agreed actions with any individuals who failed to attend requested 
surgery meetings.   
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6.6 Results 
 
The Antibiotic Database itself was used to analyse the short and long term impact of its use at 
all surgeries during October to December 2009 (quarter 3 of financial year 2009/2010).  Short 
term impact will be classed as prescribing during quarter 3 of financial year 2009/2010 and 
long term impact will be classed as prescribing up to, and including quarter 3 2010/2011.  
Quarterly prescribing data will be analysed in preference to annual data in order to allow 
direct comparison of prescribing in quarter 3 of the pre-intervention (quarter 3 2008/2009), 
intervention and post-intervention period.  Annual Sandwell antibiotic prescribing data will 
also be compared to the annual average SHA and national prescribing data for overall 
antibiotics, cephalosporin and quinolones.  The significance of changes to antibiotic 
prescribing will be determined through log odds ratio (95% CI) calculations using StatsDirect 
(2007). 
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6.6.1 The total number of antibiotics prescribed within 
Sandwell PCT 
 
Figure 33 shows the total number of antibiotics prescribed within Sandwell PCT since March 
2007.   
 
Figure 33: The total number of antibiotics prescribed annually within Sandwell PCT 
since the financial year 2006/2007 
 
 
 
 
 
Figure 33 shows that antibiotic prescribing has seasonally fluctuated since March 2007 to 
March 2010, with the highest rates of prescribing occurring in quarter 3 (autumn/winter) of 
the financial year.  The intervention period coincided with a slight reduction in antibiotic 
prescribing in comparison to the same quarter in 2008/2009 although prescribing was still 
higher in comparison to quarter 3 in 2007/2008.  Post-intervention analysis of quarter 1 and 2 
data showed that antibiotic prescribing remained slightly lower than in the corresponding 
period in 2008/2009, but still higher than the corresponding periods in 2007/2008.  Quarter 3 
of the post-intervention period coincided with an increase in antibiotic prescribing in 
comparison to previous years. 
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6.6.2 Comparison of Sandwell PCT’s to SHA and 
National antibiotic prescribing data 
 
Figure 34 shows the comparison of overall antibiotics prescribed at Sandwell PCT, the West 
Midlands SHA and nationally. 
 
Figure 34: Overall antibiotics prescribed by Sandwell in comparison to their SHA and 
national antibiotic prescribing figures 
 
 
Figure 34 shows that antibiotic prescribing within Sandwell PCT decreased during the 
intervention period in comparison to the pre-intervention period.  However, antibiotic 
prescribing in the post-intervention period increased to higher levels in comparison to the pre-
intervention period.   This has followed the same pattern as antibiotic prescribing within the 
SHA and nationally.   Antibiotic prescribing (OR (95% CI) was not significantly reduced in 
Sandwell PCT 0.98 (0.55-1.76) in comparison to national antibiotic prescribing 0.91 (0.51-
1.65) and SHA antibiotic prescribing 0.94 (0.5.3-1.69) during the intervention period. 
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Figure 34 shows that both Sandwell PCT and the SHA are higher prescribers of antibiotics in 
comparison to the national average.  The SHA were also lower prescribers of antibiotics than 
Sandwell PCT in both the pre- and intervention period, although the SHA were higher 
prescribers in comparison to Sandwell PCT in the post-intervention period.  Antibiotic 
prescribing (OR (95% CI) in the post-intervention period did not significantly increase in 
Sandwell PCT 1.01 (0.57-1.80) in comparison to national antibiotic prescribing 1.03 (0.58-
1.85) and SHA antibiotic prescribing 1.04 (0.58-1.85). 
 
6.6.3 The number of cephalosporins prescribed 
annually within Sandwell PCT 
 
Figure 35 shows the number of cephalosporins prescribed within Sandwell PCT since March 
2007.   
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Figure 35: The total number of cephalosporins prescribed annually within Sandwell 
PCT since the financial year 2007/2008 
 
 
 
Figure 35 shows that cephalosporin prescribing has been decreasing every year since 2007 
and reached a new low level of prescribing in quarter 1 in year 2010/2011.  Analysis of the 
intervention period showed that cephalosporin prescribing decreased in comparison to 
previous years and the trend has continued with a further reduction in quarter 3 in financial 
year 2010/2011. 
 
6.6.4 The number of quinolones prescribed annually 
within Sandwell PCT 
 
Figure 36 shows the number of quinolones prescribed within Sandwell PCT since March 
2007.   
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Figure 36: The total number of quinolones prescribed annually within Sandwell PCT 
since the financial year 2007/2008 
 
 
 
Figure 36 shows that quinolone prescribing has been decreasing every year since 2007 and 
reached a new low level of prescribing in quarter 1 of year 20010/2011.  Analysis of the 
intervention period showed that quinolone prescribing reduced in comparison to the same 
quarter in previous years.  This has continued into the post-intervention period with quarter 3 
in financial year 2010/2011 also showing a further reduction in comparison to previous years. 
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6.6.5 Comparison of Sandwell PCT’s to SHA and 
National prescribing data for cephalosporins and 
quionolones 
 
Figure 37 shows cephalosporins and quinolones prescribed by Sandwell in comparison to 
their SHA and national prescribing figures. 
 
Figure 37: A comparison of the number of cephalosporins and quinolones prescribed 
within Sandwell PCT, the West Midlands SHA and England 
 
 
 
 
Figure 37 shows that cephalosporin and quinolones prescribing has been reducing in 
Sandwell PCT from the pre-to-post intervention periods.  This same pattern of prescribing has 
also been present at SHA and national level.  Figure 37 also shows that Sandwell PCT has 
been lower prescribers of cephalosporins and quinolones in comparison to SHA and national 
prescribing averages with national prescribing being higher than seen in the SHA.  However, 
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cephalosporin and quinolone prescribing (OR (95% CI) did not significantly increase in 
Sandwell PCT 0.89 (0.22-3.50) in comparison to SHA prescribing 0.90 (0.30-2.67), and 
significantly reduce in comparison to national prescribing 0.86 (0.33.3-2.21) during the 
intervention period. 
 
Cephalosporin and quinolone prescribing (OR (95% CI) in the post-intervention period did 
not significantly increase in Sandwell PCT 0.68 (0.15-2.99) in comparison to national 
antibiotic prescribing 0.72 (0.27-1.92) and SHA antibiotic prescribing 0.78 (0.25-2.40). 
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6.7 Discussion 
 
The qualitative research conducted in Chapter 5 raised the issue of how antibiotic prescribing 
was analysed at PCT level, with the use of ePACT and audits not being utilised to maximise 
data analysis.  Therefore objective 1 was set to produce a prescribing analysis tool to provide 
detailed analysis of antibiotic prescribing for all surgeries within Sandwell PCT.  In doing so 
the Antibiotic Database was produced and used, not only to analyse prescribing, but also as an 
intervention to improve antibiotic prescribing. 
 
6.7.1 The Antibiotic Database 
 
The Antibiotic Database was an innovative feedback system produced to analyse antibiotic 
prescribing.  It ensured that antibiotic prescribing was always analysed in a consistent manner 
which therefore saved time and money spent on producing ad hoc visual electronic outputs to 
analyse antibiotic prescribing using an inaccurate outcome measure or time period for 
analysis.  The advantage of using prescription numbers as the outcome measure for the 
Prescribing Table was the ease with which the use of particular antibiotics could be analysed. 
 
As the data provided by the National Prescribing Service allowed analysis of prescribing at 
PCT, SHA and DH level the Antibiotic Database could also be used to analyse antibiotic 
prescribing within all Primary Care arenas in more detail and thus provide a national feedback 
system.  This is further aided by the compatibility of the Antibiotic Database with all 
Microsoft applications in order to evaluate any intervention used.  Therefore the aim of 
devising and implementing an antimicrobial prescribing analysis tool within a Primary Care 
Trust was achieved. 
 
The advantages of the Antibiotic Database include the production of detailed analysis for each 
practice within Sandwell PCT.  The production of the Antibiotic Database initially took 30 
minutes, which could then be updated in five minutes when the new data from the National 
Prescribing Service was retrieved every quarter.  The outputs were easy to understand and the 
database could be easily manipulated with Microsoft Excel. 
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A key disadvantage of the Antibiotic Database was the requirement of an individual 
Antibiotic Database to analyse prescribing for any given PCT or practice.  This could be 
overcome by the conversion of the Antibiotic Database from Microsoft Excel to a web based 
output.  In doing so the database would be more robust and allow analysis of any practice or 
PCT on one database. 
 
A second disadvantage of the Antibiotic Database was the reliance on ePACT to provide the 
required data.  In doing so, the latest data contained within the Antibiotic Database was 
always three months in arrears. 
 
6.7.2 Impact of the Antibiotic Database as an 
intervention tool  
 
The Antibiotic Database was used to provide personalised antibiotic prescribing data to all 
surgeries within Sandwell PCT in the form of PowerPoint presentations at practice meetings 
between the months of October to December in 2009 (quarter 3 in financial year 2009/2010).  
The impact of the intervention was analysed on two levels and covering prescribing of overall 
antibiotics, cephalosporins and quinolones.   
 
The first type of analysis focused on trend analysis of prescribing within Sandwell PCT since 
the start of the 2007/2008 financial year.  Data was divided quarterly in order to compare the 
prescribing within the intervention period to the same periods in years before and after 
intervention implementation.  This form of analysis was important in order to determine the 
effectiveness of the intervention by comparing the prescribing data to that seen in the same 
time period in different years, thus achieving long term intervention analysis.  Data was 
divided into quarterly periods to analyse what impact the intervention has had in the long term 
within Sandwell and also to highlight the seasonal variations present in antibiotic prescribing.  
Figure 33 highlights the seasonal variation in antibiotic prescribing and thus provides support 
to the comparison of antibiotic prescribing to the same quarterly periods (financial). 
 
The second form of analysis involved the comparison of total antibiotics, cephalosporins and 
quinolones within Sandwell PCT to those seen within the West Midlands SHA and the 
national averages.  The data was presented for the pre-intervention period (October-December 
2008), the intervention period (October-December 2009) and the post-intervention period 
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(October-December 2010).  This type of analysis helped to ensure attempts were made to 
account for confounding factors.  Log odds ratio calculations were used to determine the 
significance of changes to antibiotic prescribing produced by the intervention in comparison 
to that achieved at SHA and national level. 
 
6.7.3 Analysis of overall antibiotic prescribing 
 
The results showed that the Antibiotic Database did not provide a significant reduction in 
antibiotic prescribing in comparison to the same period in the previous year (pre-
intervention).  Long term (post-intervention) analysis showed that both Sandwell PCT and the 
SHA were higher prescribers of antibiotics in comparison to the national average.  However 
the increase in antibiotic prescribing was not significant in comparison to antibiotic 
prescribing at SHA and national level.  These results suggest that the Antibiotic Database had 
no significant short or long term impact on antibiotic prescribing. 
 
6.7.4 Analysis of cephalosporin and quinolone 
prescribing 
 
The results showed that cephalosporin and quinolone prescribing had consistently reduced 
since the pre-intervention period.  However this reduction was not significant in comparison 
to SHA and national cephalosporin and quinolone prescribing figures.  The reductions in 
prescribing seen since the pre-intervention period have also been achieved on a SHA and 
national level.  This suggests a factor, other than the Antibiotic Database, produced the 
reductions achieved at Sandwell PCT, SHA and national levels. 
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6.7.5 Factors affecting antibiotic prescribing 
 
The Antibiotic Database produced no significant reductions in antibiotic prescribing in 
comparison to SHA and national level.  The key reason for this result was the level of 
engagement obtained by prescribers to use the Antibiotic Database, or any other intervention 
to improve their antibiotic prescribing at Sandwell PCT, the SHA or national level. However, 
it must also be noted that there may have been surgeries, PCTs or regions within England that 
have produced significant reductions in prescribing. Therefore more research is required to 
determine whether significant reductions in antibiotic prescribing have been achieved at any 
surgery, PCT or regional level and if so, how prescribers were engaged to improve their 
prescribing.    
 
6.7.6 Limitations in the development and 
implementation of the Antibiotic Database 
 
There were many limitations that may have impacted on the influence of the Antibiotic 
Database as an intervention, and can be divided into; developmental, implementation and 
analytical limitations. 
 
6.7.6.1 Developmental limitations 
 
A key decision made at the developmental stage of the Antibiotic Database was to use ePACT 
as the source of data.  In doing so, the objectives 1, 2 and 3 were achieved and data was easily 
obtained and accurate.  However, ePACT data was produced by a third party organisation and 
thus the production of the Antibiotic Database was reliant on ePACT providing the required 
data.  Changes that could be made without consultation could have included, the outcome 
measures used to analyse prescribing and access to ePACT itself.  Although audits were 
considered a labour intensive process, total control of the data obtained would have been a 
key advantage with its use.  
 
A second key limitation of using ePACT was the three month delay in providing new 
prescribing data.  If audits were used as the source of data then real time data was a 
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possibility, although section 4.5.2.1 describes the difficulties in completing audits, such as 
access to surgeries to complete audits and time taken to complete audits. 
 
If real time data was used, the Antibiotic Database would have been considered as a 
surveillance tool rather than a feedback tool.  A surveillance tool may have had a further 
impact on prescribing as prescribers could have been made aware of their current prescribing 
and thus influenced before further prescriptions were provided.  Instead the feedback tool 
allowed their normal prescribing practices to continue for three months before being 
reviewed. 
 
6.7.6.2 Implementation limitations 
 
The implementation of Antibiotic Database involved presentations at a PLT event and 
practice meetings.  To ensure consistency in presentation and content were achieved, a 
standardised presentation was produced for all prescribers.  The Antibiotic Database was then 
used to provide personalised data to all surgeries.  Key limitations of the implementation 
process were the lack of consistency in attendees to both the PLT and surgery meetings and 
the timing of the presentations at surgery meetings. 
 
The PLT was used as a platform to address the issues around antibiotics and promote the 
Antibiotic Database and thus can be classed as a stage of the intervention process.  If 
prescribers attended both the PLT and practice meetings then it could be argued that they 
were exposed to an intervention twice.  Inconsistency in the intervention process was 
therefore present as some prescribers may not have attended either the PLT or practice 
meeting and thus be exposed to the intervention only once.   It could be argued that the more 
a prescriber is exposed to the intervention, the more they are likely to change their prescribing 
and thus the results may have been affected. 
 
The timing of practice meeting presentations was also a key factor in determining the impact 
of the intervention.  The intervention period was set between October and December in 2009 
and the intervention data analysis was also set within this time period.  Therefore a limitation 
of the present research was the varying times that surgeries were presented with their 
antibiotic prescribing data.  Those surgeries that had their presentations conducted at the start 
of the intervention period had further time to improve their antibiotic prescribing in 
comparison to those surgeries having their presentations at the end of the intervention period.   
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A limitation of the development and implementation of the Antibiotic Database was the lack 
of integration with standard approaches, such as the MRC Framework for developing 
complex interventions (2000).  However, the present semi-structured interviews highlighted 
the need for the production of a prescribing feedback tool in order to provide consistency in 
the analysis of antibiotic prescribing undertaken at PCT level (see section 5.10.5.2). These 
views should have been balanced with consideration of literature on implementation Science 
that raises concerns in the use of a prescribing feedback tool.   
 
The present systematic review highlighted the use of guidelines and pharmacists to improve 
antibiotic prescribing, and these interventions could have been utilised more effectively 
within the development of the Antibiotic Database.  For example, the graphs produced from 
the Antibiotic Database could have been combined with current guidelines to further inform 
prescribers of how antibiotic prescribing could be improved during the meetings conducted.  
In addition, even though the Antibiotic Pharmacist produced the Antibiotic Database and met 
all prescribers to improve their prescribing, no analysis of the Antibiotic Pharmacist‟s ability 
to present, educate and influence prescribers to modify their prescribing was taken into 
account.  The effectiveness of the Antibiotic Pharmacist could have been analysed by 
qualitative research conducted with prescribers and thus was an oversight in evaluation of the 
intervention.  A more clinical approach to the meetings, based on audits conducted at 
surgeries and detailed reference to guidelines may have produced a more significant impact 
than meetings based on trend analysis of antibiotic prescribing.  
 
Finally, randomisation of prescribers within Sandwell PCT was also not considered when 
implementing the interventions as their effects were considered to be so potentially large that 
confounding the underlying trends were unlikely to explain differences before and after 
exposure to the intervention.  However, randomisation of prescribers into experimental and 
control groups should have been considered in order to reduce selection bias and thus can be 
considered a limitation of the present research. 
 
6.7.6.3 Analytical limitations 
 
The Antibiotic Database was produced to analyse antibiotic prescribing using defined 
outcome measures and thus the appropriateness of antibiotic prescribing could not be 
determined.  For example, a practice prescribing a high number of antibiotics may have been 
classed as poor prescribers of antibiotics even though those antibiotics were prescribed 
appropriately, therefore highlighting a key limitation of the Antibiotic Database.  Using audits 
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as the source of data would have overcome this issue as the reason for prescribing could also 
have been accounted for.   
 
 
6.7.7 Future research 
 
The Antibiotic Database has highlighted two key areas for future research.  Firstly, analysis of 
the impact of the Antibiotic Database should be increased to a further year to determine 
whether the Antibiotic Database reduced overall prescribing further when compared to 
national prescribing.  Secondly, the intervention period set for analysis should be modified to 
ensure that all practices are presented with the required data before analysis of their 
prescribing is measured. 
 
The results of this present research has also highlighted that there could be many confounding 
factors that have impacted on antibiotic prescribing at PCT to national scale.  Therefore more 
research should be conducted to determine what these confounding factors are and how 
effective they have been to improve prescribing.   
 
The results of this present research have also highlighted that reductions in antibiotic 
prescribing may not necessarily equate to improved antibiotic prescribing.  Therefore data 
from audits should be incorporated into the Antibiotic Database in order to provide reasons 
for why antibiotics have been prescribed. In doing so, the quality of prescribing can also be 
measured. 
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6.8 Conclusion 
 
In conclusion the Antibiotic Database was developed and implemented as not only a method 
of monitoring antibiotic prescribing, but also an intervention within Sandwell PCT.  In doing 
so the aim and objectives set at the beginning of this chapter were met. 
 
The Antibiotic Database was developed using Microsoft Excel and allowed users to analyse 
prescribing of any antibiotic over an extended period of time.  The Antibiotic Database was 
updated quarterly, with data also broken down to quarterly level as antibiotic prescribing 
fluctuated greatly between quarterly periods.  The Antibiotic Database proved that antibiotic 
prescribing was highest during the months between October and December, and lowest 
between July and September. 
 
The source of data used to populate the Antibiotic Database was generated from ePACT, 
using the number of prescriptions and Items per STAR-PU as the outcome measures of 
choice.  Users were able to view antibiotic prescribing using both outcome measures in table 
form (Prescribing Table), five summary graphs, and four key antibiotic analysis graphs. 
 
The Antibiotic Database was used as an intervention tool between October and December in 
2009, with personalised Sandwell PCT data being presented at a local PLT event and 
personalised surgery level data being presented at all surgery meetings within Sandwell.  The 
success of the intervention was based on a reduction in overall antibiotic, cephalosporin and 
quinolone prescribing within Sandwell PCT from pre-to-post intervention periods.  These 
results were then compared to prescribing of overall antibiotic, cephalosporins and quinolones 
at local SHA and national level to account for any confounding factors.   
 
The results showed that there were reductions to overall antibiotic prescribing during the 
intervention period at Sandwell.  However, these reductions were not significant in 
comparison to antibiotic prescribing at SHA and national level.  The reduction in post-
intervention antibiotic prescribing at Sandwell PCT was also not significant in comparison to 
post-intervention prescribing at SHA and national level. 
 
Analysis of cephalosporin and quinolone prescribing within Sandwell showed that prescribing 
reduced during the intervention period and then continued to reduce in the post-intervention 
period.  However these positive results were also matched by the same pattern being present 
 165 
at SHA and national level, thus providing no significant reductions in cephalosporins and 
quinolones at Sandwell PCT.  Therefore more research is required to determine how 
prescriber engagement has been achieved at surgeries, PCTs or regions that have produced 
significant reductions in antibiotic prescribing.  
 
Overall, the Antibiotic Database is a useful tool to analyse antibiotic prescribing and as an 
intervention to reduce antibiotic prescribing, however more research is required to determine 
how prescribers can be motivated to improve antibiotic prescribing. Therefore the Antibiotic 
Database should be used nationally within all healthcare departments, especially within DH, 
SHAs and PCTs.  In doing so antibiotic prescribing can be continually monitored and 
intervention use can be analysed on a much larger scale.   
 
In order to improve intervention analysis, Medicines Management teams within PCTs, SHAs 
and the DH have to record all interventions used to control antibiotic prescribing.  The 
records should contain details of; what the intervention is, how the intervention is 
implemented, what the aims of the intervention are, who the target audience is, who is 
responsible for the implementing the intervention, how long the intervention will be used for 
and the actual presentation of the intervention used.   
 
The improved analysis and recording of interventions will therefore provide a platform to 
discover the true impact of interventions used nationally to control antibiotic prescribing over 
an increased duration of time. 
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7. General Discussion 
 
Overall, the aims and objectives set in section 2 have been achieved throughout the present 
research through the conduct of a systematic review and qualitative research to explore 
interventions aimed at improving antibiotic prescribing.  As a result, pharmacy intervention 
and guidelines were considered as two interventions that could improve antibiotic prescribing 
and were thus incorporated into the development and implementation of the Antibiotic 
Database within Sandwell PCT.  As these two interventions were key within all areas of the 
present research, pharmacy intervention and guidelines will be discussed further in order to 
conclude the significance of the present research and how antibiotic prescribing can be 
improved in the future. 
 
Pastel (1992), Dranitsaris (2001) and Seager (2006) were three review studies that highlighted 
the impact of pharmacy intervention to improve antibiotic prescribing within the present 
systematic review (Chapter 4).   Pastel (1992) used pharmacy intervention as a sole 
intervention to improve antibiotic prescribing, with Dranitsaris (2001) and Seager (2006) 
using pharmacy intervention within a multifaceted intervention.  Guidelines were the most 
commonly used intervention within the review studies and also used by both Dranitsaris 
(2001) and Seager (2006) within their multifaceted approach.   
 
A key limitation of the present systematic review was the lack of detail necessary to explain 
how interventions were conducted and thus the variability within studies could not be 
precisely accounted for.  For example, Pastel (1998), Dranitsaris (2001) and Seager (2006) 
concluded that pharmacy intervention was an effective intervention although caution was 
needed when generalising these findings to other settings as these studies provided 
insufficient detail and comparisons in how pharmacy intervention was best achieved.   
 
Studies reporting the use of guidelines also failed to provide the necessary detail of how they 
were developed and implemented and thus studies producing a low log odds ratio score 
actually may have used poor “guidelines” and/or failed to implement “guidelines” effectively 
during the intervention period.  Therefore, the use of guidelines may have been incorrectly 
perceived as an ineffective intervention to improve antibiotic prescribing within these studies.  
In cases where there have been multiple interventions adopted, little information was 
provided on how interventions were combined, why certain combinations were chosen and 
who exactly implemented them.  However, the lack of detail provided could have been 
overcome by contacting the authors of the studies to provide the omitted information. 
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The semi-structured interviews conducted (Chapter 5) also supported the results of the present 
systematic review, with two possible successful interventions being the use of pharmacist 
intervention and the implementation of guidelines. However, interviewees also failed to 
provide sufficient information in order to determine how pharmacists and guidelines were 
able to improve antibiotic prescribing.  The insufficient detail provided by interviewees was 
overcome through the conduct of the combined approach (Chapter 5) which allowed the 
provision of information to determine the target audience, duration of implementation, format 
and content of guidelines and how the pharmacist was able to influence antibiotic prescribing.   
 
A key finding of the combined approach was that Sandwell PCT did have an antibiotic 
formulary within the main PCT formulary, although the information had not been updated for 
two years and had no input from the microbiologists working within the local acute trust.  In 
addition there was no information available at Sandwell PCT to determine how many 
prescribers actually read the formulary or used it to guide their prescribing and thus the 
interviewee‟s views that guidelines influenced prescribing must be questioned when there 
were no results to support this statement.  
 
A second key finding of the combined approach was the variance in strategies used by 
pharmacists to improve antibiotic prescribing. Therefore there needs to be a distinction made 
from whether the pharmacist themselves, or the intervention(s) they use that actually produce 
the improvement in antibiotic prescribing. Therefore more research is required in order to 
define what an intervention is and who is required to develop and implement any given 
intervention.  With regards to the Antibiotic Database, the Specialist Antibiotic Pharmacist 
had sole control over its development and implementation.  However, the Specialist 
Antibiotic Pharmacist may not have had the ability to use the Antibiotic Database effectively 
in order to produce improvements in antibiotic prescribing and thus not produced significant 
improvements in antibiotic prescribing.     
 
Overall, the Antibiotic Database proved that there were no significant improvements in 
antibiotic prescribing in comparison to the West Midlands SHA and national data. Therefore 
the pharmacy intervention and guidelines used within Sandwell PCT did not influence 
prescribing in comparison to all other interventions used across the rest of England. However, 
the development and implementation of the Antibiotic Database within Sandwell may not 
have maximised pharmacists and guidelines as interventions to improve antibiotic 
prescribing. 
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The results obtained at Sandwell PCT, West Midlands SHA and national level suggest that 
reductions in specific antibiotics (cephalosorins and quinolones) were achieved although 
reductions in overall antibiotic prescribing were not.  This supports this view of Arnold and 
Straus (2005) who stated that “Interventions aimed at increasing the prescribing of certain 
recommended first-line antibiotics for specific infections are more likely to produce 
substantial changes in prescribing than those interventions targeting overall inappropriate 
antibiotic use.”   
 
This present research therefore highlights a key issue that has not been raised through the 
completed systematic review, semi-structured interviews and combined approach of engaging 
prescribers into any intervention used, especially in order to reduce overall antibiotic 
prescribing.  Therefore all future research on improving antibiotic prescribing should focus on 
how to improve prescriber engagement with any chosen intervention or intervention(s) used 
to improve antibiotic prescribing.  This may require particular focus on the abilities of 
individual(s) employed to develop and implement an intervention, in addition to analysis of 
the intervention alone. 
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7.1 How to measure improvements in antibiotic 
prescribing 
 
The present systematic review highlighted two studies by Van Driel (2007) and Briel (2006) 
that achieved higher log odds ratio scores when reporting results in terms of compliance 
rather than number of prescriptions.  This may have been the result of both Van Driel (2007) 
and Briel (2006) using guidelines (as part of a multifaceted intervention) to advise prescribers 
on what antibiotics to prescribe for any given condition and thus led to increased compliance 
in prescribing, rather than a reduction in prescribing.  A limitation of the present research may 
have been to determine improvements in antibiotic prescribing in terms of a reduction in 
antibiotic prescribing and thus there needs to be universal agreement on how the impact of 
any given intervention is measured. 
 
7.2 Generalisation of results achieved 
 
The present research focused all post-systematic review research within Primary Care, with 
semi-structured interviews conducted with NHS managers working within Medicines 
Management departments in the West Midlands and the combined approach utilised within 
Sandwell PCT.  Therefore, limitations of the post-systematic review research were the lack of 
research conducted within; Secondary Care, Primary Care regions (other than the West 
Midlands), and other NHS Primary Care departments which also aim to improve antibiotic 
prescribing (such as Infection Prevention teams).  The present research also failed to 
encompass the conduct of research on an international level.  As a result, the analysis of 
interventions used to improve antibiotic prescribing may not be generalised to these other 
healthcare departments or sectors.  This is possibly owing to; structural differences within 
departments and sectors, the ability of individuals to improve antibiotic prescribing (i.e. 
qualifications and experience), the importance placed on improving antibiotic prescribing and 
differences in patient demand for antibiotics.   
 
The use of the Antibiotic Database, as a tool to analyse prescribing, can be generalised to all 
healthcare departments or sectors as the contents of the Database can be modified to include 
other antibiotics and outcome measures to analyse prescribing.  The only aspect of the 
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Antibiotic database that cannot be generalised is how it is used as an intervention to improve 
antibiotic prescribing. 
 
7.3 Strengths and weaknesses 
 
 
The present research has highlighted a number of limitations which have restricted the quality 
of the results obtained.  These limitations must be juxtaposed with the potential significance 
of the results achieved. 
 
The systematic review has successfully reviewed all studies reporting interventions aimed at 
improving antibiotic prescribing.  This provided the platform for the conduct of qualitative 
research which evaluated the impact of interventions used within the United Kingdom 
Primary Care arena.  The result was the production of an innovative intervention called the 
Antibiotic Database which can revolutionise the analysis of interventions used to control 
antibiotic prescribing.   
 
This research has not been previously completed and the results can be used to influence 
future work and improve how research in this area is conducted, how the findings are 
presented and how antibiotic prescribing can be improved. 
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8. Overall Conclusions 
 
In conclusion the present research has identified and determined the effectiveness of all 
interventions that have been used to improve antibiotic prescribing through the conduct of a 
systematic review, qualitative research and development and implementation of the Antibiotic 
Database.   
 
As the present systematic review contained a number of studies analysing interventions with 
varying scope and intensity, it was essential to pragmatically classify outcome measures and 
interventions into broad groups.  This may be perceived as a limitation within the present 
research, however adopting this approach has helped to determine the effectiveness of 
interventions in improving antibiotic prescribing.  Overall, the systematic review results 
suggested that the implementation of interventions actually increased antibiotic prescribing in 
comparison to baseline and follow-up periods.   
 
Semi-structured interviews with selected NHS managers were conducted in order to 
determine how antibiotic prescribing could be improved within Primary Care and produced 
nine separate areas of analysis, with the quality of answers varying greatly for each area and 
also from each interviewee (horizontal and vertical variability).  The answers provided by 
interviewees have to be balanced qualitatively with factors affecting their openness in 
answering questions.  These include, the working environment where interviews were 
conducted, the time available to complete interviews, the interviewee interest in antibiotics 
resistance and the experience of the interviewees in their current roles.  All attempts were 
made to keep the interviews as consistent as possible, however the nature of semi-structured 
interviews means any bias present may have affected the approach adopted by interviewees.  
 
The most commonly mentioned interventions within the semi-structured interviews were 
incentive schemes, practice based pharmacists (pharmacy intervention), formularies or 
guidelines and meeting GPs on a one-to-one basis.  However the fact that all interviewees 
failed to agree on the use of any one intervention to improve antibiotic prescribing highlights 
the lack of analysis of interventions or lack of interviewees‟ knowledge of how to improve 
antibiotic prescribing.  The combined approach allowed further elaboration on the key issues 
highlighted through the systematic review and semi-structured interviews and identified a key 
intervention that was not even mentioned throughout the semi-structured interviews (audits).  
Also the combined approach allowed the gathering of explicit detail required to determine 
how interventions were developed and implemented within Primary Care.  This knowledge 
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identified the need for a database feedback tool (The Antibiotic Database) that provided an 
intervention to improve antibiotic prescribing as well as improved analysis of antibiotic 
prescribing.   
 
8.1 Future work 
 
The implementation of the Antibiotic Database failed to provide any significant reductions in 
antibiotic prescribing when compared to the West Midlands SHA and national antibiotic 
prescribing figures.  Therefore it is essential for future research to focus on how interventions 
are used by individuals to engage prescribers into improving antibiotic prescribing. 
 
In order to achieve this, future research must define and document intervention(s) and record 
the effects of baseline, follow-up and during-intervention prescribing, in addition to the 
inclusion criteria set for this systematic review.  The records should contain details of; what 
the intervention is, how the intervention is implemented, what the aims of the intervention 
are, who the target audience is, who is responsible for implementing the intervention, how 
long the intervention will be used for and the actual presentation of the intervention used.  
The role of individuals who implement interventions must also be analysed in further detail in 
order to determine how prescribers were engaged to use their chosen interventions and why 
this strategy was used. 
 
 
8.2 Recommendations to control antibiotic use 
 
Regardless of the improvements required within future research, the results of the present 
research do indicate that a combination of three interventions can improve antibiotic 
prescribing.  Firstly an IT based intervention, such as the Antibiotic Database should be used 
within all sectors of the NHS in order to analyse antibiotic prescribing and provide a platform 
to discover the true impact of interventions used nationally to control antibiotic prescribing 
over an increased duration of time. 
 
Secondly, guidelines and finally pharmacists have the greatest potential to improve antibiotic 
use.  Therefore pharmacists should be employed within healthcare systems to achieve 
appropriate prescribing by educating prescribers with the use of antibiotic guidelines. 
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Appendix 2:  Search term combinations used for the present systematic review conducted 
 
  Search 
Engine 
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Search strategy 
term 
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line 
Med-line Cochrane 
Number 
of 
abstracts 
in search 
results 
Number 
of 
relevant 
abstracts 
Number 
of 
abstracts 
in search 
results 
Number 
of 
relevant 
abstracts 
Number 
of 
abstracts 
in search 
results 
Number 
of 
relevant 
abstracts 
Antibiotic + 
control 
299 57 63307 205 253 2 
Antibiotic + 
prescribing + 
control 
95 20 602 111 41 3 
Antibiotic + 
prescribing + 
control failure 
0 0 24 0 5 0 
Consequences 
+ antibiotics + 
control failure 
0 0 45 0 2 0 
Antibiotic + 
prescribing + 
control + 
mechanisms 
1 1 18 0 2 1 
Antibiotic + 
control + 
mechanism 
6 1 2276 0 6 0 
Antibiotic + 
control + 
effectiveness 
19 3 2219 29 95 2 
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Antibiotic + 
restriction or 
control + 
effectiveness 
138 1 45570 0 1444 0 
Antibiotic + 
control + 
restriction 
500 20 656 18 0 0 
Antibiotic + 
restriction 
22 3 4752 33 25 0 
Antibiotic + 
prescribing + 
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Patient + 
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antibiotics 
0 0 506 0 0 0 
Influence of 
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Secondary care 
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Hospitals + 
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Appendix 3:  Quality assessment used for the review studies 
 
1) ABSTRACT 
 
DOES EACH SECTION OF THE ABSTRACT ACCURATELY REFLECT THE EQUIVALENT 
SECTION IN THE REVIEW 
 
- BACKGROUND 
- OBJECTIVES  
- SEARCH STRATEGY 
- SELECTION CRITERIA 
- DATA COLLECTION AND ANALYSIS 
- MAIN RESULTS 
- REVIEWERS‟ CONCLUSIONS 
 
2) OBJECTIVES 
 
WERE THE MAIN OBJECTIVES SPECIFIED IN TERMS OF INTERVENTIONS, CLINICAL 
PROBLEM, POPULATION AND OUTCOMES 
 
3) SEARCH STRATEGY 
- WAS THE SEARCH STRATEGY INCLUDED 
- WERE THE DATES THAT EACH SOURCE WAS SEARCHED IDENTICATED 
- WERE THE FOLLOWING DATA SOURCES SEARCHED? 
- COCHRANE 
- MEDLINE 
- EMBASE 
- REFERENCE LISTS OF TEXT BOOKS, REVIEWS (INCLUDING PREVIOUS 
SYSTEMATIC REVIEWS), AND PREVIOUS TRIALS 
- CONFERENCE PROCEEDINGS 
- DID THE AUTHOR CONTACT EXPERTS IN THE FIELD 
- WERE THE APPROPRIATE KEY WORDS SEARCHES USED 
- WERE STUDIES IN LANGUAGES OTHER THAN ENGLISH INCLUDED 
- DID THE REVIEWERS IDENTIFY AND DEAL WITH DUPLICATE PUBLICATIONS 
OF THE SAME TRIAL IN THE WAY THAT THEY SAID THEY WOULD IN THE 
PROTOCOL 
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- IF NOT, DID THEY DEAL WITH DUPLICATE PUBLICATIONS IN A WAY THAT 
WOULD REDUCE BIAS 
 
B) METHODS OF THE REVIEW 
 
DID AT LEAST TWO AUTHORS OF THE REVIEW: 
- PERFORM THE LITERATURE SEARCH 
- DETERMINE STUDY ELIGIBILITY 
- ASSESS STUDY QUALITY 
- EXTRACT DATA 
- ENTER DATA IN REVMAN 
 
- DID REVIEWERS WORK INDEPENDENTLY 
- WAS THERE CONSESUS AND/OR LIAISON WITH A THIRD REVIEWER TO RESOLVE 
DISAGREEMENT BETWEEN THE PRIMARY REVIEWERS 
- WERE AUTHORS OF PRIMARY STUDIES CONTACTED FOR CLARIFICATION OF 
UNCLEAR DATA OR TO OBTAIN MISSING INFORMATION? 
- IF SO, WAS THE INFORMATION PROVIDED TO THE REVIEWERS 
- DID THE REVIEWERS ATTEMPT TO ANALYSE FOR POSSIBLE PUBLICATION BIAS 
USING FUNNEL PLOTS OR OTHER METHODS 
- IF NOT, DID THE REVIEWERSSTATE WHY THIS COULD NOT BE DONE 
 
C) DESCRIPTION OF STUDIES, CHARACTERISTICS OF INCLUDED 
STUDIES/CHARACTERISTICS OF EXCLUDED STUDIES 
 
- WERE THE IMPORTANT DETAILS OF THE INCLUDED STUDIES SUMMARISED IN 
THE TEXT OF THE REVIEW 
- WERE THE IMPORTANT DETAILS OF STUDY DESIGN, PARTICIPANTS, 
INTERVENTIONS AND DEFINITION OF OUTCOMES INCLUDED IN  THE TABLE 
“CHARACTERISTICS OF EXCLUDED STUDIES” 
- IF STUDIES WERE EXCLUDED, ARE THE REASONS FOR EXCLUSION 
CONSISTENT WITH THE INCLUSION/EXCLUSION CRITERIA IN THE SECTION ON 
“CRITERIA FOR CONSIDERING STUDIES FOR THE REVIEW” 
- ARE YOU AWARE OF ANY OTHER STUDIES THAT SHOULD HAVE BEEN 
INCLUDED 
 
D) METHODOLOGICAL QUALITY OF THE INCLUDED STUDIES 
 240 
 
- WAS THERE A TABLE LISTING THE QUALITY ITEMS FOR EACH INCLUDED 
STUDY 
- WAS A SHORT SUMMARY OF THE QUALITY ASSESSMENT OF THE INCLUDED 
STUDIES INCLUDED IN THE TEXT 
 
E) RESULTS/COMPARISON TABLE 
 
KEY RESULTS 
- ARE THE KEY RESULTS OF THE REVIEW PROVIDED IN THE TEXT 
- DID THE KEY RESULTS ADDRESS THE OBJECTIVES OF THE REVIEW 
 
META ANALYSIS 
- IF THE RESULTS WERE POOLED, WAS THIS APPROPRIATE 
- DID HETEROGENECITY BETWEEN STUDIES EXIST, IF YES WAS IT 
APPROPRIATELY EXPLAINED 
 
     OUTCOMES 
- WERE ALL OUTCOMES DESCRIBED IN THE PROTOCOL INCLUDED IN THE 
RESULTS 
 
SUBGROUP ANALYSIS 
- WERE PLANNED SUBGROUP ANALYSIS INCLUDED 
- IF PLANNED SUBGROUP ANALYSES WERE NOT INCLUDED, DID THE 
REVIEWERS EXPLAIN THE REASON FOR THIS 
- WERE SUBGROUP ANALYSES THAT WERE NOT SPECIFIED IN THE PROTOCOL 
PERFORMED, IF SO, WERE THESE ANALYSES DESCRIBED AS BEING POST HOC 
 
F) DISCUSSION 
 
KEY RESULTS 
- WERE THE PRINCIPAL RESULTS SUMMARISED 
- WAS THE POTENTIAL IMPORTANCE OF THESE RESULTS DISCUSSED 
- ARE THE CONCLUSIONS OF THE STUDY CONSISTENT WITH THE RESULTS 
 
CONSISTENCY OF RESULTS 
- WAS THE CONSISTENCY/INCONSISTENCY OF TRIALS DISCUSSED 
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LIMITATIONS OF THE STUDY 
- PUBLICATION BIAS 
- TRIAL QUALITY 
- IMPRESSION OF RESULTS 
- UNCERTAINTY OF HARMS (rigid in research, unwilling to see problem) 
 
COMPARISON WITH OTHER DATA 
- WERE THE REVIEW OF FINDINGS DISCUSSED IN RELATION TO RELEVANT 
EVIDENCE FROM OTHER STUDIES OR REVIEWS 
 
G) REVIEWERS‟ CONCLUSION 
 
IMPLICATIONS FOR PRACTICE 
- DID THE REVIEWERS ATTEMPT TO DEMONSTRATE THE APPLICABILITY OF THE 
RESULTS OF BENEFITS AND RISKS 
 
IMPLICATIONS FOR RESEARCH 
- DID THE REVIEWERS DETERMINE WHICH QUESTIONS HAD BEEN ANSWERED 
BY THE REVIEW, IF SO DO YOU AGREE 
- DID THE REVIEWERS DETERMINE WHICH QUESTIONS REQUIRE FURTHER 
TRIALS, IF SO DO YOU AGREE 
- DID THE REVIEWERS SUGGEST NEW STUDIES BASED ON THE REVIEWED 
RESEARCH, IF SO DO YOU BELIEVE THAT THESE STUDIES ARE APPROPRIATE 
- CAN YOU SUGGEST FURTHER STUDIES THAT SHOULD BE DONE 
 
ARE BIASES AND STUDY LIMITATIONS IDENTIFIED AND DISCUSSED 
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QUALITY ASSESSMENT FOR RANDOMISED CONTROLLED TRIALS 
 
1) ABSTRACT 
 
DOES EACH SECTION OF THE ABSTRACT ACCURATELY REFLECT THE EQUIVALENT 
SECTION IN THE REVIEW 
 
- BACKGROUND 
- OBJECTIVES  
- METHOD 
- DATA COLLECTION AND ANALYSIS 
- MAIN RESULTS 
- REVIEWERS‟ CONCLUSIONS 
 
2) OBJECTIVES 
 
WERE THE MAIN OBJECTIVES SPECIFIED IN TERMS OF INTERVENTIONS, CLINICAL 
PROBLEM, POPULATION AND OUTCOMES 
 
3) TYPES OF PARTICIPANTS 
 
- WERE THE TYPE OF PARTICIPANTS REQUIRED INCLUDED AND WHY THEY 
INCLUDED DESCRIBED 
- WERE THE POPULATION GROUPS TO BE EXCLUDED SPECIFIED 
- WERE THE NUMBER OF PARTICIPANTS USED STATED IN BOTH INTERVENTION 
AND CONTROL GROUPS 
- WERE THE GROUPS COMPARABLE 
- IS THE COMPARISON FAIR 
- WAS EVERYONE WHO ENTERED THE STUDY ACCOUNTED FOR AT THE END 
- WERE THE CRITERIA EQUALLY APPLIED TO ALL GROUPS 
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4) TYPE OF STUDY 
 
             HIERARCHY OF STUDY DESIGNS 
H) SYSTEMATIC REVIEW 
I) EXPERIMENTAL STUDIES 
- RANDOMISED CONTROLLED TRIALS (WITHOUT CONCEALMENT ALLOCATION) 
- EXPERIMENTAL STUDY WITHOUT RANDOMISATION E.G. QUASI-
EXPERIMENTAL OR QUASI RANDOMISED OR PSEUDO RANDOMISED STUDIES 
-  
J) OBSERVATIONAL STUDY 
- COHORT STUDY 
- CASE CONTROLLED STUDIES 
- CROSS SECTIONAL STUDY 
- BEFORE AND AFTER STUDY 
- CASE SERIES 
-  
K) CASE REPORTS, PATHOPHYSIOLOGICAL STUDIES OR BENCH RESEARCH, 
EXPERT OPINION OR CONSENSUS 
 
5) TYPES OF INTERVENTION AND COMPARISONS 
 
- WERE THE STUDY INTERVENTIONS DESCRIBED 
- WERE THE CONTROL INTERVENTIONS DESCRIBED 
- WERE RELEVANT INTERVENTIONS USED TO ANSWER THE QUESTION 
IDENTIFIED 
- WERE THE INTERVENTIONS INCLUDED DESCRIBED AND APPROPRIATE 
 
6) TYPES OF OUTCOMES 
 
- WERE THE OUTCOME MEASURES FOR THE BENEFITS AND HARMS OF 
INTERVENTION CLEARLY DEFINED IN NATURE AND IN TIMING 
- IF SPECIFIC OUTCOMES HAVE BEEN INCLUDED, DID THEY CONFORM WITH 
THE QUESTION ASKED 
- WERE THE MEASUREMENT OF THE OUTCOME THE SAME IN EACH GROUP 
- WERE THE PERIOD OF FOLLOW UP LONG ENOUGH FOR IMPORTANT 
OUTCOMES TO OCCUR 
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- WERE OTHER FACTORS ACCOUNTED FOR (MEASURED) THAT COULD AFFECT 
OUTCOMES 
-  
7) ASSESSMENT OF QUALITY 
 
WERE THE CRITERIA USED TO ASSESS STUDY QUALITY REPORTED? 
- ALLOCATION CONCEALMENT 
- ALLOCATION TO TREATMENT GROUPS CONCEALED 
- STUDY BLINDED IF POSSIBLE 
- BLINDING OF PARTICIPANTS 
- BLINDING OF INVESTIGATORS 
- BLINDING OF OUTCOME ASSESSMENT 
- INTENTION TO TREAT ANALYSIS 
- ALL RANDOMIZED PARTICIPANTS INCLUDED IN THE ANALYSIS (INTENTION 
TO TREAT) 
- COMPLETENESS OF FOLLOW UP 
- RANDOMISATION 
- METHODS USED TO GENERATE RANDOMISATION SCHEDULES ACCURATE 
AND UNBIASED 
- DESCRIPTION OF WITHDRAWALS 
- WITHDRAWAL/DROPOUTS REASONS GIVEN FOR EACH GROUP 
- WERE PROTOCOLS DESCRIBED FOR ALL REGIMENS STUDIED 
 
WERE THESE ITEMS ASSESSED SEPARATELY RATHER COMBINED IN A SCORING 
SYSTEM 
 
 
 
8) STATISTICAL ANALYSIS 
 
- WERE THE STATISTICAL ANALYSES ADEQUATE IN DESCRIBING THE RESULTS 
- WERE CORRECT STATISTICAL TESTS USED AND ASSUMPTIONS OF TEST NOT 
VIOLATED 
- WERE STATISTICS REPORTED WITH LEVELS OF SIGNIFICANCE AND/OR 
CONFIDENCE INTERVALS 
- WAS “INTENT TO TREAT” ANALYSIS F OUTCOMES DONE 
 245 
- WERE ADEQUATE ADJUSTMENTS MADE FOR EFFECTS OF CONFOUNDING 
FACTORS THAT MIGHT HAVE AFFECTED THE OUTCOMES (E.G. MULTIVARIATE 
ANALYSES) 
- WAS CLINICAL SIGNIFICANCE ASWELL AS STATISTICAL SIGNIFICANCE 
REPORTED 
- IF NEGATIVE FINDINGS, WAS A POWER CALCULATION REPORTED TO ADDRESS 
TYPE 2 ERROR 
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QUALITY ASSESSMENT OF COHORT STUDIES 
 
9) ABSTRACT 
 
DOES EACH SECTION OF THE ABSTRACT ACCURATELY REFLECT THE EQUIVALENT 
SECTION IN THE REVIEW 
 
- BACKGROUND 
- OBJECTIVES  
- SEARCH STRATEGY 
- SELECTION CRITERIA 
- DATA COLLECTION AND ANALYSIS 
- MAIN RESULTS 
- REVIEWERS‟ CONCLUSIONS 
 
10) OBJECTIVES 
 
WERE THE MAIN OBJECTIVES SPECIFIED IN TERMS OF INTERVENTIONS, CLINICAL 
PROBLEM, POPULATION AND OUTCOMES 
 
11) TYPES OF PARTICIPANTS 
 
- WERE THE TYPE OF PARTICIPANTS REQUIRED INCLUDED AND WHY THEY 
INCLUDED DESCRIBED 
- WERE THE POPULATION GROUPS TO BE EXCLUDED SPECIFIED 
- WERE THE NUMBER OF PARTICIPANTS USED STATED IN BOTH INTERVENTION 
AND CONTROL GROUPS 
- WERE THE GROUPS COMPARABLE 
- IF GROUPS USED: COMPARABLE AT BASELINE.  IF PRE EXISTING 
DIFFERENCES PRESENT, ARE APPROPRIATE ADJUSTMENTS MADE USING 
STATISTICAL ANALYSIS 
- IS THE COMPARISON FAIR 
- WAS EVERYONE WHO ENTERED THE STUDY ACCOUNTED FOR AT THE END 
- WERE THE CRITERIA EQUALLY APPLIED TO ALL GROUPS 
- >80% AGREED TO PARTICIPATE 
- ALL ELIGIBLE SUBJECTS SELECTED OR RANDOM SAMPLE 
- SUBJECTS FREE OF OUTCOMES ON INTEREST AT STUDY INCEPTION 
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12) TYPE OF STUDY 
             HIERARCHY OF STUDY DESIGNS 
K) SYSTEMATIC REVIEW 
L) EXPERIMENTAL STUDIES 
- RANDOMISED CONTROLLED TRIALS (WITHOUT CONCEALMENT ALLOCATION) 
- EXPERIMENTAL STUDY WITHOUT RANDOMISATION E.G. QUASI-
EXPERIMENTAL OR QUASI RANDOMISED OR PSEUDO RANDOMISED STUDIES 
M) OBSERVATIONAL STUDY WITHOUT CONTROL GROUP 
- COHORT STUDY 
- CASE CONTROLLED STUDIES 
N) OBSERVATIONAL STUDIES WITHOUT CONTROL GROUPS 
- CROSS SECTIONAL STUDY 
- BEFORE AND AFTER STUDY 
- CASE SERIES 
O) CASE REPORTS, PATHOPHYSIOLOGICAL STUDIES OR BENCH RESEARCH, 
EXPERT OPINION OR CONSENSUS 
 
13) TYPES OF INTERVENTION AND COMPARISONS 
 
- WERE THE STUDY INTERVENTIONS DESCRIBED 
- WERE THE CONTROL INTERVENTIONS DESCRIBED 
- WERE RELEVANT INTERVENTIONS USED TO ANSWER THE QUESTION 
IDENTIFIED 
- WERE THE INTERVENTIONS INCLUDED DESCRIBED AND APPROPRIATE 
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14) TYPES OF OUTCOMES 
 
- WERE THE OUTCOME MEASURES FOR THE BENEFITS AND HARMS OF 
INTERVENTION CLEARLY DEFINED IN NATURE AND IN TIMING 
- IF SPECIFIC OUTCOMES HAVE BEEN INCLUDED, DID THEY CONFORM WITH 
THE QUESTION ASKED 
- WERE THE MEASUREMENT OF THE OUTCOME THE SAME IN EACH GROUP 
- WERE THE PERIOD OF FOLLOW UP LONG ENOUGH FOR IMPORTANT 
OUTCOMES TO OCCUR 
- WERE OTHER FACTORS ACCOUNTED FOR (MEASURED) THAT COULD AFFECT 
OUTCOMES 
- MEASUREMENT OF OUTCOMES UNBIASED (BLINDED TO GROUP) 
 
15) ASSESSMENT OF QUALITY 
 
WERE THE CRITERIA USED TO ASSESS STUDY QUALITY REPORTED? 
- ALLOCATION CONCEALMENT 
- BLINDING OF PARTICIPANTS 
- BLINDING OF INVESTIGATORS 
- BLINDING OF OUTCOME ASSESSMENT 
- INTENTION TO TREAT ANALYSIS 
- COMPLETENESS OF FOLLOW UP – FOLLOW UP SUFFICIENT DURATION 
- FOLLOW UP COMPLETE AND EXCLUSIONS ACCOUNTED FOR (>80% INCLUDED 
IN FINAL ANALYSIS) 
- RANDOMISATION 
- DESCRIPTION OF WITHDRAWALS 
- POTENTIAL CONFOUNDERS(astounding results) ACCOUNTED FOR 
 
WERE THESE ITEMS ASSESSED SEPARATELY RATHER COMBINED IN A SCORING 
SYSTEM 
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16) STATISTICAL ANALYSIS 
 
- WERE THE STATISTICAL ANALYSES ADEQUATE IN DESCRIBING THE RESULTS 
- WERE CORRECT STATISTICAL TESTS USED AND ASSUMPTIONS OF TEST NOT 
VIOLATED 
- WERE STATISTICS REPORTED WITH LEVELS OF SIGNIFICANCE AND/OR 
CONFIDENCE INTERVALS 
- WAS “INTENT TO TREAT” ANALYSIS F OUTCOMES DONE 
- WERE ADEQUATE ADJUSTMENTS MADE FOR EFFECTS OF CONFOUNDING 
FACTORS THAT MIGHT HAVE AFFECTED THE OUTCOMES (E.G. MULTIVARIATE 
ANALYSES) 
- WAS CLINICAL SIGNIFICANCE ASWELL AS STATISTICAL SIGNIFICANCE 
REPORTED 
- IF NEGATIVE FINDINGS, WAS A POWER CALCULATION REPORTED TO ADDRESS 
TYPE 2 ERROR 
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QUALITY ASSESSMENT OF CASE CONTROL STUDIES 
 
17) ABSTRACT 
 
DOES EACH SECTION OF THE ABSTRACT ACCURATELY REFLECT THE EQUIVALENT 
SECTION IN THE REVIEW 
 
- BACKGROUND 
- OBJECTIVES  
- SEARCH STRATEGY 
- SELECTION CRITERIA 
- DATA COLLECTION AND ANALYSIS 
- MAIN RESULTS 
- REVIEWERS‟ CONCLUSIONS 
 
18) OBJECTIVES 
 
WERE THE MAIN OBJECTIVES SPECIFIED IN TERMS OF INTERVENTIONS, CLINICAL 
PROBLEM, POPULATION AND OUTCOMES 
 
19) TYPES OF PARTICIPANTS 
 
- WERE THE TYPE OF PARTICIPANTS REQUIRED INCLUDED AND WHY THEY 
INCLUDED DESCRIBED 
- WERE THE POPULATION GROUPS TO BE EXCLUDED SPECIFIED 
- WERE THE NUMBER OF PARTICIPANTS USED STATED IN BOTH INTERVENTION 
AND CONTROL GROUPS 
- WERE THE GROUPS COMPARABLE 
- GROUPS COMPARABLE WITH RESPECT TO POTENTIAL CONFOUNDERS 
- IS THE COMPARISON FAIR 
- WAS EVERYONE WHO ENTERED THE STUDY ACCOUNTED FOR AT THE END 
- WERE THE CRITERIA EQUALLY APPLIED TO ALL GROUPS 
- ELIGIBLE SUBJECTS DIAGNOSED AS CASES OVER A DEFINED PERIOD OF 
TIME OR DEFINED CATCHMENT AREA OR A RANDOM SAMPLE OF SUCH 
CASES 
- CASE CONTROLS DEFIFNITIONS ADEQUATE AND VALIDATED 
- CONTROLS SELECTED FROM SAMPLE POPULATION AS CASES 
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- CONTROLS REPRESENTATIVE (INDIVIDUALLY MATCHED) <80% AGREED TO 
PARTICIPATED 
 
20) TYPE OF STUDY 
             HIERARCHY OF STUDY DESIGNS 
O) SYSTEMATIC REVIEW 
P) EXPERIMENTAL STUDIES 
- RANDOMISED CONTROLLED TRIALS (WITHOUT CONCEALMENT ALLOCATION) 
- EXPERIMENTAL STUDY WITHOUT RANDOMISATION E.G. QUASI-
EXPERIMENTAL OR QUASI RANDOMISED OR PSEUDO RANDOMISED STUDIES 
Q) OBSERVATIONAL STUDY WITHOUT CONTROL GROUP 
- COHORT STUDY 
- CASE CONTROLLED STUDIES 
R) OBSERVATIONAL STUDIES WITHOUT CONTROL GROUPS 
- CROSS SECTIONAL STUDY 
- BEFORE AND AFTER STUDY 
- CASE SERIES 
E) CASE REPORTS, PATHOPHYSIOLOGICAL STUDIES OR BENCH RESEARCH, 
EXPERT OPINION OR CONSENSUS 
 
21) TYPES OF INTERVENTION AND COMPARISONS 
 
- WERE THE STUDY INTERVENTIONS DESCRIBED 
- WERE THE CONTROL INTERVENTIONS DESCRIBED 
- WERE RELEVANT INTERVENTIONS USED TO ANSWER THE QUESTION 
IDENTIFIED 
- WERE THE INTERVENTIONS INCLUDED DESCRIBED AND APPROPRIATE 
22) TYPES OF OUTCOMES 
 
- WERE THE OUTCOME MEASURES FOR THE BENEFITS AND HARMS OF 
INTERVENTION CLEARLY DEFINED IN NATURE AND IN TIMING 
- IF SPECIFIC OUTCOMES HAVE BEEN INCLUDED, DID THEY CONFORM WITH 
THE QUESTION ASKED 
- WERE THE MEASUREMENT OF THE OUTCOME THE SAME IN EACH GROUP 
- WERE THE PERIOD OF FOLLOW UP LONG ENOUGH FOR IMPORTANT 
OUTCOMES TO OCCUR 
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- WERE OTHER FACTORS ACCOUNTED FOR (MEASURED) THAT COULD AFFECT 
OUTCOMES 
- OUTCOME STATUS ASCERTAINED OBJECTIVELY 
- WAS CASE DEFINITION EXPLICIT AND CASE ASCERTAINMENT NOT 
INFLUENCED BY EXPOSURE STATUS 
- POTENTIAL CONFOUNDERS CONTROLLED FOR 
- MEASUREMENT OF EXPOSURE UNBIASED (BLINDED TO GROUP) 
 
23) ASSESSMENT OF QUALITY 
 
WERE THE CRITERIA USED TO ASSESS STUDY QUALITY REPORTED? 
- ALLOCATION CONCEALMENT 
- BLINDING OF PARTICIPANTS 
- BLINDING OF INVESTIGATORS 
- BLINDING OF OUTCOME ASSESSMENT 
- INTENTION TO TREAT ANALYSIS 
- COMPLETENESS OF FOLLOW UP 
- RANDOMISATION 
- DESCRIPTION OF WITHDRAWALS 
- >80% SELECTED SUBJECTS INCLUDED IN ANALYSIS 
 
WERE THESE ITEMS ASSESSED SEPARATELY RATHER COMBINED IN A SCORING 
SYSTEM 
 
24) STATISTICAL ANALYSIS 
 
- WERE THE STATISTICAL ANALYSES ADEQUATE IN DESCRIBING THE RESULTS 
- WAS AN APPROPRIATE STATISTICAL ANALYSIS USED (I.E. MATCHED OR 
UNMATCHED) 
- WERE CORRECT STATISTICAL TESTS USED AND ASSUMPTIONS OF TEST NOT 
VIOLATED 
- WERE STATISTICS REPORTED WITH LEVELS OF SIGNIFICANCE AND/OR 
CONFIDENCE INTERVALS 
- WAS “INTENT TO TREAT” ANALYSIS F OUTCOMES DONE 
- WERE ADEQUATE ADJUSTMENTS MADE FOR EFFECTS OF CONFOUNDING 
FACTORS THAT MIGHT HAVE AFFECTED THE OUTCOMES (E.G. MULTIVARIATE 
ANALYSES) 
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- WAS CLINICAL SIGNIFICANCE ASWELL AS STATISTICAL SIGNIFICANCE 
REPORTED 
- IF NEGATIVE FINDINGS, WAS A POWER CALCULATION REPORTED TO ADDRESS 
TYPE 2 ERROR 
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QUALITY ASSESSMENT OF CROSS SECTIONAL SURVEY 
 
25) ABSTRACT 
 
DOES EACH SECTION OF THE ABSTRACT ACCURATELY REFLECT THE EQUIVALENT 
SECTION IN THE REVIEW 
 
- BACKGROUND 
- OBJECTIVES  
- SEARCH STRATEGY 
- SELECTION CRITERIA 
- DATA COLLECTION AND ANALYSIS 
- MAIN RESULTS 
- REVIEWERS‟ CONCLUSIONS 
 
26) OBJECTIVES 
 
WERE THE MAIN OBJECTIVES SPECIFIED IN TERMS OF INTERVENTIONS, CLINICAL 
PROBLEM, POPULATION AND OUTCOMES 
 
27) TYPES OF PARTICIPANTS 
 
- WERE THE TYPE OF PARTICIPANTS REQUIRED INCLUDED AND WHY THEY 
INCLUDED DESCRIBED 
- SELECTED SUBJECTS ARE REPRESENTATIVE (ALL ELIGIBLE OR A RANDOM 
SAMPLE) 
- WERE THE POPULATION GROUPS TO BE EXCLUDED SPECIFIED 
- WERE THE NUMBER OF PARTICIPANTS USED STATED IN BOTH INTERVENTION 
AND CONTROL GROUPS 
- WERE THE GROUPS COMPARABLE 
- IS THE COMPARISON FAIR 
- WAS EVERYONE WHO ENTERED THE STUDY ACCOUNTED FOR AT THE END 
- WERE THE CRITERIA EQUALLY APPLIED TO ALL GROUPS 
28) TYPE OF STUDY 
 
             HIERARCHY OF STUDY DESIGNS 
S) SYSTEMATIC REVIEW 
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T) EXPERIMENTAL STUDIES 
- RANDOMISED CONTROLLED TRIALS (WITHOUT CONCEALMENT ALLOCATION) 
- EXPERIMENTAL STUDY WITHOUT RANDOMISATION E.G. QUASI-
EXPERIMENTAL OR QUASI RANDOMISED OR PSEUDO RANDOMISED STUDIES 
U) OBSERVATIONAL STUDY WITHOUT CONTROL GROUP 
- COHORT STUDY 
- CASE CONTROLLED STUDIES 
V) OBSERVATIONAL STUDIES WITHOUT CONTROL GROUPS 
- CROSS SECTIONAL STUDY 
- BEFORE AND AFTER STUDY 
- CASE SERIES 
E) CASE REPORTS, PATHOPHYSIOLOGICAL STUDIES OR BENCH RESEARCH, 
EXPERT OPINION OR CONSENSUS 
 
29) TYPES OF INTERVENTION AND COMPARISONS 
 
- WERE THE STUDY INTERVENTIONS DESCRIBED 
- WERE THE CONTROL INTERVENTIONS DESCRIBED 
- WERE RELEVANT INTERVENTIONS USED TO ANSWER THE QUESTION 
IDENTIFIED 
- WERE THE INTERVENTIONS INCLUDED DESCRIBED AND APPROPRIATE 
 
30) TYPES OF OUTCOMES 
 
- WERE THE OUTCOME MEASURES FOR THE BENEFITS AND HARMS OF 
INTERVENTION CLEARLY DEFINED IN NATURE AND IN TIMING 
- IF SPECIFIC OUTCOMES HAVE BEEN INCLUDED, DID THEY CONFORM WITH 
THE QUESTION ASKED 
- WERE THE MEASUREMENT OF THE OUTCOME THE SAME IN EACH GROUP 
- WERE THE PERIOD OF FOLLOW UP LONG ENOUGH FOR IMPORTANT 
OUTCOMES TO OCCUR 
- WERE OTHER FACTORS ACCOUNTED FOR (MEASURED) THAT COULD AFFECT 
OUTCOMES 
- EXPOSURE/OUTCOME STATUS ASCERTAINED STANDARDISED WAY 
 
31) ASSESSMENT OF QUALITY 
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WERE THE CRITERIA USED TO ASSESS STUDY QUALITY REPORTED? 
- ALLOCATION CONCEALMENT 
- BLINDING OF PARTICIPANTS 
- BLINDING OF INVESTIGATORS 
- BLINDING OF OUTCOME ASSESSMENT 
- INTENTION TO TREAT ANALYSIS 
- COMPLETENESS OF FOLLOW UP 
- RANDOMISATION 
- DESCRIPTION OF WITHDRAWALS 
- WAS THE NUMBER, CHARACTERISTICS OF WITHDRAWALS (I.E. DROPOUTS, 
LOST TO FOLLOW UP, ATTRITION RATE) AND OR RESPONSE RATE DESCRIBED 
FOR EACH GROUP (>80% AGREED TO PARTICIPATE) 
 
WERE THESE ITEMS ASSESSED SEPARATELY RATHER COMBINED IN A SCORING 
SYSTEM 
 
32) STATISTICAL ANALYSIS 
 
- WERE THE STATISTICAL ANALYSES ADEQUATE IN DESCRIBING THE RESULTS 
- WERE CORRECT STATISTICAL TESTS USED AND ASSUMPTIONS OF TEST NOT 
VIOLATED 
- WERE STATISTICS REPORTED WITH LEVELS OF SIGNIFICANCE AND/OR 
CONFIDENCE INTERVALS 
- WAS “INTENT TO TREAT” ANALYSIS F OUTCOMES DONE 
- WERE ADEQUATE ADJUSTMENTS MADE FOR EFFECTS OF CONFOUNDING 
FACTORS THAT MIGHT HAVE AFFECTED THE OUTCOMES (E.G. MULTIVARIATE 
ANALYSES) 
- WAS CLINICAL SIGNIFICANCE ASWELL AS STATISTICAL SIGNIFICANCE 
REPORTED 
- IF NEGATIVE FINDINGS, WAS A POWER CALCULATION REPORTED TO ADDRESS 
TYPE 2 ERROR 
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QUALITY ASSESSMENT OF CASE SERIES 
 
33) ABSTRACT 
 
DOES EACH SECTION OF THE ABSTRACT ACCURATELY REFLECT THE EQUIVALENT 
SECTION IN THE REVIEW 
 
- BACKGROUND 
- OBJECTIVES  
- SEARCH STRATEGY 
- SELECTION CRITERIA 
- DATA COLLECTION AND ANALYSIS 
- MAIN RESULTS 
- REVIEWERS‟ CONCLUSIONS 
 
34) OBJECTIVES 
 
WERE THE MAIN OBJECTIVES SPECIFIED IN TERMS OF INTERVENTIONS, CLINICAL 
PROBLEM, POPULATION AND OUTCOMES 
 
35) TYPES OF PARTICIPANTS 
 
- WERE THE TYPE OF PARTICIPANTS REQUIRED INCLUDED AND WHY THEY 
INCLUDED DESCRIBED 
- WERE THE POPULATION GROUPS TO BE EXCLUDED SPECIFIED 
- ARE CRITERIA FOR EXCLUSION EXPLICIT 
- WERE THE NUMBER OF PARTICIPANTS USED STATED IN BOTH INTERVENTION 
AND CONTROL GROUPS 
- WERE THE GROUPS COMPARABLE 
- IS THE COMPARISON FAIR 
- WAS EVERYONE WHO ENTERED THE STUDY ACCOUNTED FOR AT THE END 
- WERE THE CRITERIA EQUALLY APPLIED TO ALL GROUPS 
- IS THE STUDY BASED ON A REPRESENTATIVE SAMPLE FROM A RELEVANT 
POPULATION 
 
36) TYPE OF STUDY 
             HIERARCHY OF STUDY DESIGNS 
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W) SYSTEMATIC REVIEW 
X) EXPERIMENTAL STUDIES 
- RANDOMISED CONTROLLED TRIALS (WITHOUT CONCEALMENT ALLOCATION) 
- EXPERIMENTAL STUDY WITHOUT RANDOMISATION E.G. QUASI-
EXPERIMENTAL OR QUASI RANDOMISED OR PSEUDO RANDOMISED STUDIES 
Y) OBSERVATIONAL STUDY WITHOUT CONTROL GROUP 
- COHORT STUDY 
- CASE CONTROLLED STUDIES 
Z) OBSERVATIONAL STUDIES WITHOUT CONTROL GROUPS 
- CROSS SECTIONAL STUDY 
- BEFORE AND AFTER STUDY 
- CASE SERIES 
E) CASE REPORTS, PATHOPHYSIOLOGICAL STUDIES OR BENCH RESEARCH, 
EXPERT OPINION OR CONSENSUS 
 
37) TYPES OF INTERVENTION AND COMPARISONS 
 
- WERE THE STUDY INTERVENTIONS DESCRIBED 
- WERE THE CONTROL INTERVENTIONS DESCRIBED 
- WERE RELEVANT INTERVENTIONS USED TO ANSWER THE QUESTION 
IDENTIFIED 
- WERE THE INTERVENTIONS INCLUDED DESCRIBED AND APPROPRIATE 
 
38) TYPES OF OUTCOMES 
 
- WERE THE OUTCOME MEASURES FOR THE BENEFITS AND HARMS OF 
INTERVENTION CLEARLY DEFINED IN NATURE AND IN TIMING 
- IF SPECIFIC OUTCOMES HAVE BEEN INCLUDED, DID THEY CONFORM WITH 
THE QUESTION ASKED 
- WERE THE MEASUREMENT OF THE OUTCOME THE SAME IN EACH GROUP 
- WERE THE PERIOD OF FOLLOW UP LONG ENOUGH FOR IMPORTANT 
OUTCOMES TO OCCUR 
- WERE OTHER FACTORS ACCOUNTED FOR (MEASURED) THAT COULD AFFECT 
OUTCOMES 
- WERE OUTCOMES ASSESSED USING OBJECTIVE CRITERIA 
 
39) ASSESSMENT OF QUALITY 
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WERE THE CRITERIA USED TO ASSESS STUDY QUALITY REPORTED? 
- ALLOCATION CONCEALMENT 
- BLINDING OF PARTICIPANTS 
- BLINDING OF INVESTIGATORS 
- BLINDING OF OUTCOME ASSESSMENT 
- INTENTION TO TREAT ANALYSIS 
- COMPLETENESS OF FOLLOW UP 
- RANDOMISATION 
- DESCRIPTION OF WITHDRAWALS 
 
WERE THESE ITEMS ASSESSED SEPARATELY RATHER COMBINED IN A SCORING 
SYSTEM 
 
40) STATISTICAL ANALYSIS 
 
- WERE THE STATISTICAL ANALYSES ADEQUATE IN DESCRIBING THE RESULTS 
- WERE CORRECT STATISTICAL TESTS USED AND ASSUMPTIONS OF TEST NOT 
VIOLATED 
- WERE STATISTICS REPORTED WITH LEVELS OF SIGNIFICANCE AND/OR 
CONFIDENCE INTERVALS 
- WAS “INTENT TO TREAT” ANALYSIS F OUTCOMES DONE 
- WERE ADEQUATE ADJUSTMENTS MADE FOR EFFECTS OF CONFOUNDING 
FACTORS THAT MIGHT HAVE AFFECTED THE OUTCOMES (E.G. MULTIVARIATE 
ANALYSES) 
- WAS CLINICAL SIGNIFICANCE ASWELL AS STATISTICAL SIGNIFICANCE 
REPORTED 
- IF NEGATIVE FINDINGS, WAS A POWER CALCULATION REPORTED TO ADDRESS 
TYPE 2 ERROR 
 260 
QUALITY ASSESSMENT FOR QUALITATIVE STUDIES 
 
41) ABSTRACT 
 
DOES EACH SECTION OF THE ABSTRACT ACCURATELY REFLECT THE EQUIVALENT 
SECTION IN THE REVIEW 
 
- BACKGROUND 
- OBJECTIVES  
- SEARCH STRATEGY 
- SELECTION CRITERIA 
- DATA COLLECTION AND ANALYSIS 
- MAIN RESULTS 
- REVIEWERS‟ CONCLUSIONS 
 
42) OBJECTIVES 
 
WERE THE MAIN OBJECTIVES SPECIFIED IN TERMS OF INTERVENTIONS, CLINICAL 
PROBLEM, POPULATION AND OUTCOMES 
 
43) TYPES OF PARTICIPANTS 
 
- WERE THE TYPE OF PARTICIPANTS REQUIRED INCLUDED AND WHY THEY 
INCLUDED DESCRIBED 
- WERE THE POPULATION GROUPS TO BE EXCLUDED SPECIFIED 
- WERE THE NUMBER OF PARTICIPANTS USED STATED IN BOTH INTERVENTION 
AND CONTROL GROUPS 
- WERE THE GROUPS COMPARABLE 
- IS THE COMPARISON FAIR 
- WAS EVERYONE WHO ENTERED THE STUDY ACCOUNTED FOR AT THE END 
- WERE THE CRITERIA EQUALLY APPLIED TO ALL GROUPS 
- CRITERIA FOR SELECTING SAMPLE CLEARLY DESCRIBED 
 
 
44) TYPE OF STUDY 
             HIERARCHY OF STUDY DESIGNS 
AA) SYSTEMATIC REVIEW 
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BB) EXPERIMENTAL STUDIES 
- RANDOMISED CONTROLLED TRIALS (WITHOUT CONCEALMENT ALLOCATION) 
- EXPERIMENTAL STUDY WITHOUT RANDOMISATION E.G. QUASI-
EXPERIMENTAL OR QUASI RANDOMISED OR PSEUDO RANDOMISED STUDIES 
CC) OBSERVATIONAL STUDY WITHOUT CONTROL GROUP 
- COHORT STUDY 
- CASE CONTROLLED STUDIES 
DD) OBSERVATIONAL STUDIES WITHOUT CONTROL GROUPS 
- CROSS SECTIONAL STUDY 
- BEFORE AND AFTER STUDY 
- CASE SERIES 
E) CASE REPORTS, PATHOPHYSIOLOGICAL STUDIES OR BENCH RESEARCH, 
EXPERT OPINION OR CONSENSUS 
 
45) TYPES OF INTERVENTION AND COMPARISONS 
 
- WERE THE STUDY INTERVENTIONS DESCRIBED 
- WERE THE CONTROL INTERVENTIONS DESCRIBED 
- WERE RELEVANT INTERVENTIONS USED TO ANSWER THE QUESTION 
IDENTIFIED 
- WERE THE INTERVENTIONS INCLUDED DESCRIBED AND APPROPRIATE 
 
46) TYPES OF OUTCOMES 
 
- WERE THE OUTCOME MEASURES FOR THE BENEFITS AND HARMS OF 
INTERVENTION CLEARLY DEFINED IN NATURE AND IN TIMING 
- IF SPECIFIC OUTCOMES HAVE BEEN INCLUDED, DID THEY CONFORM WITH 
THE QUESTION ASKED 
- WERE THE MEASUREMENT OF THE OUTCOME THE SAME IN EACH GROUP 
- WERE THE PERIOD OF FOLLOW UP LONG ENOUGH FOR IMPORTANT 
OUTCOMES TO OCCUR 
- WERE OTHER FACTORS ACCOUNTED FOR (MEASURED) THAT COULD AFFECT 
OUTCOMES 
- ANALYSIS METHODS USED RIGOROUS 
- EVIDENCE OF EFFORTS TO ESTABLISH VALIDITY/RELIABILITY 
 
47) ASSESSMENT OF QUALITY 
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WERE THE CRITERIA USED TO ASSESS STUDY QUALITY REPORTED? 
- ALLOCATION CONCEALMENT 
- BLINDING OF PARTICIPANTS 
- BLINDING OF INVESTIGATORS 
- BLINDING OF OUTCOME ASSESSMENT 
- INTENTION TO TREAT ANALYSIS 
- COMPLETENESS OF FOLLOW UP 
- RANDOMISATION 
- DESCRIPTION OF WITHDRAWALS 
- METHODS OF DATA COLLECTION ADEQUATELY DESCRIBED 
- RESPONDENT VALIDATION (FEEDBACK OF DATA/RESEARCHER’S 
INTERPRETATION TO PARTICIPANTS) 
- INTERPRETATION SUPPORTED BY DATA 
 
WERE THESE ITEMS ASSESSED SEPARATELY RATHER COMBINED IN A SCORING 
SYSTEM 
 
48) STATISTICAL ANALYSIS 
 
- WERE THE STATISTICAL ANALYSES ADEQUATE IN DESCRIBING THE RESULTS 
- WERE CORRECT STATISTICAL TESTS USED AND ASSUMPTIONS OF TEST NOT 
VIOLATED 
- WERE STATISTICS REPORTED WITH LEVELS OF SIGNIFICANCE AND/OR 
CONFIDENCE INTERVALS 
- WAS “INTENT TO TREAT” ANALYSIS F OUTCOMES DONE 
- WERE ADEQUATE ADJUSTMENTS MADE FOR EFFECTS OF CONFOUNDING 
FACTORS THAT MIGHT HAVE AFFECTED THE OUTCOMES (E.G. MULTIVARIATE 
ANALYSES) 
- WAS CLINICAL SIGNIFICANCE ASWELL AS STATISTICAL SIGNIFICANCE 
REPORTED 
- IF NEGATIVE FINDINGS, WAS A POWER CALCULATION REPORTED TO ADDRESS 
TYPE 2 ERROR 
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Appendix 4: Studies meeting inclusion criteria and eligible for quantitative analysis 
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BASELINE 
ALTINER 
(2007) 
GERMANY 
T+PL+
P/AP 
GPs 
NOT 
SPECIFIED 
CLUSTER 
RANDOMISED 
CONTROLLED 
TRIAL 
274 753 36.4 491 898 54.7 
  
ANGUNAW
ELA (1991) 
SRI LANKA W/AP 
ALL 
PATIENTS 
NOT 
SPECIFIED 
RANDOMISED 
CONTROLLED 
TRIAL 
273 867 31.5 363 1127 32.2 
  
ANGUNAW
ELA (1991) 
SRI LANKA 
W+S/A
P 
ALL 
PATIENTS 
NOT 
SPECIFIED 
RANDOMISED 
CONTROLLED 
TRIAL 
442 1121 39.4 363 1127 32.2 
  
ARNOLD 
(2006) 
USA 
AMT+
G/AP 
PHYSICIA
NS 
NOT 
SPECIFIED 
COHORT 
STUDY 
1147 1550 74.0 880 1257 70.0 
  
BJERRUM 
(2006) 
SPAIN G/AP 
ALL 
PATIENTS 
RESPIRATOR
Y TRACT 
INFECTIONS 
PROSPECTIVE 
BEFORE AND 
AFTER STUDY 
401 1114 36.0 788 2462 32.0 
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DE SANTIS 
(1994) 
AUSTRALIA 
E+MB
+G+A
D/AP 
NOT 
SPECIFIE
D 
TONSILITIS 
RANDOMISED 
CONTROLLED 
TRIAL 
389 1032 37.7 417 1357 30.7 
  
GONZALES 
(1999) 
USA 
PEM+
PP/AP 
ADULTS BRONCHITIS 
PROSPECTIVE 
NON 
RANDOMISED 
CONTROLLED 
STUDY 
2019 2462 82.0 1920 2462 78.0 
  
GONZALES 
(1999) 
USA 
PCE+P
P/AP 
ADULTS BRONCHITIS 
PROSPECTIVE 
NON 
RANDOMISED 
CONTROLLED 
STUDY 
1822 2462 74.0 1920 2462 78.0 
  
HICKMAN 
(2003) 
USA 
E+PR+
SM+O
TC+P+
N/AP 
CLINICIA
NS 
BRONCHITIS 
NON 
RANDOMISED 
CONTROLLED 
TRIAL 
142 446 31.8 888 1840 48.3 
  
MAINOUS 
(2000) 
USA 
PEM/A
P 
CHILDRE
N 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
RANDOMISED 
CONTROLLED 
TRIAL 
9430 29562 31.9 11663 37622 31.0 
  
MAINOUS 
(2000) 
USA F/AP 
CHILDRE
N 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
RANDOMISED 
CONTROLLED 
TRIAL 
9886 34810 28.4 11663 37622 31.0 
  
MAINOUS 
(2000) 
USA 
PEM+
F/AP 
CHILDRE
N 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
RANDOMISED 
CONTROLLED 
TRIAL 
7818 22728 34.4 11663 37622 31.0 
  
MELANDER 
(1999) 
SWEDEN A/AP GPs 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
COHORT 
STUDY 
618 1124 55.0 788 1313 60.0 
 265 
  
MOLSTAD 
(1989) 
SWEDEN E/AP 
NOT 
SPECIFIE
D 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
RANDOMISED 
CONTROLLED 
TRIAL 
146 216 67.6 466 663 70.3 
  
MONETTE 
(2007) 
CANADA E/AP 
PHYSICIA
NS 
NOT 
SPECIFIED 
PROSPECTIVE 
PAIR MATCHED 
CLUSTER 
RANDOMISED 
CONTROLLED 
TRIAL 
156 274 56.9 89 157 56.7 
  
SMABREKK
E (2002) 
NORWAY 
E+G/A
P 
CHILDRE
N 
OTITIS 
MEDIA 
CONTROLLED 
BEFORE-AND-
AFTER STUDY 
318 355 89.6 126 133 94.7 
INTERVENTION 
ALTINER 
(2007) 
GERMANY 
T+PL+
P/AP 
GPs 
NOT 
SPECIFIED 
CLUSTER 
RANDOMISED 
CONTROLLED 
TRIAL 
198 675 29.3 526 885 59.4 
  
ANGUNAW
ELA (1991) 
SRI LANKA W/AP 
ALL 
PATIENTS 
NOT 
SPECIFIED 
RANDOMISED 
CONTROLLED 
TRIAL 
524 2039 25.7 1238 2866 43.2 
  
ANGUNAW
ELA (1991) 
SRI LANKA 
W+S/A
P 
ALL 
PATIENTS 
NOT 
SPECIFIED 
RANDOMISED 
CONTROLLED 
TRIAL 
1138 3135 36.3 1238 2866 43.2 
  
ARNOLD 
(2006) 
USA 
AMT+
G/AP 
PHYSICIA
NS 
NOT 
SPECIFIED 
COHORT 
STUDY 
1441 1550 93.0 1131 1257 90.0 
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BRIEL 
(2006) 
SWITZERLA
ND 
T+E+G
+S/AP 
ADULTS 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
CLUSTER 
RANDOMISED 
CONTROLLED 
TRIAL 
46 293 15.7 61 285 21.4 
  
BRIEL 
(2006) 
SWITZERLA
ND 
T+E+G
+S+F/
AP 
ADULTS 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
CLUSTER 
RANDOMISED 
CONTROLLED 
TRIAL 
35 259 13.5 61 285 21.4 
  
BRIEL 
(2006) 
SWITZERLA
ND 
T+E+G
+S/C 
ADULTS 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
CLUSTER 
RANDOMISED 
CONTROLLED 
TRIAL 
26 293 8.9 30 285 10.5 
  
BRIEL 
(2006) 
SWITZERLA
ND 
T+E+G
+S+F/
C 
ADULTS 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
CLUSTER 
RANDOMISED 
CONTROLLED 
TRIAL 
21 259 8.1 30 285 10.5 
  
BUISING 
(2008) 
AUSTRALIA AD/AP DOCTORS 
COMMUNITY 
ACQUIRED 
PNEUMONIA 
PRE-TEST-POST 
TEST COHORT 
STUDY 
143 208 68.8 211 341 61.9 
  
BUISING 
(2008) 
AUSTRALIA 
CDSS/
AP 
DOCTORS 
COMMUNITY 
ACQUIRED 
PNEUMONIA 
PRE-TEST-POST 
TEST COHORT 
STUDY  
13 126 10.3 211 341 61.9 
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DE SANTIS 
(1994) 
AUSTRALIA 
E+MB
+G+A
D/AP 
NOT 
SPECIFIE
D 
TONSILITIS 
RANDOMISED 
CONTROLLED 
TRIAL 
214 567 37.7 265 708 37.4 
  
DRANITSAR
IS (2001) 
CANADA A/AP 
ALL 
PATIENTS 
NOT 
SPECIFIED 
PROSPECTIVE 
RANDOMISED 
PROSPECTIVE 
STUDY 
122 162 75.3 102 147 69.4 
  
GONZALES 
(1999) 
USA 
PEM+
PP/AP 
ADULTS BRONCHITIS 
PROSPECTIVE 
NON 
RANDOMISED 
CONTROLLED 
STUDY 
1662 2027 82.0 1581 2027 78.0 
  
GONZALES 
(1999) 
USA 
PCE+P
P/AP 
ADULTS BRONCHITIS 
PROSPECTIVE 
NON 
RANDOMISED 
CONTROLLED 
STUDY 
1500 2027 74.0 1581 2027 78.0 
  HADI (2008) INDONESIA 
G+PB+
TSPD/
AP 
ALL 
PATIENTS 
FEVER 
PROSPECTIVE 
INTERVENTION 
56 103 54.4 187 212 88.2 
  HADI (2008) INDONESIA 
G+PB+
TSPT/
AP 
ALL 
PATIENTS 
FEVER 
PROSPECTIVE 
INTERVENTION 
20 110 18.2 187 212 88.2 
  HADI (2008) INDONESIA 
G+PB+
TSPRC
/AP 
ALL 
PATIENTS 
FEVER 
PROSPECTIVE 
INTERVENTION 
16 76 21.1 187 212 88.2 
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  HADI (2008) INDONESIA 
G+PB+
TSPB/
AP 
ALL 
PATIENTS 
FEVER 
PROSPECTIVE 
INTERVENTION 
206 289 71.3 187 212 88.2 
  
HICKMAN 
(2003) 
USA 
E+PR+
SM+O
TC+P+
N/AP 
CLINICIA
NS 
BRONCHITIS 
NON 
RANDOMISED 
CONTROLLED 
TRIAL 
102 321 31.8 924 2392 38.6 
  
MAINOUS 
(2000) 
USA 
PEM/A
P 
CHILDRE
N 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
RANDOMISED 
CONTROLLED 
TRIAL 
13155 29562 44.5 20128 37622 53.5 
  
MAINOUS 
(2000) 
USA F/AP 
CHILDRE
N 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
RANDOMISED 
CONTROLLED 
TRIAL 
15177 34810 43.6 20128 37622 53.5 
  
MAINOUS 
(2000) 
USA 
PEM+
F/AP 
CHILDRE
N 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
RANDOMISED 
CONTROLLED 
TRIAL 
11296 22728 49.7 20128 37622 53.5 
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MCGREGOR 
(2006) 
USA 
ASP+C
DS/AP 
ALL 
PATIENTS 
NOT 
SPECIFIED 
RANDOMISED 
CONTROLLED 
TRIAL 
1325 2270 58.4 1315 2237 58.8 
  
MELANDER 
(1999) 
SWEDEN A/AP GPs 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
COHORT 
STUDY 
417 926 45.0 838 1309 64.0 
  
MOLSTAD 
(1989) 
SWEDEN E/AP 
NOT 
SPECIFIE
D 
ACUTE 
RESPIRATOR
Y TRACT 
INFECTION 
RANDOMISED 
CONTROLLED 
TRIAL 
93 212 43.9 359 576 62.3 
  
MONETTE 
(2007) 
CANADA E/AP 
PHYSICIA
NS 
NOT 
SPECIFIED 
PROSPECTIVE 
PAIR MATCHED 
CLUSTER 
RANDOMISED 
CONTROLLED 
TRIAL  
205 351 58.4 211 348 60.6 
  NG (2008) 
HONG 
KONG 
ASP+L
+F+G/
AP 
ALL 
PATIENTS 
NOT 
SPECIFIED 
PRE-TEST-
POST-TEST 
ANALYSIS 
293 2385 12.3 693 3537 19.6 
  
PASTEL 
(1992) 
USA PI/AP 
PHYSICIA
NS 
NOT 
SPECIFIED 
PROSPECTIVE 
STREAMLINE 
STUDY 
18 28 64.3 12 41 29.3 
  PAUL (2006) 
ISRAEL, 
GERMANY, 
ITALY 
CDS/A
P 
ALL 
PATIENTS 
BACTERIAL 
INFECTION 
PROSPECTIVE 
COHORT 
STUDY 
216 297 72.7 176 273 64.5 
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RAUTAKOR
PI (2006) 
NORWAY 
G+EM/
AP 
ALL 
PATIENTS 
UPPER 
RESPIRATOR
Y TRACT 
INFECTIONS 
RANDOMISED 
CONTROLLED 
TRIAL 
2099 4881 43.0 13868 29043 47.7 
  
SCHWARTZ 
(2007) 
USA E/AP 
NOT 
SPECIFIE
D 
NOT 
SPECIFIED 
PROSPECTIVE 
PAIR MATCHED 
BEFORE AND 
AFTER 
CLUSTER 
RANDOMISED 
CONTROLLED 
TRIAL 
30 77 39.0 8 73 11.0 
  
SEAGER 
(2006) 
WALES 
G+E/A
P 
DENTISTS 
NOT 
SPECIFIED 
RANDOMISED 
CONTROLLED 
TRIAL 
131 451 29.0 157 490 32.0 
  
SEAGER 
(2006) 
WALES 
E+AD/
AP 
DENTISTS 
NOT 
SPECIFIED 
RANDOMISED 
CONTROLLED 
TRIAL 
128 556 23.0 157 490 32.0 
  
SEAGER 
(2006) 
WALES 
G+E/A
P 
DENTISTS 
NOT 
SPECIFIED 
RANDOMISED 
CONTROLLED 
TRIAL 
383 451 84.9 402 490 82.0 
  
SEAGER 
(2006) 
WALES 
E+AD/
AP 
DENTISTS 
NOT 
SPECIFIED 
RANDOMISED 
CONTROLLED 
TRIAL 
517 556 93.0 402 490 82.0 
  
SMABREKK
E (2002) 
NORWAY 
E+G/A
P 
CHILDRE
N 
OTITIS 
MEDIA 
CONTROLLED 
BEFORE-AND-
AFTER STUDY 
318 355 89.6 126 133 94.7 
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VAN DRIEL 
(2007) 
BELGIUM 
G+AD
+PR+S
G/AP 
GPs 
ACUTE 
RHINOSINUSI
TIS 
CLUSTER 
RANDOMISED 
CONTROLLED 
TRIAL 
116 204 56.9 119 204 58.3 
  
VAN DRIEL 
(2007) 
BELGIUM 
G+AD
+PR+S
C/C 
GPs 
ACUTE 
RHINOSINUSI
TIS 
CLUSTER 
RANDOMISED 
CONTROLLED 
TRIAL 
70 204 34.3 60 204 29.4 
  
WALKER 
(1998) 
USA  PI/AP PATIENTS 
COMMUNITY 
ACQUIRED 
PNEUMONIA  
OPEN LABEL, 
RANDOMISED 
STUDY  
9 25 36.0 22 25 88.0 
FOLLOW-UP 
ALTINER 
(2007) 
GERMANY 
T+PL+
P/AP 
GPs 
NOT 
SPECIFIED 
CLUSTER 
RANDOMISED 
CONTROLLED 
TRIAL 
289 787 36.7 596 920 64.8 
  
ANGUNAW
ELA (1991) 
SRI LANKA W/AP 
ALL 
PATIENTS 
NOT 
SPECIFIED 
RANDOMISED 
CONTROLLED 
TRIAL 
870 2762 31.5 879 2764 31.8 
  
ANGUNAW
ELA (1991) 
SRI LANKA 
W+S/A
P 
ALL 
PATIENTS 
NOT 
SPECIFIED 
RANDOMISED 
CONTROLLED 
TRIAL 
870 2762 31.5 879 2764 31.8 
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BJERRUM 
(2006) 
SPAIN G/AP 
ALL 
PATIENTS 
RESPIRATOR
Y TRACT 
INFECTIONS 
PROSPECTIVE 
BEFORE AND 
AFTER STUDY 
402 1674 24.0 788 2462 32.0 
  
DE SANTIS 
(1994) 
AUSTRALIA 
E+MB
+G+A
D/AP 
NOT 
SPECIFIE
D 
TONSILITIS 
RANDOMISED 
CONTROLLED 
TRIAL 
341 730 46.7 286 685 41.8 
  
MONETTE 
(2007) 
CANADA E/AP 
PHYSICIA
NS 
NOT 
SPECIFIED 
CLUSTER 
RANDOMISED 
CONTROLLED 
TRIAL 
207 309 67.0 89 154 57.8 
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Appendix 5: Semi-structured interview transcripts 
                                                Interviewee 1 
 
Location: Private office desk 
 
Time: 26 minutes and 7 seconds 
 
Interviewer 
I just have to ask a few basic questions first…the first question is...what is your role within the pct? 
 
Interviewee 1 
I am assistant director for the professional services responsible for medicines management 
 
Interviewer  
The second question is…is there an antimicrobial specialist that you use within the pct? 
 
Interviewee 1 
Not a pharmacist...not an antimicrobial pharmacist.  There is one in the local acute trust.  There was a 
government initiative a few years ago to fund antibiotic pharmacist in secondary care and there is one 
at the local acute trust who we can call upon. 
 
Interviewer 
Do you use any other initiatives or incentives at the moment? 
 
Interviewee 1  
We don‟t use incentives as such here.  We have a lot of prescribing initiatives, which we determine 
every year.  What those target things are, and antibiotics feature again this year.  The huge emphasis 
now is due to MRSA and C DIFF infections and these are much more prevalent and can be fatal...you 
can have dire consequences so there is a huge push on infection prevention control and also decreased 
amount of antibiotics prescribed.  We have been trying to identify a link between antibiotic prescribed 
and C DIFF, but it is very difficult. 
 
Interviewer 
You haven‟t been successful? 
 
Interviewee 1  
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No you would have to do it on a much larger scale because the incidences are terrible when they 
happen, but are few and far between.  You can‟t prove cause and link. 
 
Interviewer 
When you follow an avenue like that do you get someone to lead that area of investigation? 
 
Interviewee 1 
If we are having a look we have…the set up we have here…we have pharmacists working (our own 
team) in every GP practice, so whenever we want to just have a quick look, we‟ve got the facility to 
do so. 
 
Interviewer 
Who controls what is implemented and what‟s not? 
 
Interviewee 1 
Our ideas, our initiatives come from what is topical in the press and what we know in the evidence 
and stuff that comes through.  We put an emphasis on it, but of course we can‟t control prescribers.  
The best you can do is influence them positively.  So In terms of those initiatives that‟s me I 
suppose...here! In terms of what we are doing in the practices and what initiatives we take on you 
know...we have campaigns from time to time around antibiotic prescribing.  
 
Interviewer 
Mainly leaflets? 
 
Interviewee 1 
Errm...yes…we have done.  What we are doing in this moment in time is every practice every month 
gets a very detailed report of the antibiotic prescribing. Well actually it goes to the localities.  The 
practices are arranged into six localities in this pct, and that‟s groups of practices together in the 
locality, and so the locality gets a very detailed report with all of the figures for all the practices 
presented in lots of different ways, so that they can actually benchmark themselves, each other against 
national average, the England err the local average…if you like pct…and that is to bring it to their 
attention.  We also do leaflets and we have different language leaflets and we also do pads which are 
non prescription pads so they can actually write on it cold and flu symptoms, these are what you 
do…tear one off and give it to the patient so they go away with a piece of paper, but its not a 
prescription.  Other methods, we do post dated scripts, or some surgeries do one ready and the save it 
and if the symptoms are not cleared in three days come back and get a prescription and so if people 
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are still ill they can come back and get a prescription and take it away otherwise they will find it not 
collected. 
 
Interviewer 
Have you found any of them to be successful? 
 
Interviewee 1 
Well ALL OF THESE HAVE BEEN INITIATIVES WHICH WE SUGGESTED PEOPLE DO AND 
THEY HAVE BEEN DONE LOCALLY that we haven‟t measured in any practice to say… 
the only measure we have is the overall measure of antibiotic prescribing and err when it was high on 
the agenda a few years ago there was a national list of where your place was and the highest number 
of prescriptions and this pct at that time was the highest prescriber of antibiotics, and through a series 
of badgering GPs, putting out information, leaflets, I think some training events they got that down to 
80
th
 out of 300..or whatever it was! 
In PCT X we were also fairly reasonably high to the top and we got it down, however it was 
approached from a different way, well the emphasis was different, but I think we approached it 
slightly differently...there may have been an incentive scheme at that time in north.  Other measures 
we done, we have PAM Birmingham antibiotic formulary that‟s agreed and updated every year with 
the local microbiologists and clinicians obviously, and that goes out and is available on our website on 
out intranet and that supports GP‟s and their prescribing and it is a guideline and formulary, you 
know…this is 1st line, this is second line… 
And why, so I am fairly confident we do prescribe pretty much to formulary but we are not sure if that 
is all appropriate and that is a very difficult thing to do to go out into the practice and go and look at 
each individual one (prescription) and even then you might not because people come in and it depends 
on what they put down on their notes really 
 
Interviewer 
True…do you get government funding at all for each pct? 
 
Interviewee 1 
Not for antibiotics...no...There is government funding coming down for infection prevention control 
but not for antibiotics, nothing related to prescribing. 
 
Interviewer 
Ok, do you get clear directives from the government on how to control antibiotic use? As in do they 
give you any ideas on how best to control? 
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Interviewee 1 
No I think its quite established, the methods you can use, there are only certain things you can do, you 
know its education, providing supporting materials, and you know its making them aware of their 
prescribing habits are all the things we are doing.  There is a national campaign at the moment on 
antibiotic prescribing, so nationally there have been produced leaflets and posters, unfortunately that 
seems to have bypassed us so I don‟t know if they have gone straight out to contractors 
 
Interviewer 
From what I am aware of, it has come out but has been a damp squib. 
 
Interviewee 1  
I think what they need is some national advertising, something to grip the nation sort of thing.  
 
Interviewer 
Do you have any figures available? 
 
Interviewee 1  
I saw that (in the e-mail of questions I would be asking).  Now the thing is what is it you are 
 looking for, you need to be a bit more specific about what you are looking for!! We don‟t  
normally release, because I don‟t hold them as such, I would have to go in and do a research  
on it on a national database which is not at this pct to get our data from but we don‟t  
normally do our practice figures because that would be unfair really.  The amount of scripts  
you write is only one indicator of what the situation is in relation to the prescribing.   
Somebody might be high and it might be highly appropriate and they may have  
patients on long term antibiotics for chronic UTI infections, depending on how you drill 
 down on the detail; they may be nebulised antibiotics, cystic fibrosis.  Items of antibiotics  
prescribed don‟t give you the full picture! So a certain amount of data is ok to release, some  
others it depends on the detail...what exactly are you looking for??  Just to get a figure  
doesn‟t mean much! 
 
Interviewer 
Yes 
 
Interviewee 1 
there was a national one that did the err what‟s it called the defined daily doses per star-pu patient 
unit, have you heard of the measures 
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Interviewer 
Yes 
 
Interviewee 1 
So that is a comparator, but you still don‟t know the detail, it is only an indicator, so its hard to draw 
conclusions.  There‟s lots of different things that need to be taken into account. 
 
Interviewer 
Ok.  The reason why I left it that broad was because I know accessing such information could be a 
problem and issue as well, so it was my way of stating that any data that you may have and can supply 
would be very welcome, but if you cant then that‟s fine! 
 
Interviewee 1 
Right 
 
Interviewer 
Because I have an idea of actual current prescribing in your pct and others in the area  
 
Interviewee 1 
Ok I will because mark is in Monday, no Tuesday errm so we will have a chat a think about  
 
(Exchanged contact details but no reply as yet) 
 
Interviewee 1 
So yes it would be what is useful to you really, and its no use if you look everywhere if you know 
what I mean. 
 
Interviewer 
Finding such data on the internet is very difficult but I was told that such information should be 
available if you go to the pct‟s themselves. 
 
Interviewee 1 
But you have got to tell me what you see, when you say figures its just, what are you looking for 
 
Interviewer 
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Basically I don‟t mind what data you have because I know you may use different measures compared 
to other pct‟s, so if antibiotic data is present in number of items, DDD‟s, whatever...I don‟t mind! 
 
(long pause) 
 
Interviewee 1 
 Ok 
 
Interviewer 
 Its just so I can get a picture of prescribing in the area! 
 
Interviewee 1 
There is the formulary although it is very generic, I‟ll check these things through and see how easy or 
what it is available ok 
 
Interviewer 
Do you know of any previous policies that you have used, which may have been recorded  
 
Interviewee 1 
The campaign they had in east was very, well greatly publicised and unfortunately they have all gone 
now (pointing to an empty shelf on her cabinet), and I don‟t know where all of those figures and work 
was.  I could have a look to see, I did look before and I can‟t actually find the data.  They have been 
prescribing initiatives really, such as raising awareness and having leaflets and posters to go out to 
community pharmacists and to be put up in surgeries.  It was quite successful but the biggest success 
is having a pharmacist in the practice so they can nag the GP‟s really.  But there is also now our non 
medical prescribers which makes it much more difficult to contain because they are scattered around 
the organisation and there aren‟t that many of them so where within a practice there is an entity and 
you can see what is…you can capture everybody...you know you know targeted in one location, with 
the non medical prescribers its sort of all over the teams here or the physios over there you know, so 
we are starting programmes in getting larger numbers of training, and the one thing they have asked 
for is antibiotics and antibiotics training so that‟s good! 
 
Interviewer 
Do you think it would be more beneficial if we brought in incentives rather than initiatives? 
 
Interviewee 1 
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There are a number of things we have to put funding into and there are safety issues like the non 
steroidals this year so what do you, what do you fund and where does the funding come from so yes 
incentives always help but you have to get the funding for it!  I think the road to go to to make the 
difference is...because the reason you are asking around all this is because of over prescribing and 
potential resistance developing and the problems we are having now with MRSA and C DIFF 
presumably, that‟s what the end game is isn‟t it? So it would be really good to focus some attention 
onto MRSA and C DIFF and read papers around the cause and effect and well association is what 
they have at the moment but if you could find something that has a causal link erm you could put it 
back to the number of exposures to antibiotics in the past or you know the most recent exposure.  I‟m 
sure there could be a load of work that could be done and that would be really useful and important to 
all of us really because we seem to be doing what we can around antibiotics.  I‟m sure errm the things 
we are doing we seem to have thought of everything although there is scope for improvement no 
doubt but what is really driving the agenda are C DIFF and MRSA with the incidence of it and the 
growing concerns around that, so if you can focus on that link and demonstrate some association there 
that‟s really important. 
 
 
Interviewer  
When you do introduce an initiative into practice, how long does it take to implement? And how long 
do you keep it running for  
 
Interviewee 1 
We do them in yearly blocks, so if you have an initiative going, we‟ve got priorities this year and 
antibiotics is up there we will continue to monitor and feeding stuff throughout the year and we will 
monitor prescribing feedback from our team and our team continue to drip feed and the reports will go 
out monthly and whatever support we can do locally we can e.g. posters, leaflets, prescription things 
we will.  We are tying some of the practices into the QUOF (quality and outcome framework) that 
GP‟s have.  There is med6 medicines management and 10 and they get points if they meet with us and 
agree 3 initiatives for the year and more points if they actually implement them if they have shown 
some improvement or achievement by the end of the year.  So we are targeting the highest prescribing 
practices in antibiotics to include that agreement, so they will do some work and based on points 
mean prizes, so I guess it‟s an incentive in a way but using the framework that is already there. 
 
Interviewer 
Just for example if something is successful, do you try and run it for as long as possible, or is there a 
certain point where you would have to cut it.   
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Interviewee 1 
If it is successful it becomes superseded by other priorities because there are always other priorities in 
prescribing that you need to address.  There might be safety issues, there may be cost issues, there 
may be quality stuff, NICE guidance, whatever.  If you‟ve been successful in something it never goes 
away totally you just monitor it until it comes again like with antibiotics, which is generally good, but 
there is all this concern and you always have to be on the ball, as it starts to creek you have to blitz 
again and we have taken a more targeted approach this year to get the highest prescribing practices to 
see what is happening there  
  
Interviewer 
Do you communicate with other PCT‟s about what is being done, what has been good or bad? 
 
Interviewee 1 
It has been done because certainly east did their campaign, they did presentations around the other 
PCT‟s.  You know if there was something really innovative we would but what we are doing is 
standard stuff because really it is identifiable what you can do within our structure and framework in 
the NHS its quite well known what you can do.  We are all doing what we know has to be done. 
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Interviewee 2 
 
Location: Desk within open plan office 
 
Time: 37 minutes and 23 seconds 
 
Interviewee 2 
The complicated factor at the moment is that some of the questions and answers are related to other 
people in the pct at the moment, I don‟t know all the answers on that perspective.  I will tell you the 
bits I know, but I don‟t know all of the answers if that‟s fine? 
 
Interviewer 
Yes that‟s fine 
 
Interviewer 
What is your role within the pct 
 
Interviewee 2 
Head of medicines management in this pct responsible for commissioning of medicine services 
 
Interviewer 
Do you have a specialist pharmacist or microbiologist that helps with antibiotics? 
 
Interviewee 2 
We don‟t have a specialist pharmacist in the PCT, the PCT does have a contract for consultant 
microbiologist from university trust hospital, and I also believe there is an infection control team 
contracted in, so we have expert consultants who lend their support to the PCT 
 
Interviewer 
Do they have quite a big involvement then with what is done within the PCT? 
 
Interviewee 2 
Well basically we are in primary care, well basically as a PCT we are quite a large PCT with a big 
provider arm, I don‟t know if you know what I mean, but basically we have got 4 GP‟s, community 
pharmacies or primary care services.  We‟ve got 1000 odd nurses, district nurses and all that lot and 
they are part of a provider unit.  We have also got the dental hospital which is a major hospital, rehab 
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unit with rehabilitation, learning distribution directorate, we‟ve got elderly care hospitals, so that is all 
part of the provider part all within this PCT, and they may be turning into a foundation trust in the 
future.  So one of the reasons of why its complex to say what does the PCT have, actually I have no 
idea what the board manages and what it does, but basically I know we have infection control teams 
that work in the pct employed, basically use the expertise at university trust that has a large 
microbiology department, we contract them to provide it.  So if there is an outbreak in the community, 
then microbiologists and community disease control team come and take control and work with our 
public health and people like that to deal with it.  So the simple answer is we have the resources 
contracted and funded to deal with… 
 
Interviewer 
Ok and they are the ones who deal with the formulary… 
 
Interviewee 2 
Ok formulary is a good one errm…yes with the formulary, we don‟t have a formulary. That was 
flagged up by..I think the healthcare commission errm so errm so that‟s an area, we do have a 
formulary but its well out of date. We are actually developing that at the moment with the consultant 
microbiologist, the antibiotic pharmacist at the acute trus who you know is part of the joint working, 
joint contract I suppose errm and this team here and it will go into consultation in the next two three 
weeks errm and it fits into the primary care target and incentives that we do.  So in other words we are 
developing a formulary and using expertise from our joint partnerships or contracts. 
 
Interviewer 
Ok so if there was a certain incentive, initiative or directives, is that past down from the directors, or 
who is responsible for  
 
Interviewee 2 
Err well from the government yes, well there is isn‟t there, we have a 30% decrease  
in C Diff or whatever they are at the moment, so yes there are different people in charge through chief 
exec directors and head of governance responsible for the C Diff targets and MRSA, and obviously I 
have got tasks like the formulary needs sorting out, we have got the children formulary in place, the 
adult one hasn‟t been done yet and that is what we are doing at the moment, also targets around use of 
Quinolones have been developed, we have already benchmarked the data of every practice so that will 
be going out at the end of this month.  So yes different roles, so that‟s my role so obviously the 
directors and different managers do different roles, so the governance team are actually monitoring 
actual C Diff and MRSA in the community, so yes everyone has different roles in this system.  It is 
certainly cascaded. 
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Interviewer 
Have you heard of the new government target for antibiotic using the campaign of advertising? 
 
Interviewee 2 
Oh about clean hands and all that stuff 
 
Interviewer 
Yes, and he was saying there were problems at the moment of actually getting the message across 
 
Interviewee 2 
Yes well the clean hospitals, there has been a lot of money, millions of pounds for this area, which 
involves more than just prescribing, but also deep clean and clean hospitals, and that relates to 
hospitals we have and the hospitals we contact like the university trust hospital, and our own 
contracted health centres and pharmacies and so yes there is a big focus on that and that‟s a whole 
different area, a whole different teams, it doesn‟t relate to me so much.  So I am aware of some of 
that, I am aware of national campaigns, but they would know about that. 
 
Interviewer 
So the government funds… 
 
Interviewee 2 
I don‟t know how it works exactly, basically the…we‟ve always had microbiology input, infection 
control…its a statutory requirement anyway, I thought pretty well, maybe not statutory but its 
certainly, you know healthcare commission requirement and it has been for years.  The media has 
changed it all now but we‟ve always had that and we couldn‟t run our hospital without that, you know 
if we had an outbreak in a care home what would we do about it if we didn‟t have a consultant 
microbiologist or expert input so that‟s always been there, that hasn‟t changed.  I know there has been 
money that has gone to hospitals I think, I don‟t know the routes…that‟s not my area so… 
 
Interviewer 
So are there any policies at the moment that are being used  
 
Interviewee 2 
Around.. 
 
Interviewer 
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Around antibiotics  
 
Interviewee 2 
Locally 
 
Interviewer 
Either locally or nationally 
 
Interviewee 2 
I‟ll show you some stuff (shows me figures off computer).  So In terms of policies errm I don‟t know 
if this is what you mean errrm.  Like I said for adults we are doing the joint formulary so around 
medicines we are making sure that not only does primary care know what to prescribe but it‟s jointly 
done with secondary care.  Hospitals have done their own formulary so we are doing; we have got 
standard methods that we use.  Not only do we have the formulary but we have the data on 
prescribing rates and different methods that will target the high and low end in comparison to PCT‟s 
in west midlands.  And that‟s some of the tools that we would use. It‟s a standard technique used in 
changing behaviour, so in terms of policies we‟ll have the formularies, things like that, the community 
pharmacists working in practices.  We‟ve also got the local health service who will pay primary of GP 
prescibers through various priorities and actions and we also use quality of outcomes frameworks and 
in there is three actions related to prescribing, you know the QUOF 
 
Interviewer 
Yes I do 
 
Interviewee 2 
These are all incentives that make things happen and we use that in areas where practices want to 
make use of, they get all the data and analysis from us.  If they have a problem around antibiotic 
prescribing, so lets say they prescribe a lot of Quinolones for Prostatitis and you know that‟s the main 
area really, and they only prescribe it on that, which the top two or three might do, then they‟ve got to 
change their practice.  We will allow them to select it as their key target for this year in practice.  Is 
that what you meant by policies? 
 
Interviewer 
Yes.  Do you have any figures available that you can provide  
 
Interviewee 2 
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Yes I wouldn‟t give you the practice level comparison as the GP‟s haven‟t had those feedback to them 
at all.  They‟re under development at the moment so we have to make sure the presentation is exactly 
right and there is no misleading etc.  But we know the benchmark, as a PCT we are joint third or 
fourth lowest prescribers in volume.  So that is your benchmark for the West Midlands.  In relative to 
the England average we are good, if low is considered good.  No-one has benchmarks Quinolones.  
They haven‟t done it so we have done it locally.  So we are trying to sort that out because even though 
we are low, you know as far antibiotics go, as far as targets go we don‟t need to look at it.  We are low 
prescribers, our GP‟s are good prescribers, consultants tell us there is no problem but we haven‟t got 
formularies so we have to do that.  We know there is clinical practice that needs to be updated in 
terms of antibiotic prescribing, you know it is a good piece of work to do, but we want to take it to the 
next level with C Diff and Quinolone and Cephalosporin targets and things.  Some of the evidence is 
woolly but we have done bits of areas of advice with consultants around that 
 
 
Interviewer 
Is there a reason why this pct is so good? 
 
Interviewee 2 
That‟s a separate study isn‟t it?  I am not saying we are good prescribers, I am just saying we are low 
prescribers in the west midlands, we have always been that way.  I mean our GP‟s are low on non 
steroidals are low on you know we are good at lots of areas but not every area.  There are lots of 
reasons but that‟s a separate study.  It could be the patient population it could be hospitals and the way 
they influence the public it could be GP training in the area, I don‟t know, it could be anything. 
 
Interviewer 
Actually we were hoping to do was to compare PCT‟s.  For example this is a good prescriber, so I 
want to know why this area is so good compared to another PCT. 
 
Interviewee 2 
Ok the first thing is we are assuming that low prescribing is good, for all we know we may people 
with raging infections being omitted which would be horrendous, that would be the worst scenario.  
So we are assuming they are good.  We have obviously done historical things as pharmacy advisors 
around otitis media and sore throat but generally we‟ve generally been low prescribers.  We don‟t 
know why that is, that‟s just the way it is  
 
Interviewer 
 So it has always been that way? 
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Interviewee 2 
Well yes for seven years, we have generally been low compared to PCT X and those that have 
merged, generally going from south always being low prescribers but we don‟t know why that is 
 
Interviewer 
Is there a good communication between the PCT‟s in this area, for example successful methods used 
to control antibiotics, is that spread across all PCT‟s? 
 
Interviewee 2 
I mean there is certainly shared practice, errm I mean we as advisors meet up and share practice, I 
mean there are avenues to do that.  For antibiotic prescribing it is difficult to...errm what works in one 
place doesn‟t necessarily work in another because the whole approach varies so much in different 
areas.  There are standard methods used to change prescribing behaviour and there‟s published 
evidence about those so like academic detailing, the newsletter type thing that doesn‟t work.  There‟s 
different ways of doing it like electronic systems used to change behaviour errm so any of those may 
work in your area you know paying people in some areas helps to change behaviour.  There‟s 
different methods isn‟t there.  For us, given our position we‟re specifically focusing on C Diff, only 
because that‟s our main area of focus.  I know there will be some GP‟s out there who are outdated in 
practice in some other areas, they will have a formulary and they will look at that but we will focus on 
C Diff and the potential areas that may impact on that because that‟s the national target and that‟s our 
local target with consultants.  We‟ll look at firstly giving them that information, sticking in some 
incentives monitoring every month so they get their position fed back to them errm if they have got 
clinical questions, we and the consultant microbiologist at that hospital be able to deal with those in 
terms of prescribing practice and clinical practice.  We may run a workshop if that‟s deemed suitable.  
You know there are different methods, we wont just use on thing send that out and say there you go, 
we will go out there and talk to those who want advice you know there are many methods.  I‟m sure 
all those PCT‟s use those methods to various degrees.  Its nothing unusual just standard stuff really. 
 
Interviewer 
If a method of intervention is seen as successful, is there a cut off point.  For example if the 
government use advertising will they give a stop date or do they say this is what we are putting in 
place and let it run 
 
Interviewee 2 
My impression is...basically the evidence around campaigns if you like is not particularly strong and 
is a problem in public health.  So if you tell people to give up smoking, they don‟t give up smoking.  
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If you use more pro active measures like clinics offering free NRT you have people knocking on their 
doors you know clinics in retail centres, whatever it is, yeah people start to come forward, but if you 
just say quit smoking they don‟t do it, and that‟s my understanding of public health.  So basically the 
idea of community pharmacies running six campaigns a year as they are contracted to do.  If they are 
just going to run poster campaigns, there is no evidence that it will change public behaviour bar one or 
two percent, but the evidence is really poor for that, so my view is that is not that you shouldn‟t use 
that, but should recognise that it is not the only thing you can do.  That is the start of it to get public 
awareness but it doesn‟t change behaviour. People become aware that cough and colds ooh I mustn‟t 
turn up.  But if they get a cough and cold they will still turn up to the GP, so if the GP hasn‟t changed 
their behaviour then they will get their antibiotics.  So to create the change you have to do different 
things.  So the government can do their campaign, it will raise public awareness, fine.  But that won‟t 
affect the volume of antibiotics prescribed.  So you need other systems, whether it be electronic, 
security guards, GP‟s saying you are not going to get a script now, if you still have the problem in 
three days time come back and it will be there for you a delayed prescription.  All those different 
techniques change prescribing.   
 
Interviewer 
The other thing I was getting to grips with is that the government only seems to get involved when 
there is a problem rather than staying on top of it 
 
Interviewee 2 
Yes the antibiotics stuff and C Diff, well I was doing C Diff when I was a junior hospital pharmacist 
back in the early nineties, what‟s different now.  Okay the rates have gone up a bit but suddenly it hits 
the media and that‟s what‟s pushing it.  That relates to the deep clean.  I‟m not saying it‟s a negative 
thing and they shouldn‟t be doing it but its great and a really good piece of work but that collective 
national approach will have an impact on one area then that‟s a bit like what we do, we choose one 
area.  So that‟s a good thing but you know is it the absolute priority in clinical care, you know.  Is 
preventing C Diff going to reduce hospital admissions or really improve national care of patients  
 
Interviewer 
Do you think there are other areas that are more important 
 
Interviewee 2 
Well cardiovascular disease and elderly care and all sorts of things, you know it is just one area that 
has been put into the top 5-10 topics within PCT‟s, you know if you took the media and public view 
away...if that‟s what they want then that‟s fine, if they are worried about getting C Diff that‟s fine but 
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I don‟t know how many cases we get nationally but you know I‟m not worried about it.  If I was in 
hospital I wouldn‟t worry about it because I‟m a young fit healthy guy. 
 
Interviewer 
I thought it would be higher on the agenda… 
 
Interviewee 2 
Well yes it is in the top 5-10 and is in the healthcare acquired section and that‟s absolutely appropriate 
from a resistance point of view it has always been important and from a C Diff point of view and also 
MRSA..dont get me wrong it is important.  It is in the top 5-10 I just wonder if other areas are of 
higher priority! 
 
Interviewer 
Just say you get a message from the SHA that you have to implement this, who is in charge of 
implementing it in the PCT 
 
Interviewee 2 
Well the SHA, I think in their role they don‟t tell us to implement, the government in their role comes 
out with their national policy, the SHA monitor that we deliver, not sure but that‟s what I think they 
do, they don‟t tell us! 
 
Interviewer 
 Say you get a list of things to do from the government... 
 
Interviewee 2 
Well they produce white papers don‟t they, and the white paper, and there‟s lot of different types 
every week, and they will lead to a number of different policy directives.  We get the money from the 
government and then we commission services to deliver on certain areas, and we can set on national 
areas like infections and 18 weeks wait and things like that.  And we can set our local objectives 
based on our local needs, so all those processes happens through different mechanisms.  We talk to 
clinicians about what the issues are locally.  But ultimately if it is a national directive then it is a must 
do and there are mechanisms to make it happen from the board.   
 
Interviewer 
Do you have any audits that you carry out? 
 
Interviewee 2 
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That‟s a part of what we are doing at the moment, development of the formulary will be audited, 
previously for antibiotics we have used items per star-pu and the number of scripts per patient, and we 
have used that as a measure in many incentive schemes and so that brings volume down a bit because 
people take notice of it.  That‟s what we have done before, we haven‟t done a clinical audit at a 
patient and practice level, like we have done with non-steroidals, and I think that will be where we 
will be moving to this year. 
 
Interviewer 
Do you have any suggestions of what avenues I could take from here...as in what could be an 
interesting area for PCT‟s in general? 
 
Interviewee 2 
Aren‟t you better off looking at PCT‟s that have changed, at the end of the day we have been low 
prescribers for the past seven years and there isn‟t anything we have done locally to do that, I have to 
hold my hands up and say.  How do we make the highest prescribing GP‟s change their practice, 
that‟s interesting? 
 
Interviewer 
But that‟s what interests me in this area.  Why do GP‟s prescribe less antibiotics in this are compared 
to others? 
 
Interviewee 2 
You can do a questionnaire but they won‟t know! 
 
Interviewer 
Is there some kind of message being relayed to those GP‟s 
Interviewee 2 
No.  I‟m more interested at looking at individual drug categories where actually it could be those five 
practices on the bar chart that are actually the highest prescribers in the west midlands, no one has 
done a benchmark on Quinolones so we may be high prescribers of Quinolones, we just don‟t know.  
So that is how we are going to look at it.  Patient demand is a real issue, at the end of the day you have 
got to look at the type of populations I think our public are just not as demanding.  If you put our GP‟s 
into a high prescribing PCT area they may resist to prescribing more because they are not used to it 
and think hang on this isn‟t right, however their volume would go up more because demand is more.  
It maybe more a public issue rather than a prescribing issue. 
 
 
 290 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 291 
Interviewee 3 
 
Location: Desk within open plan office 
 
Time: 38 minutes and 21 seconds 
 
Interviewer 
 What is your job title within the PCT 
 
Interviewee 3 
 I am the head of medicine‟s management 
 
Interviewer 
With regards to antibiotics, do you have any specialist microbiologists or pharmacists that deal 
with…? 
 
Interviewee 3  
We don‟t within this PCT, but we have access to that from PCT X…because we work very closely 
with them and have a joint formulary with them and the other PCT‟s so if we need that we can access 
it. 
 
Interviewer 
 Is that with PCT Y? 
 
Interviewee 3  
No that is with PCT X because it is the same acute provider 
 
Interviewer 
Do you have good communication with other PCT‟s as well? 
 
Interviewee 3 
Yes we work with the other 2 Birmingham PCT‟s quite closely, but we meet as a group...the heads of 
medicines management 
 
Interviewer 
But you work very closely with PCT X 
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Interviewee 3 
Yes because the patients visiting the hospitals are the same 
 
Interviewer 
Have you got any initiatives or schemes that are being used at the moment? 
 
Interviewee 3 
I will tell you what we are doing at the moment, we are doing nothing in particular with antibiotics at 
the moment, and the reason for that is we‟ve done it!  I have been in post for five years and when I 
came back to work for this PCT we were incredibly bad at prescribing antibiotics.  Historically 
Birmingham always was really high users of antibiotics in general practice, when I say bad I mean in 
volume, but not in what they use because it‟s all simple things like amoxicillin, pen v, erythromycin.  
It‟s not the ciprofloxacins and quinolones and these sorts of things.  So that was my top priority for 
the first couple of years.  At that time there were 304 PCT‟s and at that time we were the 4th highest 
prescribers of antibiotics, 300
th
 out of 304!  Within two years we had moved from 300
th
 to 62
nd
 and 
going from 20% above the national average to 10% below in prescribing antibiotics.  And since then 
we have consistently been at that level.  Because of the way we work as a small team we focus on a 
few things.  And this is the first time that antibiotics have not been a priority because it is under 
control. 
 
Interviewer 
So what can you say was the reason for why you were successful? 
 
Interviewee 3 
Main reason is because of the way we work.  If you looked at the whole medicines management 
agenda and tried to cover everything, you will never achieve anything because there is too much to 
do.  So if you prioritise and say right in the next year these are the 3 things we are going to focus on 
and just go after them, then that is successful.  We‟ve done it statins, antibiotics and clopidogrel, and 
benzodiazepines…just different things every year.  What you find is that we carry some over, so with 
antibiotics it was a high priority in the first few years and then we kept it as a low priority over the 
next few years, it‟s only this year we have dropped it for the first time.  Statins and clopidogrel have 
been in there for 3 years.  We keep a consistent picture by maybe bringing one thing in and taking one 
thing out every year, and we work on a model that‟s very much like industry, where you need to 
deliver your message at least 6 times to a prescriber that changes behaviour and that maintains that 
change.  So my team, originally I and then another pharmacist, and we built on it slowly with a couple 
of part time pharmacists.  They will meet the practice twice a year on a one-to-one basis to discuss, 
and even if they weren‟t high prescribers of antibiotics we would still talk antibiotics with them 
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although a lot of them were high prescribers.  We do newsletters, we do learning events, we do six of 
those a year where we sit all the practices down and they all get together and we do a learning event 
and we‟ve always got a medicine management team within that with antibiotics in there.  So there‟s 
lots of way of keeping the message going, we don‟t just say don‟t prescribe antibiotics but try to be 
more subtle about it.  If you keep telling them the same thing, eventually the will change their 
behaviour.  If you tell them that thing at the start of the year and then don‟t mention it again all year, it 
wont happen 
 
Interviewer 
Now that antibiotics are not a priority this year, do you expect prescribing of antibiotics to rise this 
year? 
 
Interviewee 3 
I‟m not simply because of the way we work! Antibiotics are a really good example because you cant 
put pharmacists into practice to change antibiotic prescribing because they are directly on acute basis, 
so you cant expect a pharmacist to sit over the GP‟s shoulder…you just cant.  If you go and change all 
prescriptions for statins from atorvastatin to simvastatin you won‟t change behaviour, you will just 
change prescriptions.  As soon as you take pharmacists out of that practice the GP‟s will just carry on 
with their same behaviour. What we have done is change patient and GP‟s behaviour towards 
antibiotics.  We still have the odd one that is a high prescriber but most are now low, I can show you 
all the figures when we go upstairs.  Because we have changed behaviour it is not common practice 
for them to write sore throat…antibiotics, cold…antibiotics!  Now they are going the other way.  We 
also have one of the biggest minor ailments schemes in the country, certainly in terms of turnover, and 
certainly in terms of cash wise.  We have around 120000 hits a year with the minor ailments scheme 
and the majority of that is for cough, colds and sore throats, stuff that the GP might have given 
antibiotics for.  Now they go directly to the pharmacy.  Okay they get their cough medicine and 
paracetamol, they probably don‟t need it most of the time, but we now take them away from their 
GP‟s, so that will help maintain that. 
 
Interviewer 
Minor ailments are quite interesting… 
 
Interviewee 3 
Well they have to change behaviour first, and it‟s not easy, it‟s a lot of work for the GP to change 
their ways, but it does help change patients perceptions as well.  If the GP says right I am not going to 
prescribe you antibiotics because there is no point, and we also have literature which we can give 
patients which say why we are not prescribing antibiotics today, and we concentrate on upper 
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respiratory infections and urinary tract infections.  At then end of the day the line we give to GP‟s is 
that if you think its appropriate, we will think its appropriate, but you have to be happy it is 
appropriate.  And there was a great article out there, probably from 1998 stating that if patients went 
to their GP expecting antibiotics, they were four times more likely to get it, but if the GP thinks the 
patient wants antibiotics, they are ten times more likely to get it.  So we had 2 change both 
perceptions.  I remember going to one of our practices and mentioning all this stuff and say this will 
be six months hard work for you, but once those patients stop coming in because they know you are 
not going to prescribe any, you are going to reduce your workload. 
 
Interviewer 
So do you try and educate your patients through your doctors 
 
Interviewee 3 
Yes there have been some campaigns locally but mainly we do it through the GP because it‟s the GP 
that has to refuse antibiotics and state the reasons why 
 
Interviewer 
So you took it on your own head to make these changes, rather than waiting for a message above 
 
 
Interviewee 3 
Yes 
 
Interviewer 
Did you have to put any finance towards that  
 
Interviewee 3 
No we only originally had me in the team, and then a few extra.  You have to remember changing 
antibiotics isn‟t about cost, but because we have done it we‟ve probably saved around 250000 pounds 
a year on reduced prescribing within this pct, so you can justify doing it anyway.  We‟ve spent a bit 
on GP supporting material and information to patients, but not a lot. 
 
Interviewer 
We were interested in this pct because we were aware of how antibiotic prescribing reduced a lot over 
the past few years… 
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Interviewee 3 
Yes we use a model called “selling the salami”.  It‟s not just for antibiotics but used for everything.  If 
you think of salami and you cut it up into pieces, every slice looks slightly different.  It‟s still salami!  
So you have got to decide on what your message is going to be to reduce antibiotic prescribing and 
then just use slightly different ways to get that message across.  So In a newsletter you would write 
something like, countries with the lowest level of antibiotic prescribing have the lowest incidence of 
MRSA.  In the next newsletter you would put something like the detail mentioned from the article I 
mentioned earlier, and then when you see GP‟s you talk about that and you talk about 
appropriateness.  So each time you add another layer on layer, but ultimately you are saying the same 
thing each time.  And that‟s how the industry works very successfully and that‟s why they invest 
millions of pounds on GP reps each year. 
 
Interviewer 
So what is your background? Have you always been involved with medicines management all the way 
through? 
 
Interviewee 3 
I did 10 years of community pharmacy originally.  And after being qualified for five years, there was 
a programme run by the then FHSA in Birmingham where they were looking six community 
pharmacists to deliver prescribing advice.  So I came into this that way.  So that was part-time one day 
a week.  And then I worked for the health authority doing something similar when that finished.  And 
then I left this field for a couple of years and worked in the prison service, but actually it is very much 
a primary care setting in the prison because the message is still the same.  I came back into this when 
the primary care groups were formed and I worked for the PCG in small heath, and then I went to 
work in industry for a few years.  I worked for Lilly for three years in sales and marketing, and then I 
came back here in 2003.   
 
Interviewer 
What is your relationship like with other PCT‟s? 
 
Interviewee 3 
No, you have got to look…it‟s very easy to do all the flowery work saying we are doing this, this and 
this, but actually we are here to deliver efficient healthcare.  You have got to decide what we want to 
do and we have made the decision we will work on prescribing efficiency and allow that resource to 
do all the other work..errm they‟ve not, because we work independent…no… we‟ve certainly had the 
SHA have me talk to other PCT‟s.  I did a workshop on what we did and how we delivered it, some 
take it on board and some don‟t.  what we are finding more and more, and this year especially the 
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prescribing efficiencies are built into our overall and other PCT‟s ask how we have done it because 
there is money involved and we have had tangible results. More and more people are, but a lot aren‟t 
interested. 
 
Interviewer 
well I went to see a Interviewee 1 a few weeks back, who stated that their antibiotic prescribing was 
low, although the figures suggest different, and when I asked if you are open to change to improve, 
her answer was very much we are doing what we can, we have been told what to do and we are not 
going to do much more.   
 
Interviewee 3 
You have to pick your own priorities and I understand where Interviewee 1 is coming from.  When we 
were 301
st
 out of 304, east was 304
th
!  So they were the highest prescriber of antibiotics in the 
country.  But they have done a lot of old work in the old team.  I know they did a lot of work on 
reducing, with a lot of community involvement by going to schools, that was successful then but I 
don‟t think they will take it on now! 
 
Interviewer 
Do you have any funding at all from the government at all?  So let‟s say they want to implement an 
advertising scheme, will they filter down money for each PCT? 
 
Interviewee 3 
Not really, no.  They might do for other bits and pieces that we can bid for but they will never be that 
specific.  We are fairly lucky because we are a fairly cash rich PCT, and because of the work my team 
has done, if I wanted another post to do something specific, I can always get funding for that from this 
PCT.  Other PCT‟s are not so lucky!  I can go to the board and say that the work that my team has 
done has probably saved 2 million pounds last year.  It‟s not really saved because it is invested as well 
but we can be more efficient.  Our staff last year went up by 16%, but our cost went down by 30%.  
So I can usually get the board to agree with what I want to do.   
 
Interviewer 
What is the relationship like between the SHA and PCT‟s…do you think that‟s a good relationship 
you have there? 
 
Interviewee 3 
The problem is that it has never been that well-established of exactly what their role is.  It‟s been easy 
for us because we have all worked with Nigel one way or another, when he was at Walsall…etc.  So 
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there are good relationships there.  Are they performance managers, supporters, are they meant to be 
strategic for us, we don‟t really know.   
 
Interviewer 
Are you aware of the new government campaign to reduce antibiotic prescribing 
 
 
Interviewee 3 
Yes.  We‟ve had people from the health department come here end of last year talking around C Diff 
and MRSA, and they specifically asked for medicines management because of the work we have done 
of medicines management.  They already made their mind up about what they wanted to do before 
they had asked us. They said surely you have got a formulary for antibiotics.  And I said no you 
shouldn‟t have a formulary for antibiotics because GP‟s are very simple creatures.  If you say to them 
use amoxicillin for simple chest infections, they will hear it is okay to use amoxicillin.  What you 
have got to say is this is when it is appropriate to prescribe, and that‟s the only time you should 
prescribe, and that will reduce prescriptions.  You have to be careful how you communicate with GP‟s 
because they will hear one thing…formularies is hospitals is a good, but in primary care?  Yes 
formularies in other areas such as cardiovascular…fine because it involves choosing the most cost 
effective drug to improve outcome.  From my point of view why would you have atorvastatin 10mg 
on your formulary when you have simvastatin 40mg doing a far better job, better evidence base at the 
fraction of the cost.  But for antibiotics, it doesn‟t work.   
 
Interviewer 
When you started talking to those doctors about antibiotics, did you have a target in mind? 
 
Interviewee 3 
Two years...we also have a prescribing incentive scheme, which has been knocked around in the last 
couple of years.  But if you get it right it is probably the best way to get changes in prescribing.  If you 
are very direct with what you want from it, you can get very good outcomes.  We run an incentive 
scheme over three months, the GP‟s know that between January and March every year we will be 
monitoring.  And we have a maximum of four targets and they get prizes for achievement.  Normally 
antibiotics are in there, but it isn‟t this year.  What you see in those three months is a state change in 
prescribing, because you are doing it in a concentrated time where they have to think about what they 
are doing you start to see maintenance of that.  I‟ll show you the graph upstairs but usually you see a 
drop then levelling, a drop then levelling again.   
 
Interviewer 
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What does an incentive scheme actually involve? 
 
Interviewee 3 
First of all there is an audit, all the practices that want to be involved, and we usually get a 90% 
response rate who say do the audit.  Last year it was on clopidogrel prescribing.  All we said is here is 
the NICE guidance on clopidogrel.  Here‟s all the patients, they should have a diagnosis, as start and 
stop date, if appropriate, unless there is a reason for them not to.  How many patients have you got, 
how many are on clopidogrel and how many have a stop date.  And if not, why not, you need to find 
out.  And that‟s all we had to do.  We didn‟t have to put standards or criteria in.  GP‟s came back and 
actually said it‟s the best audit we have done since we have been in general practice because it made 
them look at their practice.  We did the audit, the figures went down and then plateau‟s.  So hopefully 
that means that the patients coming onto it are equivalent to those coming off it.  Then we do points 
for prizes scheme.  Depending on our priorities, we have up to four targets, when it was antibiotics we 
said right we are going to reward those practices that are already good, why shouldn‟t they be 
rewarded for doing good.  Any practice that is below the national average I‟m happy with.  So if 
you‟re below the national average you will get 10 points.  If you are above the national average within 
that three month time period, you need to be showing a reduction.  So if you show a 10% reduction 
you will get 2 points, if you show 10-20% reduction you will get 4 points…etc.  If you show greater 
than 20% you will get 6 points.  If you are within 5% of the national average then you get 1 point.  So 
there was an incentive for those guys who were never going to get below because of how high the 
prescribing was, there was an incentive for them.  The number of points is completely arbitrary 
because if there is 40 points total for the whole scheme and two practices get all the points, they get 
all the money.  If 100 practices do it then they all get that same amount of money, but split 100 ways 
instead of 2.  We have a certain amount of money each year that the board will agree on.  The 
maximum pay out last year was £4000.  For a big practice that is nothing, but they are delighted 
because it allows them to buy those bits a pieces for the practice that they wouldn‟t buy themselves.  
There are certain criteria they can‟t use it to pay for staff because they should be doing that anyway.  
Anything to improve patient experience is fine, e.g. medical equipment.   
 
Interviewer 
Do other pct‟s use incentive schemes in this area? 
 
Interviewee 3 
There are a few and they are using our model, I know that because they have asked us for it.   
 
Interviewer 
Are antibiotics a priority at other PCT‟S? 
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Interviewee 3 
I don‟t know, you would have to ask them.  Antibiotics were a big priority in the first two years so 
you got more points for that than anything else.  In the first year antibiotics would be worth 20 points 
and benzo‟s worth 10 points.  So we prioritise by going after what we want by giving the most points.  
The only problem with certain incentive schemes is that they are too complicated.  I come back to 
GP‟s are simple creatures, they have got so much going on that they need simplicity.  If you make it 
too complicated it wont bring about change.  That‟s why we never have more than 4 targets, and I‟d 
rather have it to three. 
 
Interviewer 
Is there a mentality where you say this area is a problem so let‟s deal with this, rather than let‟s keep 
these existing figures low? 
 
Interviewee 3 
Yes there is.  You have to be brave to say I am going to only go after three or four targets this year.  It 
would be too easy to say I am going to target everything, and that‟s where people make the mistake.   
 
Interviewer 
Do you think you can take what you know and step into another PCT and get similar results. 
 
Interviewee 3 
Pretty much yes.  Because the model works, industry has proved the model works.  I think the only 
problem would be going into an interview and proving that, although I have the figures, it is such a 
step change for the NHS.  I really believe in this model.   
 
Interviewer 
Are there opportunities to help…? 
 
Interviewee 3 
Yes sure, antibiotics are still one of my six markers and so we check figures every month to make 
sure figures are not rising.  You always get seasonal variations, but if I see the trend going up I will 
intervene.  But I will also check those figures against national figures.   
 
Interviewer 
There has been a lot said about industry taking more responsibility with antibiotic production.  Do you 
think they can do more in that area, given your industry background? 
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Interviewee 3 
They are not going to develop antibiotics, not interested because why develop a drug that is only used 
short term when you can produce one that is used for five or six years.  Where‟s the profit?  They‟re 
just not going to do it.  It‟s all about long term conditions.  What they are really good at is marketing 
and marketing to the target population.  And I actually said to the department of health when they 
came down that they should ask industry how can we deliver this message, and the health department 
said what is in it for them, they‟re are not going to want us to stop prescribing their drugs.   They are 
not interested; there are no new antibiotics out there.  They couldn‟t get their head around it.  It would 
be a way for industry to work closer with the department of health. 
 
Interviewer 
The lack of communication seems to be such a barrier… 
 
Interviewee 3 
Yes it‟s the most important thing we do.  You can have all the ideas, unless you communicate well 
and implement them, what is the point!  I know the vast majority of our GP‟s know what medicine 
management is and know where to contact us, and are happy to do so.  And see medicines 
management as a useful resource because many don‟t see the pct as a useful resource, and that‟s been 
due to communication as much as anything.   
 
 
 
 
 
 
Interviewee 4 
 
Location: Desk within open plan office 
 
Time: 27 minutes and 2 seconds 
 
Interviewer 
What is your role within the PCT? 
 
Interviewee 4 
I am assistant director of medicines management, I have only been so for two weeks.   
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Interviewer 
Did you work in community pharmacy before that? 
 
Interviewee 4 
Yes I did.  I was a community pharmacist for quite a few years, and then I was invited to go work in a 
local practice actually.  After doing a bit of both they asked me whether I would like to work three 
days a week.  This fits in a lot better around children. 
 
Interviewer 
Do you have a special antimicrobial pharmacist? 
 
Interviewee 4  
I have a job description for one.  We have just secured funding for one to start in October.  Funnily 
enough I have organised a meeting tomorrow with one of my dental colleagues, and they have offered 
us funding to bring it forward so we can start by addressing antibiotic prescribing in dentists as well. 
 
Interviewer 
Ok.  Other PCT‟s have antimicrobial specialists that work in hospitals rather than onsite at the PCT.  
Are you looking for someone to specifically work within the PCT? 
 
Interviewee 4 
Yes, two antimicrobial pharmacists and that‟s why we are appointing one here, who can look at the 
use in primary care, nursing homes, that kind of thing.  And it will close the loop. 
 
Interviewer 
Who is in charge of developing the initiatives, incentives or formulary guidance that you may use? 
 
Interviewee 4 
That would be me I imagine 
 
Interviewer 
Have you got anything running at the moment for antibiotic use? 
 
Interviewee 4 
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We have got prescribing incentive scheme this year, which has got in it a little about cephalosporins 
and ciprofloxacin.  Basically if the practice has got a greater than average antibiotic use, they must 
agree to reduce the use of those antibiotics as part of their QUOFF target.  If they don‟t, they will 
have their reward reduced by 50%.  So it is fairly tough.  If they are below average then they won‟t 
have to address it because they are not too bad.  It is just the top few practices that tend to use them. 
 
Interviewer 
So if a practice is doing well then you wouldn‟t reward them? 
 
Interviewee 4 
Only if they are doing well on those particular antibiotics because those have been identified as being 
related to C Diff.  Because we did have high use on both of those, so they have come down quite a bit.   
 
Interviewer 
Is your incentive scheme similar to the one being used at PCT Z? 
 
Interviewee 4 
Yes it will be similar because PCT Z uses City (hospital). 
 
Interviewer 
(Explain the process used by Interviewee 3 for incentive schemes)   
 
Interviewee 4 
Yes it will be similar to that…but I am waiting to see because there is supposed to be some national 
promotional campaign so I am waiting to see what will happen with that. 
 
Interviewer 
I don‟t think much is going to happen with that. 
 
Interviewee 4 
Really?  That‟s disappointing actually!  I don‟t understand why when the government are looking at 
MRSA and C Diff in hospitals so bad that and that there is a link to antibiotic use, why they don‟t 
they get the message out to the public and the GP‟s.  I know there is a perception that the public are 
requesting it, but in some of our areas it actually is!   
 
Interviewer 
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It is confusing.  Before I thought that the PCT would have messages sent from the SHA on what to 
do, who in turn receive a message from the government on what to do.  However it feels as though 
you are just left to it. 
 
Interviewee 4 
Yes we are.  You need a concerted TV campaign and not just leaflets.  I mean people that live in the 
leafy suburbs that are well educated realise that most things are viral and antibiotics are not needed to 
treat them.  Whereas when you come into an area like this that‟s not the case.  When people feel ill 
they think antibiotics will treat them, and if they always get it from their GP it is very hard to break 
that.  It‟s the die hard older GP‟s in Sandwell that keep that momentum.  And if they do try to stop, 
patients jump ship to GP‟s that will provide them. 
 
Interviewer 
So Is there an issue there that GP‟s are being told not to prescribe antibiotics, but the pressure is so 
great from patients that they feel they have to? 
 
Interviewee 4 
(nods her head) 
 
Interviewer 
Okay is that still something you are trying to address? 
 
Interviewee 4 
Yes well being a pharmacy prescriber, when you are actually sitting in front of the patient it is very 
difficult.   
 
Interviewer 
Yes I have got a lot of family around here so I know what it can be like… 
 
Interviewee 4 
Yes it is very endemic in the south Asian population actually because there is that perception of being 
given something.  It does require a cultural shift, but we are aware that‟s there, but we are kind of 
addressing that.  It is very difficult for me, a white middle class British woman to do. 
 
Interviewer 
Do you have the same kind of population that they have in the PCT Y area as well? 
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Interviewee 4 
Yes it is very similar. 
 
Interviewer 
Do you think that if you initiated the same schemes they have that it would be beneficial…? 
 
Interviewee 4 
What have PCT Y been up to? 
 
Interviewer 
They try and educate patients through their doctors… 
 
Interviewee 4 
Well we have done quite a lot in that we have.  We did do a campaign when I first started, that kept 
rolling.  We were one of the worst in the country, and don‟t think we are quite as bad as now as we 
used to be…I haven‟t looked at the figures for a while… 
 
Interviewer 
No your figures are quite good actually 
 
Interviewee 4 
When I first came the questions I was asked in my interview were around addressing antibiotic use.  
We did a lot of work with the GP‟s but we also provided a lot of information leaflets for GP‟s to use 
for patients.  I think a lot of our bigger practices have got the message, often it is practice staff or 
practice nurses, practice nurses and also community pharmacists and their staff… I have been in a lot 
of situations where they have sold something and said if you don‟t feel better you will need to go see 
your GP to get antibiotics, and the boxes do say if you don‟t feel better within three days go and see 
your doctor.   
 
Interviewer 
What is your minor ailment scheme like in this area? 
 
Interviewee 4 
Very well use.  Unfortunately we have no data to prove that it reduces antibiotic prescriptions.  We‟ve 
actually got one very well used service next to a GP practice, and even that doesn‟t show a reduction.  
And we haven‟t got the time or the resources to look, and that was a one-off to see if it odes reduce 
antibiotic prescriptions…and it probably does actually. 
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Interviewer 
It may be a nice way to get the patients out of the GP surgeries and demanding… 
 
Interviewee 4 
It would nice to have more funding for minor ailments as well.  It does get patients out of GP 
surgeries.  There are a couple of issues that we have with it:  Patients tend to use it as a free 
medication service and GP‟s use is as a prescribing service to stop it coming off their budget.  So the 
patient will already be sitting with the GP and the GP will say you can go and get Calpol from the 
pharmacy for free.  That‟s not the point of it, the point of it is next don‟t come to see me go to the 
pharmacy.  So there is a little bit of that going on as well.  In an area like this it‟s a good thing to 
have…its just about making sure pharmacists can police it.  I suspect it has got the potential to reduce 
antibiotic prescribing.   
 
Interviewer 
What are your priorities for the coming year…is antibiotics one of your priorities for the coming year. 
 
Interviewee 4 
Yes it is, and hence why we are recruiting an antimicrobial pharmacist.  Errm there are no priorities as 
such, we are covering all the major areas.  It will mainly be the CV type, diabetes and antibiotics, 
obviously because of our patient population. 
 
Interviewer 
If you were to introduce a certain incentive scheme or initiative, how long would you run it for? 
 
Interviewee 4 
12 months 
 
Interviewer 
And do you assess it after those 12 months 
 
Interviewee 4 
Yes it has already gone out for this year so they have plenty of time to look at it, and then we will 
analyse the last quarter figures between January and March, so we are just waiting for the last 
quarterly figures for this year to come in and then they get allocated their funding and then they have 
two years to spend the money on whatever they want. 
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Interviewer 
Is it done on a voluntary basis (Interviewee 4s shakes her head)…is it done on a mandatory basis 
 
Interviewee 4 
Yes. We top slice it off the budget.  If they don‟t do, they won‟t get any money.  But most of them 
will get some.  We are being quite generous this year so that they get a feel of what it is like to get 
money.  We will be a bit harder next year.  the other thing is we devolved into three smaller clusters, 
similar to the old PCT‟s that are clusters of surgeries that work together, and they agreed to split the 
funding 50-50.  So if a practice got £5000, they will get £2500 and split the rest with the rest of the 
cluster. 
 
Interviewer 
Do you control what they spend their money on? 
 
Interviewee 4 
We give them guidelines, but basically it is for patient benefit. 
 
Interviewer 
So you have got government funding this year for antibiotic specialists? 
 
Interviewee 4 
No 
 
Interviewer 
So who is funding it? 
 
 
Interviewee 4 
We don‟t have any government funding, it has come out of our own PCT.  We are given a pot of 
money and we put bids in.  My predecessor and infection team put a bid in for an antimicrobial 
pharmacist and were successful.  The Department of Health decide how much money the PCT‟s get.  
The prescribing budget is allocated based upon the ASTRO-PU‟s and then each director will allocate 
the money. 
 
Interviewer 
Do you know if there have been any successful initiatives or incentives used in the past? 
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Interviewee 4 
Around two or three years ago we ran the antibiotic campaign and did the patient leaflets, and that‟s 
when we started to drop off.  But we are also starting to replace some of the old GP‟s who are retiring, 
and the younger GP‟s are coming in, so there is less emphasis on the locums who prescribe the 
Floxapen and amoxicillin, and the younger GP‟s are saying no you don‟t need antibiotics.  And there 
is that chart from 1960‟s something that you have probably seen which they can show, which tells 
them that they can have antibiotics now and feel better in X amount of days, or not take antibiotics 
and still feel better in that same time. 
 
Interviewer 
Do you have figures readily available every month? 
 
Interviewee 4 
For antibiotic use we use EPACT.  We can use that monthly if wanted, but we check it quarterly.  
Because EPACT provide a quarterly toolkit.  We look at the Ceph‟s and Ciprofloxacins on a monthly 
basis.  So yes, we know exactly what is going on.   
 
Interviewer 
Is there high prescribing of ciprofloxacin then? 
 
Interviewee 4 
Not particularly, there are a few practices that are using it, but they may have individualised patients, 
and there is no problem in using it if microbiology have said yes you need to use this.  So we just go 
to that practice and say have you got any specific patients? 
 
Interviewer 
Is there a certain way you communicate with GP‟s…do you send representatives down…? 
 
Interviewee 4 
No we have practice pharmacists and pharmacist technicians, we work differently to PCT Y in that 
way.  We have four senior pharmacists and then pharmacist support in nearly every practice.  Then we 
have got five pharmacy technicians as well and so they go around and do data collection as well.  
Practice pharmacists are very much clinical and so they can look at an individual practice basis and 
they can go to a practice meeting and say look antibiotic prescribing is rubbish, what are we going to 
do to improve it. 
 
Interviewer 
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So they communicate between the two sides? 
 
Interviewee 4 
Yes.  So if I saw one practice that was particularly high, I would literally e-mail that person and say 
can you make an appointment with so and so and talk to them about their antibiotic prescribing. 
 
Interviewer 
How long have you had practice pharmacists? 
 
Interviewee 4 
Ages 
 
Interviewer 
If you wanted to introduce a new initiative etc, who would you need to talk to in order to get 
permission? 
 
Interviewee 4 
No-one.  I might talk to our infection control types about how to reduce it and then talk to the team 
about how to introduce it and get their input on what could work and how it could be implemented, 
based on what has worked before. 
 
Interviewer 
Do you have any particular ideas on how you are going to tackle it over the coming year? 
 
Interviewee 4 
I am hoping an experienced antimicrobial pharmacist will come in and sort it out.  Hopefully we can 
use what they have learned, for example from hospitals, and implement it in primary care. 
 
Interviewer 
So what is your view on the use of formularies in primary care, do you think they are required? 
 
Interviewee 4 
Yes, a lot of our GP‟s love formularies.  Although it depends on your GP‟s actually, many of ours 
need a formulary frankly! 
 
Interviewer 
What‟s your relationship like with other PCT‟s? 
 309 
 
Interviewee 4 
Very good actually.  It‟s very good amongst this strategic health authority actually.  We do work a lot 
together. 
 
Interviewer 
Do you know what the exact role of the SHA is? 
 
Interviewee 4 
It is a strategic role.  Nigel Barnes isn‟t there any more so we are just waiting for the pharmacy side to 
be appointed.   
 
Interviewer 
Could you contact Nigel when needed?  Was he readily available? 
 
Interviewee 4 
Oh god yes.   
 
Interviewer 
Do they offer guidance? 
 
Interviewee 4 
They are liaison between the department and PCT level, so it‟s that kind of cascade of information, 
and also knowing what is best for the West Midlands as a whole.  Then it kind of breaks down with us 
knowing what is best for our population.   
 
Interviewer 
So do you readily meet up with other heads of PCT‟s? 
 
Interviewee 4 
Yes.   
 
Interviewer 
How often do you meet? 
 
Interviewee 4 
Every other month usually. 
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Interviewer 
And you discuss topics like these? 
 
Interviewee 4  
Yes 
 
Interviewer 
If you were in my position in looking within PCT‟s, what kind of avenues would you find beneficial 
or interesting? 
 
Interviewee 4 
It‟s difficult because we are addressing where we have seen gaps by bringing the antibiotic pharmacist 
in.  I do think we need some kind of public awareness campaign nationally.  A bit like the 
immunisation campaign actually to stop use, and link it into hospitals and hospital acquired infections 
because the public have a perception that it is a dirty hospital that causes MRSA and C Diff, and 
actually it is only part of the problem. 
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Appendix 6: Steps required to download the required data from ePACT and produce the 
prescribing analysis tool. 
 
ePACT was available for use within Sandwell PCT and the following steps were used to retrieve the 
required data. 
 
 
Figure 1: Screen capture of the ePACT opening screen 
 
 
 
 
 
 
 
The ePACT opening screen allows the user to select the time period for analysis, prescriber and drug 
of interest on the left hand side of the window.  The “New Report” button allows the user to 
personalise the report page required to download data as shown in Figure 2 below. 
“New Report” button 
Time Period Table 
Prescriber Table 
Drug Table 
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Figure 2: Screen capture of the "Selected Fields" window within ePACT 
 
 
 
The selected criterion within the report page was used as a template for the presentation of the 
required data.  The “Add” and “Edit” buttons (circled green) were used to change the selected fields. 
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Figure 3: Screen capture of the "Edit Fields" window within ePACT 
 
 
 
Figure 3 shows how the Current Selected Fields” section (circled green) was updated by selecting 
Patient Practice Name (circled red) and then selecting the Add Field button (circled blue).  The fields 
required for the production of the database were the: 
- Period Name. 
- BNF name. 
- Total Items. 
- Items per STAR-PU. 
 
The “Apply and Close” button can be pressed once the required fields have been selected to close the 
“Edit Fields” window.   
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Figure 4: Screen capture of the "Financial Year Summary Table" 
 
 
 
 
 
Figure 4 shows the updated “Selected Fields” window.  The time period was selected by highlighting 
“All Periods” (circled red) and then modified the degree to which the data within the quarter was 
analysed by using the Financial Year Summary Table.  This search required results to be displayed to 
“Quarter” level. 
 
 
 
 
 
 
 
 
  
Financial Year 
Summary Table 
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Figure 5: Screen capture of the "Practice Summary Level Table" 
 
 
 
 
 
 
 
Figure 5 shows the updated “Selected Organisation” window.  The level of prescribing data was 
selected by highlighting the required PCT or practice (circled red) and then selecting the detail 
required using the Practice Summary level Table.  This search required results to be displayed to 
“Practice” level. 
 
 
 
 
 
 
  
Practice 
Summary 
Level 
Table 
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Figure 6: Screen capture of the "BNF Summary Level Table" 
 
 
 
 
 
Figure 6 shows the updated “Selected drug” window.   The medication category was chosen within 
the Drug Table, which in this case was “Infections” (circled green).  The level to which medication 
was then analysed was modified using the BNF Summary Levels Table.  This search required results 
to be displayed to the “Chemical Substance” level.  Once all the criteria were chosen, the “Run Now” 
button was selected to upload the required data. 
 
 
 
 
 
 
 
  
BNF Summary 
Levels table 
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Figure 7: Screen capture of the "Default Template" window within ePACT 
 
 
 
 
Figure 7 shows the Default Template, containing the selected data.  The “Snapshot” button allowed 
the transport of selected data to a modifiable window. 
 
 
 
 
 
 
 
 
 
 
 
  
“Snapshot” button 
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Figure 8: Screen capture of the "Default Template" 
 
 
 
Figure 8 shows how the data could be selected and copied from the window to a Microsoft Excel 
sheet as shown in Figure 9 below. 
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Figure 9: Screen capture of the downloaded data from ePACT to Microsoft Excel 
 
 
 
 
This dataset could then be copied and pasted directly into the database without the need to modify the 
content. 
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Visual electronic outputs required within the prescribing 
analysis tool 
 
The downloaded data from ePACT was then used to design the visual electronic outputs in order to 
achieve the objectives of analysing trends in prescribing using drop down menus and used a number 
of visual electronic outputs with different visual displays.  The outputs included: 
  A trend analysis graph to measure any of the 117 drugs downloaded from ePACT use in 
items per STAR PU and/or prescription numbers for any given financial year. 
 Visual summaries for key antibiotics which are specific for Sandwell PCT and show 
prescribing over a 3 year period. 
 A table to provide an overview of the number of times all antibiotics have been prescribed 
within a given practice. 
 
Pilot Database production 
 
To improve the efficiency in producing the visual electronic outputs a direct link between the data 
downloaded from ePACT to the visual electronic outputs was achieved by producing a “Data Entry” 
worksheet within the database.  The Data Entry worksheet comprised of five sections called, (1) Table 
1, Total Medication List (2) Table 2, Quarter Lookup Table (3) Table 3, Main Lookup Table (4) Table 
4, Quarterly Total Prescriptions (5) Offset Graphs. 
 
 
Total Medication List 
 
The Total Medication List contained data specific to one GP practice and was designed in order to 
copy and paste all the relevant data from ePACT into the Total Medication List, as shown in Figure 
10. 
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Figure 10: Screen capture of the Total Medication List used within the Antibiotic Database 
 
 
 
The most current quarterly data could be downloaded and pasted to the bottom of the current list to 
save the time taken to update graphs. 
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Quarter Lookup Table 
 
The Quarter Lookup Table identified the start and end row of each quarterly dataset pasted into the 
total items column within the total medication list with use of the COUNTIF function.  The Quarter 
Lookup Table was used as a reference table to facilitate the creation of VLOOKUP formula for each 
quarter, as shown in Figure 11. 
 
Figure 11: A screen capture of the Quarter Lookup Table 
 
 
 
 
 
Figure 11 shows that the Quarter Lookup Table lists data in chronological order. Once new data was 
pasted into the Total Items Column, the Quarter Lookup Table updated automatically. The number of 
rows pasted into the Total Items column for each financial quarter was calculated using the COUNTIF 
function.  
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Main Lookup Table 
 
The Main Lookup Table contained data for every medication type using two outcome measures, 
PRESCRIPTION NUMBERS (Total items) and Items per STAR-PU for each quarter in the database 
(refer to section 1.12.3.4.1 for further explanation of the outcome measures used), as shown in Figure 
12. 
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Figure 12: A screen capture of the Main Lookup Table 
 
 
 
The Total Medication List, Quarter and Main Lookup Tables were used to produce the Summary 
Graphs present in the database, as shown in Figure 19, section 6.4.  This was achieved through the use 
of the VLOOK-UP functions within Microsoft Excel. 
 
Quarterly Total Prescriptions 
 
The Quarterly Total Prescription Table required the user to paste the downloaded data into the 
corresponding financial year column.  The financial year columns were divided, the first being used 
for the BNF name of the chemical substance prescribed and the second column being used for the 
number of times the chemical substance had been prescribed within a given quarter, see Figure 13. 
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Figure 13: Screen capture of the Quarterly Total Prescriptions Table 
 
 
 
The Quarterly Prescriptions Table was used to display the data within the Prescribing Table of the 
Database (see Figure 19, section 6.4) and allowed the user to select between different quarters through 
the use of VLOOKUP, OFFSET and COUNT functions. 
 
Offset Graphs 
 
The Offset table contained data for total antibiotics, cephalosporins, quinolones and co-amoxiclav in 
terms of prescription numbers and Items per STAR-PU. The graphs used an OFFSET function and 
required the user to paste the required data from ePACT into the table in order to automatically update 
graphs. See Figure 14 below. 
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Figure14: Screen capture of the Offset graphs 
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Appendix 7: Presentation provided to prescribers at the PLT event 
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Appendix 8: A standard template of presentation used for surgery visits during Quarter 3 (Autumn/Winter) Financial year 2009/2010 
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Comparison of Sandwell PCT to SHA and national antibiotic prescribing data 
 
 332 
Comparison of Sandwell PCT to SHA and national cephalosporin and quinolone prescribing data 
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Comparison of antibiotic prescribing data for all Surgeries within Sandwell PCT 
 334 
Comparison of cephalosporin and quinolone prescribing data for all Surgeries within Sandwell PCT 
 335 
Quarter 3 surgery antibiotic trend analysis graph 
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Quarter 3 surgery cephalosporin trend analysis graph 
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Quarter 3 surgery quinolone trend analysis graph 
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Top 5 antibiotics prescribed at Surgery X during Quarter 2 
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Top 5 antibiotics prescribed in Quarter   2 
Amoxicillin Items/StarPU 
Doxycycline Hyclate Items/StarPU 
Trimethoprim Items/StarPU 
Phenoxymethylpenicillin (Penicillin V) Items/StarPU 
Flucloxacillin Sodium Items/StarPU 
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Agreed actions 
 
 
1. 
 
2. 
 
3. 
 
 
 
